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Cardiac hypertrophy is a growth response elicited in the heart by intrinsic and extrinsic 
stimuli in pathological as well as physiological conditions. The insulin-like growth factor-1 
(IGF-1) propeptides regulate cardiac hypertrophy during normal development, although their 
role during pathological hypertrophy has yet to be explored. 
Previous data from our laboratory has shown that the locally acting propeptide IGF-1Ea 
inhibited angiotensin-induced pathological hypertrophy in vitro and more importantly 
regulated cardiac physiological growth in vivo. To investigate the specific role of IGF-1Ea in 
cardiac pathological growth response, I mimicked a clinical-like scenario in an animal 
model by inducing cardiac workload with the beta-adrenergic agonist isoproterenol and by 
cell-mediated delivery of IGF-1Ea and IGF-1 mature protein into the myocardial wall of 
immunodepleted mice. 
I observed that IGF-1Ea inhibited isoproterenol-induced increase of heart weight-to-body 
weight (HW/BW) ratio compared to IGF-1 treated mice. In parallel, isoproterenol-mediated 
increase of cardiomyocytes cross-sectional area was inhibited by IGF-1Ea, but not by IGF-1 
mature protein. Importantly, in vivo magnetic resonance imaging (MRI) showed that only 
IGF-1Ea maintained end-diastolic volume, stroke volume, left ventricle mass and left 
ventricle weight-to-body weight ratio similar to control levels. In conclusion, these in vivo 
data indicate that IGF-1Ea controls workload-induced maladaptive cardiac growth compared 
to IGF-1 mature protein and suggest further investigations into the role of IGF-1 propeptides 
in modulating the balance between physiological versus pathological growth response. The 
outcome will be relevant for future clinical interventions to prevent degenerating growth 
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1.1 The heart 
The heart is one of the fundamental organs in the human body and is the key organ in the 
circulatory system (Katz 2011). Its central role is to propel the blood flow to the entire body 
to allow correct oxygenation and nutrients exchange in organs, tissues and cells. Cardiac 
function integrity is continuously exposed to deterioration as a result of natural aging or 
because of intrinsic and extrinsic stimuli and genetic mutations potentially leading to 
cardiomyopathies. Lost or malfunctioning ventricular myocytes, the main contractile cells 
that make up one-third of the total cardiac cell number and 70-80% of the heart’s mass 
(Bernardo et al. 2010), cause cardiac function impairment eventually leading to heart failure 
through a complex process of muscle remodelling (Sabbah 2000). The mechanisms behind 
endogenous cardiomyocytes renewal and the potential therapies aimed at recovering 
impaired cardiac function after injury are constantly under investigation. Unlike molluscs, 
arthropods, and amphibians (Martynova 2004), mammals cannot regenerate significant 
numbers of new ventricular myocytes after birth, although it was recently shown that 
neonatal mice retain the ability to fully regenerate the heart after injury during the first week 
after birth (Haubner et al. 2012, Porrello et al. 2011). Evolutionary, this loss of intrinsic 
regenerative ability has become a significant liability only very recently, with the 
appearance of Homo sapiens sapiens and the unique ability of Western societies to meet and 
exceed daily caloric requirements (Bishopric 2005, Eaton, Konner and Shostak 1988). 
While detailed studies have focused on identifying the potential factors responsible for 
cardiomyocytes regeneration, intensive research is being undertaken on the development of 
therapies aimed at counteracting the degenerative effects of cardiac injury. The following 
sections of this chapter will describe different causes of cardiac injury and the therapies 
developed to neutralise the adverse consequences. 
 
1.2 Cardiovascular disease epidemiology 
Thanks to a combination of government policies aimed at helping people achieve healthy 
lifestyle, increased public understanding of risk factors for cardiovascular diseases (CVD) 
and improved therapeutical treatments, the relative rate of death attributable to CVD and 
related diseases has declined in industrialized countries such as United States (Go et al. 
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2013) and United Kingdom (Scarborough et al. 2010) in the last 10 years. However, the 
global burden of CVD remains high and while today CVD is the cause of approximately 17 
million deaths each year worldwide (World health organization 2013), epidemiologist 
reported that, by 2020, CVD will be responsible for 25 million deaths annually. Because of 
rapidly growing populations, the cardiovascular epidemic is advancing steadily in 
developing countries in Asia, South America and Africa, and within 10 years CVD will be 
the most common cause of death globally accounting for 36% of all deaths (Katz 2011). The 
total economic costs for the treatment of CVD are US$297.7 billion in the United States 
(Roger et al. 2012) and €196 billion in the European Union (European Heart Network and 
European Society of Cardiology, 2012) each year, and it is therefore necessary to 
appropriately evaluate the cost-effectiveness of new CVD treatments (Smith et al. 2013). 
CVD includes multiple inherited or acquired abnormalities of the cardiovascular system. As 
a result of vascular dysfunction such as high blood pressure, thrombosis or atherosclerosis, 
the function of the heart and brain can be compromised following myocardial infarction and 
stroke, respectively (Krafft et al. 2012, Thygesen et al. 2012). Among the 17 million people 
that died in 2008 from CVDs, an estimated 42% were due to coronary heart disease and 
35% were due to stroke (Global atlas on cardiovascular disease prevention and control. 
Geneva, World Health Organization, 2011). Ischemic heart disease is therefore the primary 
cause of death throughout the world, affecting high-, low- and middle-income countries 
(Lopez et al. 2006). Importantly, myocardial infarction caused by obstruction of coronary 
arteries in the heart is one of the main causes leading to heart failure. The work described in 
this thesis focuses on the cardiac remodelling initiated after myocardial infarction, with 
particular attention to the onset of pathological cardiac hypertrophy. 
 
1.3 Myocardial infarction and cardiac remodelling 
Impaired endothelial function followed by inflammation of the vessel wall leads to 
atherosclerotic lesion formation that causes myocardial infarction in the heart (i.e. coronary 
artery occlusion) and stroke in the brain. Myocardial infarction is defined as myocardial cell 
death due to prolonged ischemia, and complete cellular necrosis happens during the first two 
to four hours after MI depending on the degree of coronary arterial occlusion (i.e. persistent 
or intermittent), on the presence of collateral circulation to the ischemic zone and on the 
sensitivity of the myocytes to ischemia (Thygesen, Alpert and White 2007). Several 
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biomarkers are used to diagnose MI and influence the potential therapy that is employed for 
the treatment of each patient. For all different categories of MI (e.g. spontaneous, related to 
stent thrombosis or to coronary artery bypass grafting) the preferred biomarker is cardiac 
troponin (cTn), whose elevation in the blood reflects necrotic injury of the heart (White 
2011). The MB fraction of creatine kinase (CKMB) is also used to diagnose MI when the 
cTn assay is not available (Thygesen et al. 2012). Treatment of patients with MI involves 
rapid restoration of microvascular blood flow by pharmacological and interventional surgery, 
suppression of potentially reoccurring ischemic events and treatments aimed at mitigating 
the consequences of myocardial necrosis and preventing future events (White and Chew 
2008), as further discussed in Section 1.6. Following coronary occlusion and myocardial 
infarction, the heart undergoes micro- and macroscopic changes and the entire process 
leading to healed injured tissue after MI takes at least five-six weeks (Thygesen et al. 2012). 
Neovascularization through angiogenesis is one of these natural mechanisms occurring after 
MI in the attempt to restoring the blood supply to the injured tissue, and the increase in 
angiogenic factors (e.g. VEGF-A) is part of this beneficial process (Carmeliet 2003). During 
this period post-MI, substantial changes take place in the survived cardiac tissue, and 
cardiomyocytes display modifications in calcium handling, contractile function, energy 
metabolism resulting in increased protein synthesis and cell size in order to increase cardiac 
pump function and reduce ventricular wall tension (Spann et al. 1980, Grossman, Jones and 
McLaurin 1975). This process is defined as cardiac remodelling and the cellular growth 
initiated in cardiomyocytes can eventually lead to pathological hypertrophy and heart failure 
if not normalized (Frey and Olson 2003). 
 
1.4 Cardiac hypertrophy 
Cardiac hypertrophy is generally recognized as the increase in ventricular mass 
accompanied by higher sarcomere organization and increased protein synthesis in 
cardiomyocytes (Bernardo et al. 2010). Multiple physiological and pathological stimuli lead 
to different responses in the myocardium determining physiological or pathological growth. 
Both conditions represent a response to an augmented load, where the cardiac muscle must 
work harder to compensate the chronic increase in wall stress. Although physiological and 
pathological hypertrophy have in common the increase in ventricular mass, the pathological 
scenario is typically associated with loss of cardiac myocytes and the following replacement 
with fibrotic tissue leading to cardiac dysfunction and a higher risk of heart failure (Weber, 
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Brilla and Janicki 1993, Levy et al. 1990). Physiological hypertrophy is the increase in heart 
size occurring during postnatal development, pregnancy (Eghbali et al. 2006) and exercise 
(Fagard 2003). A specific type of physiological hypertrophy during digestion has also been 
described in snakes, which experience significant and rapid postprandial cardiac 
hypertrophy followed by regression once digestion is completed (Wall et al. 2011). Similar 
to reptiles, the hypertrophic remodelling due to pregnancy or to exercise training does not 
lead to cardiac function deterioration or cardiac disease progression and does not progress to 
heart failure (Maron and Pelliccia 2006). On the other hand, pathological hypertrophy 
develops in response to different settings of volume or pressure overload of the heart. It is 
typically induced by valvular heart disease, hypertension, myocardial infarction or ischemia 
associated with coronary artery disease, myocarditis due to infectious agents, or to genetic 
abnormalities leading to cardiomyopathies (Klein et al. 2003, Lips et al. 2003). 
Physiological and pathological hypertrophy can be commonly classified as concentric or 
eccentric depending on the differences in morphological and functional responses induced in 
the heart by different types of stimuli. While eccentric hypertrophy is stimulated by volume 
overload and results in increased ventricular volume and increased cardiomyocytes length, 
concentric hypertrophy is induced by pressure overload and refers to an increase in wall 
thickness with small reduction in ventricular chamber accompanied by an increase in 
cardiomyocytes width (Grossman et al. 1975). Aerobic exercise and pregnancy are examples 
of physiological eccentric hypertrophy, which increases the venous return to the heart 
(Eghbali et al. 2005), while aortic regurgitation or arteriovenous fistulas are responsible for 
pathological eccentric hypertrophy (Unger et al. 2004). On the other hand, pathological 
pressure overload induced by hypertension or aortic stenosis produces an increase in systolic 
wall stress and consequent concentric hypertrophy (Grossman et al. 1975). Strength exercise 
induces pressure overload on the heart and leads to physiological concentric hypertrophy 
(Pluim et al. 2000) (Figure 1.1 and Table 1.1). Both eccentric and concentric hypertrophy 
are associated with complex networks of molecular signalling and the resulting 
morphological differences aim at improving cardiac function in response to the stimulus 
received. Increased cell thickness during pressure overload provides augmented force of 
contraction required to overcome the load on the wall, whereas the increase in 
cardiomyocytes length induced by volume overload allows a greater cavity size, thereby 




Figure 1.1 Physiological and pathological hypertrophy correlate with concentric or eccentric 
cardiac remodelling Cardiac growth during neonatal development and physiological stimuli in the 
adult heart are associated with hypertrophy of ventricular wall and septum matching with an increase 
in chamber dimension (eccentric hypertrophy). Physiological hypertrophy can also produce a 
phenotype of concentric hypertrophy mainly characterized by an increase in cardiomyocyte width. 
During pathological hypertrophy, pressure overload produces ventricular wall and septum thickening 
(concentric hypertrophy), whereas increase in volume load or previous myocardial infarction induce 
dilated cardiac phenotype by increasing ventricular chamber size and decreasing ventricular wall and 
septum thickness. Source: Maillet, A. Nature 2013; 14:38-48 (Maillet et al. 2013). 	  
During pathological hypertrophy, the initial stage after the increase in workload is 
considerate as a compensatory phase. Although the heart’s induced growth is an attempt to 
normalize the workload/mass ratio and decrease ventricular wall tension to maintain cardiac 
pump function, prolonged hypertrophy can lead to deterioration of cardiac contractility and 
is correlated with an increase in heart failure and sudden death risk (Berenji et al. 2005). It is 
therefore extremely important to understand how the initiating stimuli translate in signalling 
cascades in order to develop targeted therapeutic intervention (Table 1.1). 
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Table 1.1 Multiple types of physiological and pathological hypertrophy: stimuli and 
characteristics 
 Physiological hypertrophy Pathological hypertrophy 
Stimulus 
• Chronic exercise 
• Pregnancy 
• Digestion 
• Myocardial infarction 
• Dilated cardiomyopathy 
• Sarcomeric gene mutation 
• Hypertension 
• Aortic stenosis 
Consequences 
• Normal or enhanced 
cardiac function 
• No fibrosis 
• Normal gene expression 
• Proportional chamber 
enlargement 
• Cardiac dysfunction 
• Fibrosis 
• Myocyte necrosis 
• Associated with heart 
failure and increased 
mortality 
 
1.4.1 Hypertrophic triggers 
Sustained increase in hemodynamic load induces a series of cell signals that cause changes 
in gene expression to initiate new protein synthesis and to decrease the rate of protein 
degradation in the cytoplasm. The main stimuli starting this hypertrophic response in cardiac 
myocytes are classified as biomechanical and stretch-sensitive mechanisms, which are 
mediated by internal stretch sensitive receptor, and as neurohumoral mechanisms, which are 
associated with the release of cytokines, chemokines, growth factors and hormones 
(Rouleau et al. 1993). The neurohumoral ligands are then sensed by receptors on cardiac 
cells named G-protein-coupled-receptors (GPCRs). Specific intracellular signal-transduction 
networks are mediated by activation of both neurohumoral and biomechanical stimulated 
receptors resulting in the onset of hypertrophic growth. These signalling cascades are 
interrelated and an extensive crosstalk between different pathways has been described 




Figure 1.2 Graphic and schematic overview of different cardiac molecular pathways leading to 
hypertrophic growth On the top of the figure are shown the diverse transmembrane receptors 
activated by multiple mechanical and neurohumoral stimuli (phospholipidic layers in yellow). 
Through G protein mediation or by direct phosphorylation, multiple intracellular phosphatases and 
kinases promote nuclear translocation of intermediate players and consequent regulation of gene 
transcription. Source: Bernardo 2010 Pharmacology & Therapeutics; 128:191-227 (Bernardo et al. 
2010). 	  
Mechanical stress and excessive deformation induced in neonatal and adult cardiomyocytes 
are sufficient to produce the hypertrophic phenotype (Sadoshima and Izumo 1997) through 
activation of integrins and G proteins, which are divided in small G proteins and 
heterotrimeric G proteins. The α- and β- subunits of integrins, heterodimeric transmembrane 
receptors present in cardiomyocytes, are one of the main mediators of this response by 
connecting the extracellular matrix (ECM) to the intracellular cytoskeleton (Ross and Borg 
2001). This interaction is fundamental to induce the intracellular response and the 
downstream signalling. Mice lacking the integrin-interacting molecule melusin failed to 
correctly respond to pressure overload stimulus resulting in a severely depressed cardiac 
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function (Brancaccio et al. 2006, Brancaccio et al. 2003). Integrins activation induces 
downstream effectors such as focal adhesion kinase (FAK) and small G proteins (GTPases) 
(Ross and Borg 2001). The role of small GTPases is to hydrolyse GTP to GDP and their 
activation is fundamental to mediate sarcomeric and cytoskeletal organization, and also to 
regulate membrane trafficking, cell division, survival and growth (Clerk and Sugden 2000). 
Small GTPases can be divided in 5 subfamilies (Ras, Rho, ADP ribosylation factors, Rab 
and Ran) and some of them (e.g. Rho kinase) were shown to be directly responsible for the 
development of pathological hypertrophy but not for the onset of swimming-induced 
physiological hypertrophy (Balakumar and Singh 2006). The Rho family (Rho A, Rac and 
Cdc42) specifically regulates cytoskeletal organization (Hoshijima et al. 1998), and 
activation of the Rho-associated kinase (ROCK) was shown to induce pathological 
hypertrophy in neonatal cardiomyocytes by enhancing the transcriptional activity of GATA4 
(Frey et al. 2004, Charron et al. 2001). Heterotrimeric G proteins are the second important 
subgroup of GTPases proteins together with the small GTPases. They are coupled to the 
transmembrane GPCRs and are responsible for the mediation of different types of cell stress 
leading to hypertrophy. Heterotrimeric G proteins consist of three subunits (α, β and γ) and 
the activation of GPCRs leads to exchange of GDP for GTP, dissociation of the Gα and Gβγ 
subunits and the consequent activation of intracellular signalling (Rockman, Koch and 
Lefkowitz 2002). In response to pressure-induced stress, specific hormones such as 
endothelin-1 (ET-1), angiotensin II (Ang II) and noradrenaline are released and bind to the 
correspondent cardiomyocytes GPCRs to induce cardiac growth (Yayama et al. 2004, Arai 
et al. 1995). The α subunits Gαq and Gα11 mediate cardiomyocyte hypertrophy upon 
stimulation of the Ang II, ET-1 and α-adrenergic GPCRs (Nicol, Frey and Olson 2000). 
Combined genetic ablation of both Gαq and Gα11 genes was associated with embryonic 
lethality due to myocardial hyperplasia, further confirming their importance in cardiac 
growth regulation (Nicol et al. 2000). Cardiac tissue has high expression of the GPCRs β1-
adrenergic receptor (Bristow et al. 1986), which is coupled to Gαs protein, while Gαi are 
activated upon stimulation of β2-adrenergic GPCRs. Gαi is upregulated in heart failure 
(Eschenhagen et al. 1992) and its overexpression resulted in development of 
cardiomyopathy (Redfern et al. 2000) (Figure 1.2). 
Pressure overload and post-infarction remodelling (Yoshida and Karmazyn 2000) lead to 
hypertrophy also by activating the cardiac Na+/H+-exchanger (NHE). As shown in different 
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animal models in vivo and in vitro (Yamazaki et al. 1998, Takewaki et al. 1995), increased 
NHE activity depletes the transmembrane Na+ gradient and promotes a rise of intracellular 
Ca2+ due to the activity of the Na+/Ca2+-exchanger (Cingolani and Camilion de Hurtado 
2002). This increase in Ca2+ levels stimulates several signalling cascades promoting cardiac 
hypertrophy, including protein kinase C (PKC), MAP kinases signalling and the 
calcineurin/NFAT pathway. Inhibition of NHE, which was shown to reduce cardiac 
hypertrophy after myocardial infarction in rats (Kusumoto et al. 2002) and to rescue several 
other models of cardiac hypertrophy (Engelhardt et al. 2002) represents a potential 
therapeutic treatment to block the development of pathological cardiac hypertrophy. 
Together with the biomechanical hypertrophic triggers described so far, it is also important 
to mention the mechanotransduction pathways mediated at the level of Z-disk in the 
sarcomeric structures of cardiomyocytes. Activation of the muscle LIM protein (MLP), 
which is directly connected to specific proteins at the Z-disk, is suggested to act as internal 
stretch sensor. Cardiac myocytes lacking MLP failed to respond to stretching in vitro and, 
more importantly, a human mutation of this protein was associated with dilated 
cardiomyopathy (Knoll et al. 2002). The role of MLP in these pathological conditions is to 
mediate the mechanotransduction stimulus leading to the activation of the calcineurin-
NFAT pathway (Heineke et al. 2005). 
Neurohumoral activation of hypertrophic signalling represents the second kind of 
hypertrophic trigger together with the mechanosensorial mechanisms described above. 
Neurohumoral pathways are induced by the release of hormones and vasodilators factors 
during cardiac pathology, which act as autocrine and paracrine mediators of hypertrophy. 
These neurohumoral factors include Ang II, ET-I and catecholamines (e.g. noradrenaline 
and adrenaline) and induce cardiac growth by activating GPCRs, gp130-linked receptors, 
and receptors with an intracellular tyrosine kinase or serine/threonine kinase domains 
(Bernardo et al. 2010). The GPCRs are the main player in cardiac function regulation and 
adaptation to pathological development after neurohumoral stimulation (Rockman et al. 
2002). The principal cardiac GPCRs are the adrenergic (α- and β- adrenergic receptors) and 
the muscarinic receptors, which are all coupled to GTP-binding proteins to mediate the 
hypertrophic intracellular signalling, as described above. GPCRs stimulation induces 
intracellular activation of PKC and its downstream signalling involving internal calcium 
mobilization. Ang II receptors, which are part of the GPCRs superfamily, respond to the 
24	  	  
cardiac renin-angiotensin axis and the system is stimulated upon increase in hemodynamic 
load (Yamazaki and Yazaki 1997). Ang II receptors activation was shown to induce 
hypertrophy in vitro and in mouse models mainly by induction of PKC activity, MAPK 
signalling, increased calcium levels and transactivation of epidermal growth factor receptor 
(EGFR) (Chan et al. 2006, Thomas et al. 2002). Another example of GPCRs is the ET-1 
receptor. The use of targeted antagonists for ET-1 receptors was shown to attenuate 
pathological hypertrophic responses in mice (Brunner et al. 2006). The last relevant class of 
GPCRs are the adrenergic receptors (ARs), which induce pathological hypertrophy via 
different downstream pathways upon activation by catecholamines. Heart failure patients 
show increased level of catecholamines and hyper-activation of ARs, which is beneficial 
only initially by increasing cardiac contractility. In long term, long exposure determines 
desensitization and downregulation of specific types of ARs leading to deterioration of 
cardiac function (Bristow 2000, Engelhardt et al. 1999). In the mammalian heart, there are 
six types of adrenergic receptors (i.e. three α1-ARs = α1a, α1b and α1d; three β receptors = 
β1/β2/β3) (Rockman et al. 2002) associated with different stages of pathological development. 
Importantly, high plasma levels of chatecholamines in animal models were found only 
during pathological and not during physiological hypertrophy (Perrino et al. 2006). 
Gp130-linked receptors represent another important example of neurohumoral activated 
receptors. They sense for several cytokines (i.e. interleukin 6 and 11), cardiotrophin-1 (CT-
1) and leukemia inhibitory factor (LIF) (Frey and Olson 2003). In physiological condition, 
cardiac knock-out of the gp130-linked receptor does not induce any evident phenotype 
(Hirota et al. 1999), but increased levels of cardiomyocyte apoptosis and extreme dilated 
cardiomyopathy were observed upon pressure overload. The gp130-linked receptor 
downstream signalling includes activation of MAPK and JAK/STAT pathways (Hoshijima 
and Chien 2002) with nuclear translocation of transcriptional factors and consequent up-
regulation of hypertrophic related genes (e.g. ANP) (Kunisada et al. 1998).  
The last two types of neurohumoral receptors are the receptors with a tyrosine kinase 
domain (RTKs), which are activated by growth factors such as IGF-1, Neuregulin and 
EGFR (Ullrich and Schlessinger 1990) and the receptors with intrinsic serine/threonine 
activity, with the extensively studied TGF-β receptors superfamily activated by activin, 
growth and differentiation factors (GDFs) and bone morphogenic proteins (BMPs). A 
specific description for IGF-1 receptors and downstream signalling is reported in Section 
1.7.2. 
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All the biomechanical and neurohumoral receptors described above begin a series of 
fundamental reactions of signal-transduction finally leading to expression of specific genes 
involved in the hypertrophic response. Several intracellular pathways have been reported as 
fundamental mediators of cardiac hypertrophy and the main players of these signalling 
cascades are promising potential targets for therapeutic intervention. A brief description of 
the main pathways, including MAPK, calcineurin-nuclear factor of activated T cells (NFAT) 
and phosphatidylinositol 3-kinase (PI3K)-AKT/protein kinase B (PKB), is presented in the 
next sections. 
 
1.4.2 Intracellular signalling cascades 
 A specific distinction exists between physiological and pathological hypertrophic signalling 
pathways activated upon stimulation of transmembrane receptors. A well characterized 
signalling cascade induced by post-natal growth and exercise is the IGF-1/PI3K(p110α)/Akt, 
while MAPK, calcineurin, PKC and PKD, and PI3K(p110γ) pathways are mediators of 
pathological hypertrophy (Bernardo et al. 2010). 
Stimulation of IGF-1 receptor by IGF-1 or different growth factors and ligands induces 
activation of the PI3K of the IA group (PI3Kα), which consists of a p85 or p55 regulatory 
subunits and a p110 (α, β, or δ) catalytic subunit (Oudit et al. 2004). On the other hand, 
stimulation of GPCRs can activate PI3K of the IB group (PI3Kγ) through Gβγ and the 
consequent recruitment of the catalytic subunit p110γ (Oudit et al. 2004). PI3K-p110α and 
p110γ are abundantly expressed in the heart, but their activation is associated with opposite 
hypertrophic effects. Expression of a constitutively active p110α in the heart produced 
physiological cardiac hypertrophy via activation of PDK1/Akt and inhibition of ERK 1/2 
translocation into the nucleus (Shioi et al. 2000). In contrast, knock-out mice for p110γ 
showed protection from pathological stimuli, with improved cardiac function and less 
fibrosis and hypertrophy compared to controls (Oudit et al. 2003). PI3K-p110γ contributes 
to cardiac dysfunction by direct binding to β-AR kinase 1 (β-ARK1) (Naga Prasad et al. 
2001), which leads to internalization and downregulation of β-ARs, a deleterious 
mechanisms for cardiac function (Perrino et al. 2007). An alternative cascade determined by 
PI3K-p110γ involves reduction of cardiomyocyte contractility by regulation of 
phosphodiesterases (PDEs) (Kerfant et al. 2007). Inhibition of PDEs improves contractility 
by increasing the levels of the second messenger cAMP, a fundamental regulator of 
intracellular Ca2+ (Osadchii 2007).  Both PI3K-p110γ and PI3K-p110α were shown to 
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activate Akt/PKB-GSK3β-mTOR pathway, as described in Section 1.7.4. 
The hypertrophic response induced upon activation of adrenergic receptors depends on 
which agonists and which class of receptors (α or β) are involved. Adrenaline, 
norepinephrine (NE) or isoproterenol stimulate β1 or β2 ARs, which couple to the 
heterotrimeric Gαs and Gαi proteins (Akhter et al. 1998) and interfere with the Ca2+ 
uptake/release from the sarcoplasmic reticulum (SR). Overexpression of β1-receptors in the 
heart initially increases contractile function by increasing the levels of Ca2+ released from 
the SR but eventually results in fibrosis and cardiomyocytes hypertrophy (Bisognano et al. 
2000, Engelhardt et al. 1999, Gaudin et al. 1995). Restoring SR Ca2+ content by decreasing 
β-ARs activity (Rockman et al. 1998) or by overexpressing the SR Ca2+ pump SERCA2a 
(del Monte et al. 2001, Schmidt et al. 2000) have been investigated and successfully tested 
as therapeutic approaches to block different types of hypertrophy and to avoid cardiac 
function deterioration leading to heart failure. 
On the other hand, activation of α-ARs, as well as Ang II and ET-1 receptors, leads to 
different intracellular cascades. Upon stimulation, these receptors couple to the 
heterotrimeric Gαq/α11 protein and to phospholipase Cβ (PLCβ), which activates PKC 
leading to production of inositol-1,4,5-triphosphate (IP3) (Rockman et al. 2002). IP3 then 
binds to its receptor on the endoplasmic reticulum and mobilizes the intracellular Ca2+ level, 
which leads to hypertrophy through calcineurin/NFAT pathway (Wilkins and Molkentin 
2004). Moreover, Gαq/α11 were shown also to be a primary activator of the MAPK 
signalling (Clerk and Sugden 1999). 
MAPK signalling cascades represent a fundamental connection between extra-cellular 
stimuli and the nucleus thanks to their activity of phosphorylation and regulation of multiple 
transcription factors inducing the reprogramming of cardiac gene expression. Three main 
MAPKs subfamilies have been described: p38-MAPKs, the extracellular signal-regulated 
kinases (ERKs), and the c-jun amino-terminal kinases (JNKs) (Widmann et al. 1999). 
MAPKs pathways are activated by signalling cascades originated by multiple stimulated 
trans-membrane receptors, including IGF-1 receptor, gp130 receptor, receptor 
serine/threonine kinase, and also by stretch stimuli (Sugden and Clerk 1998) and by cardiac 
pressure overload (Sadoshima et al. 1995, Yamazaki et al. 1993). MAPKs are activated by 
different upstream mediators, known as MAPK kinases (MAPKK or MEK). p38 kinase is 
phosphorylated by MKK3 and MKK6, whereas JNK is directly activated by MKK4 and 
MKK7. ERK1 and ERK2 phosphorylation is induced by MEK1 and MEK2, and MEK5 is 
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the upstream activator of ERK5 (Heineke and Molkentin 2006). In general, all three MAPKs 
subfamilies are involved in cardiac hypertrophy signalling, but their exact role has not been 
fully clarified. 
p38 is a critical component of stress response pathways (Bassi et al. 2008). Although it was 
found to be upregulated in cardiac tissue of ischemic heart disease patients (Cook, Sugden 
and Clerk 1999), experimental studies in transgenic and knockout mouse models have 
shown contradictory results. p38 activity is induced in pressure overload (Takeishi et al. 
2001) and ET-1/phenylephrine (Ueyama et al. 1999, Clerk, Michael and Sugden 1998) 
stimulation. The expression of activated MEK3 or MEK6, leading to substantial activation 
of p38, did not promote cardiac hypertrophy but was associated with a phenotype of 
increased fibrosis and reduced cardiac function in physiological condition (Liao et al. 2001). 
Cardiac-specific transgenic mice overexpressing dominant-negative MEK3, MEK6 or the 
p38α isoform produced an increase in cardiac growth at baseline and an exaggerated 
hypertrophic response was found in p38α dominant negative mice after pressure overload, a 
mechanism acting via calcineurin/NFAT pathway (Braz et al. 2003). Consistent with this 
results, animals overexpressing a dominant-negative p38β isoform did not produce cardiac 
hypertrophy under basal condition and did not show differences in the hypertrophic 
response after pressure overload compared to non-transgenic mice (Zhang et al. 2003). p38 
isoforms might have distinct roles depending on different regulations induced by MEK3 or 
MEK6 (Wang et al. 1998b), but in general p38 MAPKs might actually negatively regulate 
the hypertrophic response (Heineke and Molkentin 2006). Similarly to p38, controversial 
results and discrepancies between in vitro and in vivo studies have not elucidated the exact 
role of JNK in cardiac hypertrophy. Pathological hypertrophy stimulation by mechanical 
stretching (Komuro et al. 1996), ET-1 (Choukroun et al. 1998) or Ang II (Yano et al. 1998) 
induces rapid JNK phosphorylation. On the contrary, in vivo inhibition of JNK1/JNK2 
promoted cardiac growth in both physiological and pathological conditions (Haldeman et al. 
1999) and cardiac specific MEK4 knock-out mice showed increased hypertrophic gene 
transcription, cardiac growth and fibrosis compared to wild-type mice after aortic banding 
and β-AR stimulation (Liu et al. 2009). Targeting JNKs signalling for therapeutic purposes 
remains complicated, confirmed also by the finding that inhibition of the upstream MAPKK 
MEK1 was associated with augmented dilated cardiomyopathy and failed to prevent 
pressure-overload induced hypertrophy (Sadoshima et al. 2002). 
Among the three different MAPKs subfamilies, the only signalling that has been clearly 
28	  	  
associated with positive regulation of pathological hypertrophy is the ERK MAPKs pathway. 
A specificity of MEK5-ERK5 in promoting cardiac hypertrophy in vivo leading to dilated or 
eccentric growth has been established (Nicol et al. 2001). Similarly, specific stimulation of 
ERK1/2 in transgenic mice expressing activated MEK1 clearly promoted concentric 
hypertrophic with a substantial increase in heart weigh-to-body weight ratio (Bueno et al. 
2000). ERK1/2 seems to contribute to hypertrophy in two distinct ways by activating a 
range of cytosolic and nuclear substrates (Chen et al. 2001). Binding of GPCRs to Gαq 
protein promotes ERK1/2 activation which leads to phosphorylation of cytosolic targets, 
such as p90 ribosomal S6 kinase, and consequent increase in protein synthesis (Lorenz et al. 
2009). Moreover, interaction of the activated ERK1/2 complex with the Gβγ protein results 
in ERK1/2 auto phosphorylation and nuclear localization, where it phosphorylates specific 
targets leading to transcription of hypertrophic genes (Bernardo et al. 2010). 
Even though extensive investigation on MAPKs involvement in hypertrophy has shown a 
direct correlation between the two, it is still unclear how this knowledge could be translated 
into precise and effective therapeutic approaches. Identification of defined signalling 
pathways directly responsible for the onset of pathological hypertrophy has been difficult 
not only for the multiple roles played by single proteins involved and for the adverse 
synergies among parallel pathways, but also because of the molecular complexity behind the 
hypertrophic physio-pathology. 
Different MAPKs were shown to interact with one of the central pro-hypertrophic signalling 
pathways, the calcineurin/NFAT signalling (Braz et al. 2003, Liang et al. 2003, Antos et al. 
2002). Calcineurin is a Ca2+ dependent serine/threonine protein-phosphatase consisting of a 
catalytic A subunit (CnA) and a regulatory B subunit (CnB). Although different genes 
encode for CnA and CnB, only CnAα, CnAβ and CnB1 are expressed in the mammalian 
heart (Klee, Ren and Wang 1998). The activation of calcineurin is directly associated with 
changes in intracellular calcium levels and elevation of cytoplasmic calcium concentration 
promotes association of calmodulin with calcineurin, with consequent activation of the latter 
(Olson and Williams 2000). Activated calcineurin dephosphorylates transcription factors of 
the nuclear factor of activated T-cells (NFAT) family, which are translocated to the nucleus 
and induce expression of pro-hypertrophic genes (Wilkins and Molkentin 2004). Calcineurin 
and NFAT are both necessary and sufficient to induce cardiac hypertrophy (Molkentin et al. 
1998) and calcineurin was found to be activated in hypertrophied and failing human hearts 
(Haq et al. 2001). Moreover, several pharmacological (Molkentin et al. 1998) and genetic 
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(Bueno et al. 2002, Wilkins et al. 2002, Zou et al. 2001) animal models have shown that 
calcineurin/NFAT signalling is coupled to pathological cardiac growth. Genetic inhibition of 
molecules that associate with and inhibit calcineurin catalytic subunit (e.g. Cain/Cabin) 
resulted in attenuation of isoproterenol and pressure overload induced cardiac hypertrophy 
in vivo (De Windt et al. 2001). All together, these observations on calcineurin/NFAT 
association with hypertrophy make this pathway an attractive therapeutic target for heart 
failure prevention and treatment. However, the therapeutic potential of inhibiting directly 
this pathway to block onset of hypertrophy of the heart is complicated because of the 
toxicity, lack of tissue specificity and in general the side effects associated with the available 
therapies and drugs (Heineke and Molkentin 2006). 
 
1.4.3 The hypertrophic phenotype 
All the above signalling cascades are part of complex changes in the cellular metabolism, 
structure and function, and molecular and biochemical features of the heart. These changes 
are associated with further stimulation of hypertrophic pathways, becoming at the same time 
cause and consequence of the cardiac growth. Specific differences have been identified 
between physiological and pathological hypertrophy. For example, substrate utilization 
differentiated physiological from pathological growth, with enhanced fatty acid utilization 
and glucose oxidation in the former, and decreased fatty acid oxidation and increased 
glycolysis in the latter (Lehman and Kelly 2002). These differences are useful markers that 
identify the onset of distinct types of cardiac growth, with a general profile that resembles 
that of the fetal heart typical of pathological growth. A specific gene expression signature 
identifies pathological hypertrophy, with a shift of myosin isoforms from the α myosin 
heavy chain (α-MHC) to the slow β-myosin isoform (β-MHC) in order to allow the heart to 
produce tension at a lower cost by reaching it more slowly (Lowes et al. 1997). Furthermore, 
ventricular production of natriuretic peptides (atrial, ANP and brain, BNP), which represents 
an helpful mechanism to increase sodium excretion and to support adaptation to heart failure, 
is typical of pathological growth (Yoshimura, Yasue and Ogawa 2001). Decrease of 
SERCA2a and increase of alpha SA are also well recognized markers of pathological 
hypertrophy. Main structural changes are identified in myocytes apoptosis and necrosis and 
the following replacement by excessive collagen and fibrosis is a major contributor of the 
transition from hypertrophy to heart failure as a consequence of reduced capillary density 
and increased distances for oxygen diffusion (Gunasinghe and Spinale 2004). 
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1.5 From hypertrophy to heart failure 
Pathological cardiac hypertrophy and the associated cardiac remodelling ultimately result in 
heart failure, a cardiac condition in which the heart is unable to pump blood at a sufficient 
rate to meet the demands of the body. There are two major types of heart failure: one is 
associated with abnormal heart filling (sometimes called diastolic heart failure or heart 
failure with preserved ejection fraction), and the other is associated with abnormal heart 
emptying (also called systolic heart failure or heart failure with reduced ejection fraction) 
(Krum and Teerlink 2011). Pathological hypertrophy is an independent risk of heart failure 
(Weber and Brilla 1991), but this can occur also as consequence of genetic predisposition or 
infectious disease (Ginsberg and Parrillo 2013). However, most patients who develop heart 
failure have had a prior injury or stress on the heart that caused the heart to weaken. 
 
1.6 Treatment of the injured heart 
Since the first successful heart transplantation in 1967, more than 55000 patients worldwide 
underwent cardiac replacement (www.ishlt.org). Heart transplant is a valuable solution to 
treat the growing number of patients with heart failure, but the very low availability of organ 
donors indicates that this surgical intervention will continue to play a very limited 
quantitative role in the treatment of heart failure patients (Deng 2002, Hosenpud et al. 2000). 
Invasive interventional cardiology is widely used for the treatment of ischemic disease. 
Coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI) 
are the main options used to revascularize the injured heart, and their application has 
improved the prognosis for patients with ischemia and arrhythmias (Deb et al. 2013). 
Nevertheless, many patients are still left with significant morbidity despite those therapies 
(Wolfram and Donahue 2013). Several strategies for the treatment of ischemic disease to 
block cardiac remodelling and prevent heart failure have been explored, including 
implantable devices (Park et al. 2012) as well as cell-based (Ptaszek et al. 2012) gene-based 
(French et al. 1994) and pharmacological approaches (Krum and Teerlink 2011). An 
overview of these therapeutical strategies is presented in the next paragraphs. 
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1.6.1 Cardiac assist devices 
Heart failure patients with an advanced state of pathology that are not eligible or not able to 
wait for cardiac transplantation are often treated with mechanical assist devices which offer 
an alternative life-saving therapy (Givertz 2011). Multiple mechanical devices have been 
designed and tested, from total artificial hearts (de Mol and Lahpor 2013) to ventricular 
assist devices. Implantable ventricular assist device (LVAD) have the purpose of unloading 
the failing heart to maintain the correct blood flow to vital organs, and are usually employed 
as a bridge to recovery from heart failure, bridge to heart transplantation, or destination 
therapy for patients with higher age or concomitant end-organ dysfunction (Kinugawa 2011). 
Among the beneficial effects associated with LVAD implantation are reduced 
cardiomyocyte hypertrophy, improved coronary artery perfusion, decreased chronic 
ischemia and lowered ventricular wall tension (Klotz, Jan Danser and Burkhoff 2008, 
Burkhoff, Klotz and Mancini 2006). LVADs have been successful also when implanted in 
children as a bridge-to-transplantation, showing no differences in long-term quality of life 
assessment in patients pre-treated with LVAD compared to patients that underwent directly 
heart transplantation (Ezon et al. 2013). LVADs offer improvement of quality of life in heart 
failure patients and reduce the need for urgent cardiac transplantation (John et al. 2010), but 
are not free of complications. Obstacles include bleeding, stroke caused by blood cloth 
leaving the pump (Boyle et al. 2013) and right ventricular failure after LVAD implantation 
(Meineri, Van Rensburg and Vegas 2012). Overall, 80% to 90% of patients are alive after 
one year from transplantation, and 60% to 70% after two years from surgery. 
Pharmacological treatment in support of LVAD implanted patients has shown controversial 
results. Post-operative administration of the β–adrenergic agonist clenbuterol did not 
improve cardiac function but increased skeletal muscle mass and strength (George et al. 
2006), whereas preoperative treatment of patients with lower doses of β-blockers improved 
the outcome in LVAD implantation as a bridge to recovery (Imamura et al. 2013). Although 
LVADs represent a significant temporary alternative to heart transplantation and are 
effective in certain patient populations, they impose significant lifestyle restrictions and 
require continuous care. 
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1.6.2 Cell and gene therapy 
The mechanisms of action of cell-based therapies remain opaque, and many details with 
regard to characterization, quality control and cell delivery remain to be worked out. 
However, regenerative cell therapy has garnered much attention recently, as preliminary 
results seem promising (Bolli et al. 2011). Prior to widespread of cell therapy for the 
treatment of cardiac remodelling and heart failure, substantial research has to be conducted 
on finding the most effective cell population/pool of cell populations and on defining the 
side effects induced by cell delivery. Cell therapy is mainly employed to improve the 
contractile component (i.e. active component) of the heart, which is lost after ischemic 
injury, via transplantation and engraftment of cells in order to replenish the mechanical 
force in the cardiac muscle.  On the other hand, gene-based therapies have the objective of 
enhancing the function of the heart by stimulating vessel formation, reducing fibrotic tissue 
and modulating deleterious molecular pathways (i.e. passive component). As discussed in 
the next sections, both approaches have been employed in patients, and preliminary clinical 
trials have shown controversial results. 
 
1.6.3 Exogenous and endogenous cell-based treatments 
Different strategies have been investigated to improve cardiac function in the injured 
myocardium by stimulating the endogenous ability of the heart to proliferate or by 
delivering cells from an heterologous source to replace lost cardiomyocytes. The 
mammalian heart has been traditionally considered as a terminally differentiated organ with 
no endogenous regeneration, but recent studies using different methodologies have revealed 
that heart cells are generated in the adult heart. The frequency of generation and the source 
of new heart cells are not yet known and this critical aspect of the regenerative mechanism 
is currently under investigation. Using radiocarbon dating of human post-mortem cardiac 
tissue, Bergmann and colleagues showed that cardiomyocytes turnover in the adult heart 
occurs at a rate of 1% per year (Bergmann et al. 2009), while another study showed a much 
higher frequency (Kajstura et al. 2010). The source of newly generated cardiac myocytes is 
also under debate and it has been attributed both to the division of existing myocytes 
(Kikuchi et al. 2010) or to progenitor cells originated in the heart (Beltrami et al. 2003). A 
recent study from Senyo and colleagues employed a sophisticated methodology combining 
ion microscopy and mass spectrometry to show that new cardiomyocytes are formed at a 
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rate of 0.76% per year from pre-existing cardiomyocytes and that cardiac stem cells (CSCs) 
do not have a significant function in this process (Senyo et al. 2013). Nevertheless, CSCs, 
together with mesenchymal stem cells (MSCs), represent a potential endogenous source of 
cells for the replacement of lost cardiomyocytes. The notion that CSCs have the ability to 
differentiate into multiple cardiac lineages has been discussed during the last ten years with 
evidences showing that this cell population has specific stem cell-related markers such as 
Sca-1 (Oh et al. 2003) and c-kit (Beltrami et al. 2003) and is able to contribute to 
regenerative processes in the heart. Isolation and injection of CSCs in post-MI models 
produced cardiomyocytes, vascular smooth muscle cells and endothelial cells and some 
studies reported improved cardiac function (Messina et al. 2004, Beltrami et al. 2003). 
Notably, Messina and colleagues showed that upon isolation from human biopsies, these 
cells first self-organized into spherical clusters termed ‘cardiospheres’ and then engrafted 
and improved heart function when injected into post-MI SCID mouse hearts. Delivery of a 
consistent, controlled and reproducible cell product is one of the main challenges in cardiac 
cell therapy. Because of the wide inter-patient variability in cell functionality, the 
employment of cells originated from different sources may result in significant differences 
in their therapeutic potential (Menasche 2011). MSCs have gained an increased interest 
because they may be employed to reduce the inter-patient variability by preparing a master 
bank with an off-the-shelf cell product readily available. Moreover, they have an immune 
privilege attributed to their lack of major histocompatibility complex and the prevention of 
T cell responses (Poncelet et al. 2007, Uccelli, Pistoia and Moretta 2007). On the other hand, 
MSCs have the limitation of being unable to convert into structurally and functionally 
integrated new cardiomyocytes (Caplan and Dennis 2006). 
The employment of endogenous cell populations to stimulate regeneration and cardiac repair 
has the advantage of avoiding an immune response in patients. However, the limited 
efficiency of these cells to differentiate into cardiac myocytes has encouraged researchers to 
look also in different directions. Multiple candidate cell types of exogenous origin have 
been employed in preclinical models to repair the injured heart, including embryonic stem 
cells (ESCs) (Dai et al. 2007, Laflamme et al. 2007), induced pluripotent stem cells (iPSCs) 
(van Laake et al. 2010), neonatal cardiomyocytes (Reffelmann et al. 2003, Muller-Ehmsen 
et al. 2002a) and skeletal myoblasts (Menasche et al. 2008). All these alternatives present 
positive and negative characteristics for the application in cardiac cell therapy. ESCs are 
derived from the developing embryo and retain the capacity of self-renewal, they can be 
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easily expanded in vitro and differentiated in cardiomyocytes (Huber et al. 2007, Murry and 
Keller 2008). Delivery of cardiomyocytes derived from ESCs in infarcted tissues was shown 
to improve cardiac function and create new cardiac tissue even in big animal models (Kehat 
et al. 2004). However, the unlimited differentiation potential of ESCs can be dangerous for 
the application in cell therapy because of the possible formation of tumours (Nussbaum et al. 
2007) and moreover ESCs have the ethical complication of being obtained from discarded 
embryos after in vitro fertilization. One of the multiple cell lines derived from ESCs is the 
P19 embryonal-carcinoma cell line (P19EC). In particular, the P19 Clone 6 (P19CL6) 
derived from P19EC has shown higher levels of differentiation into cardiac myocytes 
(Habara-Ohkubo 1996), with cardiac structural proteins, spontaneous beating and functional 
calcium channels (van der Heyden and Defize 2003), proposing them as one of the potential 
candidate for cardiac cell therapy. P19EC are easy to maintain and manipulate in culture 
compared to embryonic cells and they don’t require a feeder layer to grow. However, these 
cells were originated from teratocarcinoma, which limits considerably their potential 
application for therapeutical therapies. 
A revolutionary technique was introduced by the Yamanaka group seven years ago by trans-
differentiation of adult somatic cells into pluripotent embryonic-like stem cells (iPSCs) 
(Takahashi et al. 2007). iPSCs closely resemble ESCs and can be differentiated in any 
desired cell type, including functional cardiomyocytes, as previously demonstrated by using 
cells derived from mouse (Narazaki et al. 2008) and humans (Zhang et al. 2009). Deriving 
iPSCs has no ethical issues and has the clear advantage that each patient may be able to 
obtain iPSCs from his own somatic cells, avoiding any potential immune response when 
used in cell therapy. Inducible PSCs have a significant therapeutic potential for cell-based 
treatment of cardiovascular disorders, but given the early stages of development of this 
technology, significant obstacles limits its application. Their pluripotent state is a double-
edged sword and the genetic abnormalities found in iPSCs, the high costs and the long time 
required to derive and characterize these cells from any patients preclude short-term clinical 
applicability (Malliaras and Marban 2011, Freund and Mummery 2009). So far, a consistent 
and relevant use of iPSCs has been made for disease modelling, with cell lines created from 
patients affected by heritable diseases, and for the screening of cardiovascular drugs 
(Sinnecker et al. 2012). 
The first cells to be employed in clinical tests for heart regeneration were skeletal myoblasts 
(SKMs). The SEISMIC trial showed that even though no differences were found in Left 
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Ventricular Ejection Fraction in patents with or without SKMs injection, the presence of 
these cells increased exercise tolerance in heart failure patients (Duckers et al. 2011). On the 
other hand, the MAGIC trial exhibited lack of efficacy and was interrupted before the 
planned conclusion (Menasche et al. 2008). SKMs have a natural contractile phenotype and 
are resistant to ischemia, but the lack of gap junctions create a block of electrical signal 
conduction when these cells are transplanted and group together, favouring ventricular 
arrhythmias (Abraham et al. 2005). A last cell population interesting for their plasticity and 
natural differentiation to adult cardiomyocytes is represented by neonatal cardiomyocytes. 
Since Porrello and colleagues (Porrello et al. 2011) in 2011 demonstrated that the heart has a 
transient regenerative potential that is lost after the seventh postnatal day, great efforts are 
being made to understand how undifferentiated neonatal cardiomyocytes, in combination 
with other components such as the immune system, may be responsible for the regenerative 
mechanisms observed. Neonatal cardiomyocytes have different electrophysiological 
characteristics compared to adult cardiomyocytes as a consequence of the different 
morphology and their smaller size compared to adult cardiomyocytes leads to electrical 
coupling issues (Poindexter et al. 2001). Even before Porrello’s study, cardiac 
transplantation of neonatal cardiomyocytes was investigated and showed induced neo-
angiogenesis when transplanted into the infarcted areas of a rat heart (Reffelmann et al. 
2003). In a recent publication from Sato and colleagues, morphological and functional 
analyses were performed on neonatal rat cardiomyocytes isolated at different time-points 
after they were previously transplanted into the adult rat heart. Results from this study 
showed that implanted cardiomyocytes take 4 or more weeks to approach maturity and that 
this process is proportional to the normal growth mechanisms in the host heart (Sato et al. 
2010). 
Difficulties related to cardiac cell therapy include low cell retention and engraftment, 
immune response of the host tissue and tumorigenicity of the transplanted cells. The amount 
of cells lost after delivery as a consequence of washout through the venous system or tissue 
compression during the heartbeats is a persistent obstacle. In experimental animals and in 
humans, only 10% of the injected cells is retained in the heart regardless of the cell type or 
delivery route (Blocklet et al. 2006, Hofmann et al. 2005, Hou et al. 2005, Aicher et al. 
2003). Approximately 90% of the successfully-retained cells die within the first week 
(Muller-Ehmsen et al. 2002b), making the process even more complicated (Menasche 2011). 
A critical aspect of cardiac cell therapy is represented by the delivery routes. Intracoronary 
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infusion, direct intramyocardial injection and intravenous infusion are the most diffused 
techniques and are employed in experimental models depending on the type of injury to be 
treated. Intracoronary delivery into recanalized infarct-related arteries is safe but most cells 
are washed away in the blood flow, while the intravenous approach is less invasive but is 
hampered by trapping of cells in the natural filter of lungs and kidney (Freyman et al. 2006). 
Intramyocardial cell injection results in a better retention in the host tissue compared to the 
other methodologies, but it is more appropriate for patients with chronic ischemic 
cardiomyopathies instead of patients with freshly infarcted myocardium that have an higher 
risk of tissue perforation (Malliaras and Marban 2011). An additional challenge in cell 
therapy is the understanding the mechanisms of cell delivery to acutely inflamed or sclerotic 
tissues, which both represent hostile environments resulting in poor survival and only 
modest integration of donor cells. Moreover, enhancement of transplanted cells survival 
should also be considered when optimizing a cell-based approach, given that pre-treatment 
of cells (Zhang et al. 2001) or incorporation in three-dimensional scaffolds (Zhang et al. 
2008) and pharmacological preconditioning (Niagara et al. 2007) can improve the effects of 
cell transplantation. From the evidences reported in the literature it is clear that cardiac cell 
therapy has a remarkable potential for the treatment of heart disease, but at the actual state 
of the research we are far behind from understanding which cell population is the most 
appropriate for this purpose. Although no consensus has yet emerged, the ideal cell type 
should i) not have adverse effects, ii) improve heart function, iii) be able to stimulate 
regeneration of functional cardiac muscle and vessels, iv) be deliverable by minimally-
invasive clinical methods and v) be tolerated by the immune system (Malliaras and Marban 
2011). 
Intense research is still needed to clarify whether employment of cells for the treatment of 
CVD can be really beneficial, also considering the side effects of this approach. Moreover, 
multiple studies using cell-based methodologies show that the beneficial effects induced by 
the treatment are determined by factors released from the injected cells more than by the 
mechanical support offered by the engrafted cells (Gnecchi et al. 2008, Gnecchi et al. 2006). 
Thus, understanding which paracrine/autocrine factors have relevant functions in cardiac 
physiopathology is imperative for the development of future targeted therapies. 
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1.6.4 Gene therapy 
Sequencing information from the human genome and the development of new gene transfer 
vectors have given researchers the tools to target specific genes and molecular pathways. 
Delivery of RNA molecules, DNA or genes to human cells or organs has been employed to 
improve clinical phenotypes in patients with different CVDs, including coronary artery 
disease, heart failure and arrhythmias (Wolfram and Donahue 2013, Lyon et al. 2008). 
Although the first trial in the 1990s failed to show positive results (Rosenberg et al. 1990), 
the technological advancements in delivery vectors and a better understanding of the 
therapeutic targets have encouraged further preclinical studies. In general, the prerequisites 
of success of any gene target therapy have been defined as safety, expression, specificity 
and efficacy, and the new therapies are designed by taking into account these criteria 
(Scimia, Gumpert and Koch 2013). So far, multiple gene delivery methods have been 
developed and tested using viral vectors (i.e. retroviruses, adenoviruses and adeno-
associated viruses), which have been shown to be safer and more efficient, and non-viral-
based vectors (e.g. naked DNA or DNA complexed with liposomes) (Wolfram and Donahue 
2013, Lin et al. 1990). Targets of gene therapies so far optimized vary depending on the 
cardiac disease of interest. A consequence of coronary artery disease is the obstruction of 
blood flow that blocks correct oxygenation of cardiac tissue. An angiogenic therapy 
involving administration of genes for angiogenic growth factors has been tested to augment 
collateral vessel formation in the injured heart. The factors employed include VEGF, FGF, 
platelet growth factor and hypoxia-inducible factor (Jin et al. 2012, Kilian et al. 2010, Yang 
et al. 2010, Heinl-Green et al. 2005) and some of them (e.g. VEGF) have been associated 
with improved myocardial function and perfusion in rabbit (Takeshita et al. 1994). Clinical 
trials for heart failure treatment were shown to be safe and the results detailing therapeutic 
efficacy are under investigation (Pleger et al. 2013). These include testing the 
sarcoendoplasmic reticulum calcium-ATPase 2a (SERCA2a), SDF-1 and adenylated 
cyclase-6 (AC6). SERCA2a is a key protein in calcium handling in cardiomyocytes and a 
decrease in its expression is a well-recognized marker of pathological hypertrophy and heart 
failure progression (Bers, Eisner and Valdivia 2003). In the CUPID trial, patients with 
advanced heart failure administered with high doses of adeno-associated virus encoding 
SERCA2a showed increased functional status, reversal of ventricular remodelling and in 
general a decrease in heart failure symptoms (Zsebo et al. 2013, Jessup et al. 2011). The 
potential adverse consequences of gene therapy are taken into account as a priority, and the 
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possible arrhythmogenic effects of SERCA2a were tested in different preclinical models 
demonstrating, on the contrary, beneficial reduction in ventricular arrhythmias (Sikkel et al. 
2013). In conclusion, gene therapy has produced promising results in preclinical and clinical 
studies for the treatment of coronary artery diseases, heart failure and cardiac arrhythmia. 
Combination of gene and cell therapy has the interesting feature of targeting reduced 
myocardial size following ischemic disease and depressed cardiac function related to heart 
failure. Nevertheless, safety and side effects of each of these approaches combined together 
or employed individually must be carefully investigated before proceeding to clinical studies. 
 
1.6.5 Pharmacological therapy for heart failure treatment 
On-going efforts are being made to characterize the molecular and cellular mechanisms 
playing important roles in the remodelling processes following loss of muscle due to 
myocardial infarction or after pressure overload due to hypertension. Understanding these 
pathways is fundamental to develop alternative drug therapies and pharmacological 
approaches aimed at producing bioavailable agents. Pharmacological therapies for the 
treatment of various cardiovascular disorders have been widely investigated because of the 
advantages of being industrially produced and distributed and easily administered to patients 
compared to gene and cell therapies. As previously discussed, heart failure can manifest 
with reduced left ventricular ejection fraction or with preserved ejection fraction. The 
employment of the same drug to treat both types of heart failure has shown opposite effects. 
For example, by contrast with heart failure with reduced ejection fraction for which statins 
have no benefits (Tavazzi et al. 2008, Kjekshus et al. 2007), another study has shown a 
remodelling benefit in patients with heart failure with preserved ejection fraction treated 
with the same agents (Fukuta et al. 2005). The complexity of cardiac remodelling leading to 
heart failure includes changes in gene expression in cardiomyocytes, qualitative and 
quantitative changes in cell types and composition of the extracellular matrix and changes in 
the geometry of the left ventricle (Sun 2009, Sutton and Sharpe 2000). Cardiac 
pathophysiology must be fully understood in order to design efficient pharmacological 
treatments. In the past 40 years, drug therapies for heart failure have typically involved 
angiotensin-converting enzyme (ACE) inhibitors (Levy and Bellou 2013), β-adrenergic 
blockers (Barrese and Taglialatela 2013), mineralocorticoid-receptor antagonists (van den 
Berg et al. 2013), and angiotensin-receptor blockers (Valluri, Struthers and Lang 2013) 
(Chatterjee 1996). New approaches designed to modulate specific intracellular signalling 
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pathways or gene networks (e.g. antagonists of microRNAs) have the potential to expand on 
existing pharmacological strategies (Shah and Mann 2011). Further contribution to the 
understanding of these mechanisms is given by gene network modelling and systems 
biology which attempt to understand how the interaction of several components of the cell 
(i.e. genome, transcriptome, proteome and metabolome) governs the pathobiology of cardiac 
remodelling leading to heart failure (Shah and Mann 2011). 
While each of the therapeutical approaches described so far in the previous section have 
been proven effective to some degree in clinical trials, cardiac remodelling, pathological 
hypertrophy and heart failure in particular remain critical problems with significant unmet 
needs. Cell therapy seems to be beneficial for the replacement of lost cardiac tissue, while 
factors secreted by the transplanted cells, introduced via gene therapy or released by the 
native tissue have the fundamental role of modulating the molecular signalling involved in 
cardiac protection after the injury. Thus, identification and characterization of molecules 
released during pathological stimulation which are able to counteract cardiac function 
deterioration will be fundamental to understand the regulation of reparative and regenerative 
mechanisms in the heart. In this context, specific interest has been placed on the insulin-like 
growth factor-1 (IGF-1) and its isoforms for their protective role in cardiac and skeletal 
muscle observed in multiple pathological scenarios. The following paragraphs will introduce 
important results and observations on the role of IGF-1 isoforms in cardiac physiopathology. 
 
1.7 The Insulin-like growth factor-1 family 
IGF-1 plays a pivotal role in development and growth and is involved in multiple 
mechanisms such as cell survival, proliferation and metabolism. The IGF-1/growth hormone 
(IGF-1/GH) axis is essential for the transition of fetal to neonatal existence (Li et al. 1996). 
Absence of IGF-1 in humans is characterized by poor prenatal growth (Fu et al. 2009) and 
an experimental mouse model of IGF-1 knock-out showed growth retardation in utero with a 
35% decrease in weight and postnatal deficiency of peri-pubertal growth (Baker et al. 1993). 
IGF-1 is a peptide hormone acting as a systemic growth factor mainly produced by the liver 
(75%) (Schwander et al. 1983). However, IGF-1 is also produced by extra-hepatic tissues, 
including muscle, brain, and kidney where it functions in an autocrine/paracrine manner 
(Barton 2006a). Depletion of IGF-1 production from the liver in an experimental set-up was 
not associated with particular growth deficiency on the rest of the body (Yakar et al. 1999), 
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suggesting that locally secreted IGF-1 efficiently compensates the lack of circulating IGF-1. 
	  
1.7.1 IGF-1 isoforms and post-translational modifications 
The IGF-1 gene, spanning 90 kb of genomic DNA, is highly conserved among vertebrates 
and invertebrates (Longo and Finch 2003) and its sequence has been determined in humans, 
rat, chicken, sheep and other species (Lund 1998, Adamo et al. 1993). The rodent IGF-1 has 
6 exons (Figure 1.3) and alternative splicing occurring at 3’ and 5’ generates multiple 
transcripts each encoding a different pre-pro-IGF-1 protein (Bell et al. 1986). Four different 
pre-pro-peptides combine a signal peptide of class I or II (SP1 and SP2) at the 5’ and a 
carboxy-terminal extension peptide at the 3’, consisting of an Ea peptide or an Eb peptide.  
Transcripts containing exon 1 are referred to as Class 1 whereas those containing exon 2 are 
referred to as Class 2 transcripts (Barton 2006a). The pre-pro IGF-1 polypeptides undergo 
posttranscriptional proteolytic processing and cleavage to remove the SP and the E-peptides 
giving rise to the same mature 70-amino acid IGF-1 peptide, which is conserved across 
species (Shavlakadze et al. 2005) and contains four domains (B-C-A-D), named for their 
similarity to insulin. Considered that all pre-pro-peptides undergo processing to produce the 
same mature IGF-1 protein, the specific roles of the E peptides in IGF-1 biology remain 
unclear. It is important to notice that not all carboxy-terminal E peptides are cleaved prior to 
IGF-1 secretion. IGF-1Ea, for example, was shown to be secreted by fibroblasts (Wilson et 
al. 2001, Conover et al. 1993). In combination with the finding that the Ea peptide is not 
required for the secretion of IGF-1 (Duguay et al. 1997), these observations suggest that the 
E peptides may confer specific bioactivity and a different function to the IGF-1 protein. 
Moreover, the alternative splicing giving rise to the IGF-1Ea propeptide creates two N-
glycosylation sites on the protein which may be critical for the different function of this 
isoform. Conversely, these sites are absent from the IGF-1Eb propeptide (Shimatsu and 
Rotwein 1987). In support of this hypothesis, a recent publication (Hede et al. 2012) has 
shown that Ea and Eb peptides control IGF-1 bioavailability by conferring to IGF-1 
increased affinity to the extracellular matrix. In term of expression patterns, the IGF-1Ea 
peptide is highly expressed in neonatal tissues and in the adult liver, and it is activated in 




Figure 1.3 The IGF-1 rat gene and the four isoforms The IGF-1 gene is characterized by six 
different exons (top) and alternative splicing can produce four different isoforms (bottom). Both 
class I (distinguished for the SP1) and Class II (SP2) isoforms can have either the Ea or Eb extension 
peptides at the carboxy-terminal (white). In black is shown the IGF-1 core region conserved in all 
isoforms. 
	  
1.7.2 IGF-1 receptor and downstream signalling 
The plasma membrane IGF-1 receptor (IGF-1R) belongs to the receptor tyrosine kinase 
(RTK) family and mediates the downstream signalling upon binding of the different IGF-1 
isoforms. It is the main mediator of IGF-1 cardiac bioactivity, as also shown in the 
experimental model of IGF-1R knock out mouse dying shortly thereafter birth and showing 
a phenotype of organ hypoplasia (Baker et al. 1993, Liu et al. 1993). Both α and β subunits 
of the IGF-1R have been detected in neonatal and adult cardiomyocytes (Ibarra et al. 2013), 
suggesting the pivotal role of the IGF-1 pathways in both postnatal and adult development 
and growth. Even though the different IGF-1 isoforms are sensed by the same IGF-1R 
(Holthuizen et al. 1991), it has been demonstrated that multiple downstream signalling can 
be induced depending on which isoform activates the receptor (Troncoso et al. In press, 
Stavropoulou et al. 2009). As shown in Figure 1.4, the circulating IGF-1 binds the IGF-1R 
which phosphorylates the insulin receptor substrate 1 (IRS1) (LeRoith 1997). Activated 
IRS1 interacts with specific cytoplasmic proteins containing SH2 domains, such as PI3K 
(Dhand et al. 1994), which results in sarcolemmal recruitment of the kinases Akt/PKB and 
activation of the phosphoinositide-dependent kinase-1 (PDK-1) (Cantley 2002). Akt/PKB 
enhance protein synthesis by activating mTOR (Cantley 2002), which in turn leads to 
ribosomal biosynthesis and protein translation though p70S6 kinase-1 (p70/S6K). Akt 
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induces protein synthesis also through inhibition of the glycogen synthase kinase-3β 
(GSK3β), which is an inhibitor of the NFAT transcription factors. PI3Kα activation is 
fundamental for the documented transduction of IGF-1 effects, including protein and 
glycogen synthesis (Mendez et al. 1996), inhibition of apoptosis (Dudek et al. 1997) and 
cardiomyocytes contractility (Coolican et al. 1997). A second canonical IGF-1 pathway in 
cardiomyocytes leads to phosphorylation and nuclear translocation of ERK by Ras, which is 
activated upon IGF-1R stimulation. Interestingly, an alternative pathway suggests that IGF-
1R may also be distributed in perinuclear T tubules. This alternative perinuclear IGF-1R 
localization would allow not only direct communication between cell surface and the 
nuclear signalling machinery, but also a specific association of IGF-1 pathways with Ca2+ 
signalling in the heart (Troncoso et al. In press, Bers 2013). In support of this hypothesis it 
was demonstrated that treatment with IGF-1 promoted cell contractility by increasing the 
activity of the L-type Ca2+ in cardiomyocytes (Sun et al. 2006). 
In the context of IGF-1 isoforms pathways, a specific different downstream cardiac 
signalling has been described for the IGF-1Ea isoform (Santini et al. 2007) (Figure 1.4B). 
Transgenic mice overexpressing IGF-1Ea in cardiac myocytes did not show activation of the 
canonical Akt/mTOR/p70S6K phosphorylation cascade, but led to protein synthesis and 
promoted cell survival mechanisms after injury through PDK1 and the serum and 
glucocorticoid regulated kinase-1 (SGK-1), as discussed in the next section (Santini 2007) 
(Figure 1.4B). SGK-1, which in this study was found to specifically interact with PDK-1 
under IGF-1Ea stimulation, has been associated with cardiomyocytes survival and apoptotic 
response (Aoyama et al. 2005, Firestone, Giampaolo and O'Keeffe 2003) and recently with 
angiogenesis and wound healing in the adult heart (Zarrinpashneh et al. 2013). 	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Figure 1.4 IGF-1 and IGF-1Ea signalling cascades IGF-1 signalling pathway (A) is mediated by 
transmembrane IGF-1 receptor and the downstream activation of AKT/mTOR induces 
differentiation, physiological growth and multiple mechanisms (Troncoso et al. In press). Cardiac 
overexpression of IGF-1Ea propeptide (B, right) induces phosphorylation of IGF-1 receptor and 
hyper-phosphorylation of PDK-1/SGK-1 leading to cardioprotection in a murine model of MI 
(Santini et al. 2007). 
 
The IGF-1R has multiple levels of complexity and depending on several variables such as 
location, quality of stimulus and by which IGF-1 isoforms it is bound, multiple intracellular 
signalling and responses can be induced. 
 
1.7.3 IGF-1 in muscle physio-pathology 
IGF-1 and the IGF-1Ea and IGF-1Eb isoforms have been implicated in different 
mechanisms of skeletal and cardiac protection and regeneration after injury. In skeletal 
muscle, IGF-1 released locally by myofibers in response to increased loading or muscle 
damage (Adams 2002) is important for the regenerative processes by acting in an 
autocrine/paracrine fashion. Mechanical stimulation of myotubes in vitro increases IGF-1Ea 
gene expression immediately after 1 hour (Juffer et al. 2014), which corresponds to an 
increase after exercise in vivo (Goldspink 2005). IGF-1Ea overexpression in skeletal muscle 
of adult mice determined retained proliferative response to muscle injury typical of younger 
animals (Musaro et al. 2001), and was associated with recruitment of bone marrow cells to 
the injury site and stimulation of repair mechanisms (Musaro 2005). This mechanism was 
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associated with expression of the calcineurin variant CnAβ1 (Lara-Pezzi et al. 2007). In 
humans, IGF-1 co-localizes with satellite cells during the first 72 hours post-exercise (Grubb 
et al. 2013) and it was suggested that the IGF-1Ea and IGF-1Eb levels increase at different 
time-points after exercise stimulation (Bickel et al. 2003, Hameed et al. 2003, Brahm et al. 
1997), even if not many data are available on the expression kinetics of the IGF-1 isoforms. 
In the context of cardiac protection, different experimental models have proven the positive 
effects of both circulating and locally produced IGF-1 (e.g. IGF-Ea and IGF-1Eb). Reduced 
circulating IGF-1 levels correlates with an increased risk of coronary artery disease 
(Spallarossa et al. 1996) and with the development of cardiac vasculopathy in patients 
receiving cardiac transplantation (Aharinejad et al. 2012). Furthermore, human patients with 
acute myocardial infarction presented markedly reduced IGF-1 levels during the early phase 
of the pathology (Conti et al. 2001). In experimental animal models, transgenic mice 
overexpressing IGF-1 were able to inhibit the oxidative stress in the heart induced by Ang II 
and to block the development of diabetic cardiomyopathy by attenuating p53 function and 
apoptosis (Kajstura et al. 2001). Negative regulation of apoptosis by IGF-1 was 
demonstrated by showing that administration of recombinant IGF-1 on cardiomyocytes 
during apoptotic condition attenuated caspase 3 and Bax activation (Wang et al. 1998a). 
IGF-1 mediates also important effects on cardiac progenitor cells by promoting c-Kit+ cells 
proliferation and survival in vitro (Kawaguchi et al. 2010, Linke et al. 2005) and activation 
in vivo (Davis et al. 2006). Despite the beneficial effects promoted on the cardiovascular 
system by circulating IGF-1, the therapeutic potential of systemic IGF-1 delivery remains 
problematic for its severe adverse effects related to increased growth stimulation and risk of 
cancer (Gallagher and LeRoith 2010). Overexpression of IGF-1 complementary DNA 
(cDNA) under the control of α-skeletal actin promoter (i.e. transgenic expression in cardiac 
and skeletal muscle) led to cardiac hypertrophy associated with enhanced cardiac systolic 
function up to 10 weeks, but the general function was then depressed by 52 weeks 
(Delaughter et al. 1999). IGF-1 is also associated with downregulation of anti-hypertrophic 
micro RNAs, confirming its contribution to cardiac hypertrophy (Hua, Zhang and Ren 2012). 
Transportation and storage of circulating IGF-1 in serum and tissues is mediated by the IGF-
binding proteins (IGFBPs). Although IGFBPs have high affinity for IGF-1 and are 
fundamental for controlling its bioactivity (Elis et al. 2011), their function is not sufficient to 
block potentially deleterious side effects of the growth factor on distal organs. On the other 
hand, expression of the local IGF-1 isoforms IGF-1Ea and IGF-1Eb acting in an 
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autocrine/paracrine manner may represents an effective physiological mechanism to avoid 
the adverse effects induced by excessive levels of circulating IGF-1. Overexpression of the 
IGF-1Eb isoform in adult cardiomyocytes attenuated the increase in cardiac weight, 
ventricular dilation and diastolic wall stress after coronary ligation, mainly due to prevention 
of cardiac cell death (Li et al. 1997). IGF-1Eb was also shown to preserve cardiac 
contractility and insulin signalling in a model of diet-induced cardiomyopathy (Zhang et al. 
2012). Importantly, the IGF-1Ea isoform has shown particularly interesting results in 
different models of cardiac injury. In wild-type rats, coronary artery ligation was followed 
by endogenous IGF-1Ea mRNA and protein levels increase during the 4-to-8 weeks post-
infarction period (Stavropoulou et al. 2009), which is known to correspond to the timing of 
cardiac repair and remodelling after MI (Blankesteijn et al. 2001, Lee et al. 1999). Notably, 
this upregulation in local IGF-1Ea was not accompanied by an increase in circulating IGF-1 
in the serum, once again supporting the hypothesis of a local action of IGF-1Ea. Upon 
induced myocardial infarction and cardiotoxin injection (Santini et al. 2007), overexpression 
of IGF-1Ea in cardiomyocytes of adult mice restored cardiac function and blocked the 
formation of fibrotic tissue through an alternative pathway involving PDK-1/SGK-1, rather 
than through the Akt cascades typical of others IGF-1 isoforms (Rommel et al. 2001) 
(Figure 1.5). These results were associated with reduced levels of the pro-inflammatory 
cytokines interleukin-6 (IL-6) and IL1β and increased anti-inflammatory IL10 levels 
compared to wild-type mice that underwent same pathological stimuli. Importantly, IGF-
1Ea also increased survival molecular pathways and stimulated proliferation in the area of 
damage, furthermore supporting its protective effects in the heart.  	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Figure 1.5 IGF-1Ea protects the cardiac tissue from injury Overexpression of IGF-1Ea in mouse 
cardiomyocytes correlated with reduction of fibrotic tissue, downregulation of pro-inflammatory 
cytokines and improvement of cardiac function compared with wild-type mice 2 months after 
permanent LAD artery ligation. wt = wild-type; tg = MHC-IGF-1Ea transgenic; RV and LV= right 
and left ventricles; RA and LA = right and left atria (Santini et al. 2007). 
 
Additional studies have also demonstrated that IGF-1Ea stimulates endothelial progenitors 
cells mobilization from the bone marrow to improve vascularization of the infarct border 
region (Santini et al. 2011) and protects the cardiac tissue from oxidative stress and lethality 
induced by paraquat (Vinciguerra et al. 2012). 
	  
1.7.4 IGF-1 and cardiac hypertrophy 
The IGF-1/PI3Kα/Akt pathway is the best characterized signalling cascade for mediating 
physiological hypertrophy of the heart. Expression of a constitutively active PI3Kα in the 
heart produced physiological hypertrophy with preserved ventricular function (McMullen et 
al. 2003), whereas overexpression of a dominant-negative form of PI3Kα inhibited postnatal 
cardiac growth and physiological growth following exercise in mice (McMullen et al. 2003). 
Activation of PI3Kα by IGF-1 and the consequent increase in Akt activity were shown to be 
fundamental only in exercise- and postnatal-induced growth of the heart and not during 
pathological pressure overload or aortic binding growth (McMullen et al. 2003, McMullen 
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and Jay 2007). While substantial evidences support the benefits of activating the IGF-
1/PI3Kα for clinical purposes, this pathway has numerous other deleterious effects in 
various cell types, such as allowing cancer cells to bypass normal growth-limiting controls 
(McMullen and Jay 2007). These observations confirm that circulating IGF-1 is mainly 
implicated in physiological but not pathological hypertrophy. On the other hand, positive 
results were associated with the locally acting IGF-1 isoforms in protecting the heart from 
pathological growth. The IGF-Ea overexpressing transgenic mice described in the previous 
section (Santini et al. 2007) showed a 20% increase in concentric left ventricular 
hypertrophy in baseline conditions. This cardiac hypertrophy was considered physiological 
and no particular functional changes were detected in the adult mice. In an in vitro 
experiment, isolation of neonatal cardiomyocytes from IGF-1Ea transgenic mice and in vitro 
stimulation with the pathological hypertrophic inducer Ang II showed that IGF-1Ea 
suppressed the onset of hypertrophy by blocking the fetal gene reprogramming (Figure 1.6) 
and by inhibiting cell hypertrophy through mediation of the NAD+-dependent deacetylase 
SirT1 (Vinciguerra et al. 2010). Conversely, addition of the recombinant version of the 
circulating IGF-1 on wild-type cardiomyocytes did not protect from Ang II. 	  
	  
Figure 1.6 IGF-1Ea protects cardiomyocytes from Ang II in vitro Neonatal cardiomyocytes 
overexpressing IGF-1Ea under the α-MHC promoter were isolated from 1-to-2 old mice and cultured 
in vitro. The effects of 24 hours treatment with Ang II were inhibited and the fetal gene 
reprogramming expected during pathological hypertrophy was blocked by IGF-1Ea. alpha MHC = 
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α-myosin heavy chain; beta MHC = β-myosin heavy chain; BNP = brain natriuretic peptide; 
alphaSA = α-skeletal actin; ANP = atrial natriuretic peptide; SERCA2 = sarcoendoplasmic reticulum 
calcium-ATPase 2a. 	  
Furthermore, in a different in vivo model where the IGF-1Ea mice was crossed with a mouse 
model of dilated cardiomyopathy (IGF-1Ea/SRF) demonstrated that local IGF-1Ea 
expression significantly lengthened the lifespan of the mice, delayed the process leading to 
dilated cardiomyopathy and improved cardiac function. Interestingly, these processes were 
associated with beneficial modulation of the hypertrophic gene program (Touvron et al. 
2012). 
The experimental observations reported above clearly suggest that the IGF-1 isoforms and 
IGF-1Ea in particular present several advantages in protecting the heart from ischemia, 
oxidative stress and pathological remodelling post-MI compared to the circulating IGF-1. 
The therapeutic potential of IGF-1Ea may rely on its ability to act locally in the area of 
administration with no systemic adverse effects, contrarily to the circulating version of IGF-
1, but so far no studies have been published on the therapeutic effects of direct 
intramyocardial IGF-1Ea delivery.  	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Hypothesis and Aims 
	  
Hypothesis 
Overexpression of IGF-1Ea in skeletal myocytes stimulates regeneration of skeletal muscle 
and fusion with satellite cells to replace lost tissue after induced local injury. In the heart, 
IGF-1Ea overexpression in cardiomyocytes blocks inflammation, deposition of collagen and 
improves ejection fraction in mice two months after myocardial infarction. Notably, the 
presence of the Ea propeptide at the carboxy-terminal of IGF-1 was shown to increase its 
affinity for the extracellular matrix, suggesting that the Ea propeptide facilitates IGF-1 
retention in the area of secretion. 
Considering the above observations, the hypothesis behind this thesis was that local delivery 
of IGF-1Ea mediated by direct intra-myocardial cell transplantation blocks pathological 
hypertrophy in multiple pathological scenarios. 
 
Aims 
1. To analyze the potential of combining IGF-1Ea and P19 embryonal carcinoma cells 
in protecting the heart from the hypertrophic remodelling induced by LAD ligation 
in mouse. 
2. To optimize a reproducible murine model of non-invasive cardiac hypertrophy and 
establish a model of HEK 293 cells cardiac transplantation to deliver different IGF-1 
isoforms. 
3. To determine whether IGF-1Ea plays a beneficial role in blocking the onset of 
pathological hypertrophy induced by isoproterenol. 
4. To understand whether a specific function in blocking pathological hypertrophy is 
given to the IGF-1 peptide by the presence of the Ea extension peptide. 
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2 Materials and Methods 
	  
2.1 Myocardial infarction and P19-cell mediated delivery of IGF-1Ea 
This first section describes the Material and Methods employed to produce some of the 
preliminary results reported in Chapter 3 from the experiments of P19-GFP cell-mediated 
cardiac delivery of IGF-1Ea after myocardial infarction performed in FVB wild-type mice. 
Briefly, IGF-1Ea rat cDNA was cloned in a pLenti4/TO/V5-DEST lentivirus 
(pLenti4/TO/V5-DEST-IGF-1Ea, Invitrogen, Carlsbad, CA, USA - #K4965-00) by 
Bhawana Poudel in the Rosenthal laboratory using a pENTR™/Directional TOPO® Cloning 
Kit (Invitrogen, Carlsbad, CA, USA - #K2400-20). As described by the manufacturer 
(www.lifetechnologies.com/uk/en/home/references/protocols/proteins-expression-isolation-
and-analysis/protein-expression-protocol/lentiviral-expression-systems.html), IGF-1Ea 
expression from the pLenti4/TO/V5-DEST-IGF-1Ea lentivirus is inhibited by Tet repressor 
molecules (TetR) expressed by a second lentiviral vector (pLenti/TR). TetR inhibiting 
mechanism can be reversed by adding tetracycline in combination with pLenti4/TO/V5-
DEST-IGF-1Ea and pLenti/TR lentiviruses. 
Pluripotent P19 embryonal carcinoma cells (P19-GFP) were transduced with both 
lentiviruses in order to obtain regulated expression of IGF-1Ea. P19-GFP/IGF-1Ea (group of 
interest) and P19-GFP (control group) were differentiated to adult cardiomyocytes (P19-
GFP/IGF-1Ea CM and P19-GFP CM) by adding 1% DMSO in the cell culture medium. 
After differentiation, 106 cardiomyocytes were collected by FACS sorting and injected in 5 
different areas of the left ventricle in FVB wild type mice. Immediately before cell injection, 
mice were subjected to ligation of the coronary artery to induce acute MI. Half an hour 
before ligation and cell injection, immunosuppressive drug FK506 was administered i.p. at 
5mg/kg/day concentration to facilitate cell engraftment. Ligation of the LCA was performed 
as described in the literature (Tarnavski et al. 2004). 
This model was used to determine the effects of cell transplantation and IGF-1Ea delivery in 
an acute model of MI. A total of 4 groups of mice were included in these experiments. A 
first control group did not receive LCA ligation or cardiac cell transplantation, a second 
group underwent LCA ligation and vehicle (i.e. phosphate buffer saline - PBS) 
intramyocardial injection, a third group received LCA ligation and transplantation of IGF-
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1Ea transduced cells (P19-GFP/IGF-1Ea CM) and a last group was subjected to LCA 
ligation and transplantation of un-transduced cells (P19-GFP CM). Functional cardiac 
analysis was performed using a Vevo 2100 (Visual Sonics) machine after two months. 
Morphological and molecular analyses were performed as described in the following 
sections. 
 
2.2 IGF-1Ea lentivirus cardiac delivery 
2.2.1 Lentiviruses production, purification and in vivo delivery 
Experiments of direct IGF-1Ea viral delivery into the mouse heart were performed and the 
results are reported in Section 4.2. The pLenti4/TO/V5-DEST-IGF-1Ea and pLenti/TR 
lentiviruses were produced by transfecting HEK 293 cells with a mix of Lipofectamine™ 
2000 (Lipofectamine; Invitrogen, Carlsbad, CA, USA - #11668027) and lentiviral DNA (3:1 
Lipofectamine to DNA ratio) in Opti-MEM® I Reduced Serum Medium (Invitrogen, 
Carlsbad, CA, USA - #31985-062). HEK 293 cells were transfected overnight at 37°C and 
after 24 hours the medium was replaced with complete culture medium and sodium pyruvate 
(i.e. DMEM containing 10% FBS, 2mM L-glutamine, 0.1 mM MEM Non-essential Amino 
Acids, 1% penicillin/streptomycin, and 1 mM MEM Sodium Pyruvate). Viral supernatants 
containing viral particles were harvested 48 hours after transfection and purified. To obtain 
a higher titer, ultracentrifugation step is usually performed but this also concentrates 
unwanted material toxic to target cells, such as cellular debris, membrane fragments, and 
denaturated proteins derived from culture media of virus-producing cells. To reduce these 
undesirable effects and increase gene transfer efficiency, purification of pLenti4/TO/V5-
DEST-IGF-1Ea and pLenti/TR supernatants was performed using the ViraBind™ Lentivirus 
Concentration and Purification Kit (Cambridge Biosciences, Cambridge, UK - #VPK-091), 
which does not involve ultracentrifugation, as described by the manufacturer. Stock 
lentiviruses were stored at -80°C until needed for cardiac injection. 
Expression vector (pLenti4/TO/V5-DEST-IGF-1Ea) and Tet repressor construct (pLenti/TR) 
titering was performed by transducing HT1080 cells (Manassas, VA, USA - #ATCC® CCL-
121™) with 10-fold serial dilutions of lentiviruses (i.e. from 10-2 to 10-6) and 6µg/mL of 
Polybrene (Sigma-Aldrich, Gillingham, UK, #H9268) to maximise transduction. Medium 
containing viral particles was replaced with complete culture medium after 24 hours and 
after 48 hours HT1080 cells transduced with pLenti4/TO/V5-DEST-IGF-1Ea or pLenti/TR 
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construct were treated with 1 mg/mL Zeocin or 0.01 mg/mL Blasticidin respectively. After 9 
days, cells were stained with crystal violet (Sigma-Aldrich, Gillingham, UK, #C0775) for 10 
minutes at RT and lentiviruses titer was determined by counting violet positive colonies. 
Purified pLenti4/TO/V5-DEST-IGF-1Ea and pLenti/TR were used to infect cardiac cells in 
vivo by direct injection in the left ventricular muscle. The surgical procedure to expose the 
heart for the injection is described below in Section 2.6.2. Wild type mice on the FVB 
background received intra-ventricular injection of 2x104 transducing units of 
pLenti4/TO/V5-DEST-IGF-1Ea and 4.4x104 transducing units of pLenti/TR (1:2 ratio) in 50 
µL 1X PBS over 5 injections of 10 µL each. Tetracycline (Invitrogen, Carlsbad, CA, USA - 
#q100-19) was delivered via drinking water at a concentration of 2 mg/mL, starting 24 hours 
post-surgery, to allow IGF-1Ea induced expression. Control mice were injected with 50 µL 
of 1X PBS or with same amount of lentiviruses without tetracycline in the drinking water. 
After 5 days from intra-ventricular injection, the heart was excised and RNA was extracted 
as described in Section 2.7.1 below. 
 
2.3 IGF-1Ea DNA plasmid production 
2.3.1 Amplification of IGF-1Ea cDNA 
Rat IGF-1Ea cDNA was obtained from a pGEM entry vector (Promega, UK) previously 
cloned in Nadia Rosenthal’s laboratory. The gene of interest IGF-1Ea was amplified by 
PCR (forward primer 5’ – GCG ATG GGG AAA ATC AGC AGT CTT – 3’ and reverse 
primer 5’ – CCT CCT ACA TTC TGT AGG TCT TGT – 3’) using reagents and conditions 
described in Table 2.1. 
Table 2.1 Recipes and thermocycler conditions for IGF-1Ea PCR 
REAGENT                             
(final concentration) 
AMOUNT (µL)                          




DNA template (100ng) 
MgCl2 (2mM) 
PCR Buffer (1X) 
dNTPs (1mM) 
PCR primers (1µM) 
Sterile water 








5 min at 94°C 
30X              1 min at 94°C 
                      1 min at 52°C 
                      20 sec at 72°C 





DNA amplification was performed using the cycling parameters shown above. A 10 minutes 
extension step at 72°C was included after the last cycle to ensure that the PCR product was 
full-length and 3’ adenylated, feature required for subsequent cloning. Agarose gel 
electrophoresis (2%) was used to run the PCR product at 100 Volts to verify that a single, 
discrete band of the correct size was present. 
 
2.3.2 IGF-1Ea cloning and IGF-1Stop vector 
IGF-1Ea cDNA was subsequently cloned into destination vector pcDNA™ 3.3-TOPO® TA 
(pcDNA™ 3.3 vector, Invitrogen, Carlsbad, CA, USA - #K8300-01, Figure 2.1 A). The 
IGF-1Stop cDNA cloned in a piRES2-EGFP plasmid (piRES2-IGF-1Stop, BD Biosciences, 
Clontech, UK, Figure 2.1 B) (Hede et al. 2012).	  	  
	  
Figure 2.1 Schematic representation of plasmids containing IGF-1Ea and IGF-1Stop (A) The 
pcDNATM3.3 – TOPO plasmid was used to clone the IGF-1Ea cDNA and transfect HEK 293 cells. 
(B) The pIRES2-EGFP used to clone IGF-1Stop carries a DNA sequence for GFP as reporter gene. 
 
2.3.3 Ligation of vector and IGF-1Ea insert 
The cloning reaction was performed including salt (200 mM NaCl, 10mM MgCl2) to 
increase the number of transformants 2- to 3-fold, in a total volume of 6 µL. Two µL of 
IGF-1Ea PCR product were mixed with 1 µL of salt solution, 2 µL of sterile water and 1 µL 
of pcDNA™ 3.3 vector. The reaction was mixed, incubated 5 minutes at RT and then placed 
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in ice. A separate cloning reaction with a control PCR product expressing LacZα fragment 
was included to assess cloning efficiency. 
DH5α™ One Shot® TOP10 Chemically Competent Escherichia coli (E. coli, Invitrogen, 
Carlsbad, CA, USA - #C404010) were transformed with the IGF-1Ea-pcDNA™ 3.3 vector, 
the LacZα control plasmid or the empty vector. An additional control with the pUC19 
plasmid was used to check transformation efficiency of the E. coli competent cells. Two µL 
of each cloning reaction were added to a 50 µL E. coli vial, mixed gently and incubated for 
30 minutes on ice. Heat-shock was then performed for 30 seconds in a water bath previously 
equilibrated at 42°C. On ice, 250 µL of room temperature S.O.C. Medium (Invitrogen, 
Carlsbad, CA, USA - #15544-034) were added aseptically to each vial and the mix was 
shacked horizontally at 200 rpm in a 37°C shaking incubator for 1 hour to allow cell growth. 
After incubation, two different volumes of 50 µL and 150 µL from the IGF-1Ea-pcDNA™ 
3.3 transformation reaction were spread on pre-warmed selective LB agar plates containing 
0.1 mg/mL ampicillin. For the pUC19 control, 10 µL of the transformation reaction were 
plated. To control cloning and transformation procedures, clones transformed with the 
LacZα control plasmid or with the empty vector were tested for β-galactose activity assay. 
Forty µL (40 mg/mL in dimethylformamide) X-Gal solution were pipetted onto the LB plate, 
spread evenly and let dry for 15 minutes. Two volumes of 25 µL and 50 µL from each of the 
two controls were plated on X-Gal LB plates. All plates were inverted and incubated 
overnight at 37°C. 
The following morning, 20 individual colonies were randomly picked from the plates and 
cultured overnight in 4 mL Luria-broth (LB) (Sigma-Aldrich, Gillingham, UK, #L1900) 
containing 0.05 mg/mL ampicillin in a shaker at 250 rpm at 37°C. After 16 hours, 850 µL 
from each tube containing overnight grown bacteria were added to 150 µL of sterile glycerol 
and kept at -80 for long-term storage. The remaining LB medium containing clones was 
used to isolate plasmid DNA using a QIAprep Spin Miniprep kit (Miniprep, QIAGEN, 
Crawley, UK, #27104) as described in Section 2.4.1. 
 
 
2.4 Extraction of plasmid DNA and identification of positive clones 
 
2.4.1 Plasmid DNA isolation from bacterial cells: Miniprep 
Overnight grown bacterial cells were centrifuged at 8,000 rpm for 3 minutes at RT and the 
pellet was re-suspended in 250 µL of Buffer P1 by vortexing until no cell clumps remained. 
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RNase A (0.1 mg/mL final concentration) and LyseBlue (1:1000) were added to Buffer P1 
before use to ensure RNA digestion and to provide visual identification of optimum buffer 
mixing, respectively. To allow bacterial cell lysis, 250 µL of Buffer P2 containing 
NaOH/SDS were added and the tube was gently inverted 4-6 times to avoid shearing of 
genomic DNA. SDS solubilizes the phospholipid and protein components of the cell 
membrane, leading to lysis and release of the cell content while the alkaline conditions 
denaturate the chromosomal and plasmid DNAs. This reaction was performed for a 
maximum of 5 minutes to allow maximum release of plasmid DNA without release of 
chromosomal DNA. The lysate was neutralized in the following step by addition of 350 µL 
of Buffer N3 and its high salt concentration causes denaturated proteins, chromosomal DNA, 
cellular debris, and SDS to precipitate, while the smaller plasmid DNA renaturates correctly 
and stays in solution. The solution was then centrifuged for 10 min at 13,000 rpm, resulting 
in a compact white pellet. The supernatant containing the plasmid DNA was applied to a 
QIAprep spin column and centrifuged for 1 minute at 13,000 rpm. The flow-through was 
discarded and the column was washed with 750 µL of buffer PE and centrifuged twice for 1 
min at full speed to remove residual wash buffer. In the final step of the protocol, the 
QIAprep column was placed in a clean 1.5 mL microcentrifuge tube and the plasmid DNA 
was eluted by adding 50 µL of sterile water directly onto the centre of the column. After 1 
minute of incubation at RT, column and tube were centrifuged at 13,000 rpm for 1 minute 
and after measuring plasmid DNA concentration as describe below, this was stored at -20°C 
until required. 
 
2.4.2 DNA quantification 
DNA concentration was quantified using standard spectrophotometry methodology. Stock 
DNA was diluted 1:100 (v/v) in Tris-EDTA buffer, pH 8.0 (TE, 100 mM tris-HCl, 10 mM 
EDTA) and placed in a UVette plastic cuvettes (Eppendorf, Cambridge, UK, #0030 
106.318). The photospectrometer (BioPhotometer plus, Eppendorf, Cambridge, UK) was 




2.4.3 Confirmation of correct IGF-1Ea cloning 
In order to verify the correct cloning and orientation of IGF-1Ea insert into the pcDNA™ 
3.3 vector, isolated plasmid DNA was digested using ApaI (New England BioLabs, Ipswitch, 
MA, USA, #R0114S) and SmaI (Roche Applied Science, Burgess Hill, UK, #10656348001) 
endonucleases (Table 2.2).	  
 
Table 2.2 Restriction digestion of IGF-1Ea plasmid 
REAGENT 
AMOUNT (µL) 



















*NEBuffer 4: 50mM PotassiuM Acetate, 20mM Tris-acetate, 
10mM Magnesium Acetate and 1mM DTT (pH 7.9 at 25°C). 	  
Following endonuclease digestion, the 20µL of plasmid were mixed with 6X loading buffer 
(New England Bio Labs, Ipswich, MA, USA, #B7021S) loaded on a 2% agarose gel 
containing 0.5 µg/mL ethidium bromide (Sigma-Aldrich, Gillingham, UK, #E1510) for 
visualization of DNA. A 1 Kb plus DNA ladder™ (Invitrogen, Carlsbad, CA, USA, # 
10787018) was included for identification of DNA band size. All samples were 
electrophoresed for 2 hours at 110 V. The expected and observed bands for the correct IGF-
1Ea insert cloning were 1237 bp and 4623 bp. Isolated plasmid DNA from positive clones 
was sent to the Imperial College Genomics Laboratory core facility for sequencing using the  
TOPO® CMV forward (5’-CGCAAATGGGCGGTAGGCGTG-3’) and reverse (5’-
CTTCCGTGTTTCAGTTAGC-3’) primers provided in the pcDNA™ 3.3-TOPO® kit. 
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2.4.4 Amplification of selected clones and plasmid isolation: Maxiprep 
Once confirmed by DNA sequencing that the correct IGF-1Ea DNA sequence had been 
cloned into the pcDNA™ 3.3 vector, an aliquot from the correspondent bacterial stock 
stored at -80°C was inoculated in 200 mL of LB containing 0.05 mg/mL ampicillin. The 
beaker with the inoculated bacteria was kept overnight at 37°C in a shaker at 250 rpm to 
allow bacteria to grow. After 16-18 hours, DNA extraction and purification was performed 
using the QIAGEN Plasmid Plus Maxi Kit (Maxiprep, QIAGEN, Crawley, UK, #12262) 
with modifications from the protocol provided by the manufacturer. 
Briefly, after centrifugation of bacteria at 10,000 rpm for 15 min at 4°C, the bacterial pellet 
was homogenously resuspended in 10 mL of lysis Buffer P1 supplemented with 0.1 mg/mL 
RNase A and 10 mL of lysis Buffer P2. After 5 minutes incubation at RT, 10 mL of pre-
chilled neutralization Buffer P3 were added and the tube was mixed vigorously. To remove 
the precipitated material containing genomic DNA, proteins, cell debris and potassium 
dodecyl sulphate, the lysate was centrifuged at 10,000 rpm for 15 min at 4°C. The 
supernatant lysate containing plasmid DNA was then poured into a QIAGEN-tip 500 
previously equilibrated with 10 mL of Buffer QBT. Once the lysate entered the QIAGEN-
tip 500, this was washed twice with 30 mL of Buffer QC and the plasmid DNA was eluted 
in a glass tube with 15 mL of Buffer QF. In the last part of the protocol the plasmid DNA 
was precipitated with 10.5 mL of isopropanol and resuspended in 500 µL of sterile water 
after centrifugation at 21,000 rpm for 30 min at 4°C. The tube was added with 500 µL of 
phenol-chloroform (1:1) to isolate DNA and after centrifugation at 10,000 rpm for 10 min at 
4°C the upper aqueous phase containing plasmid DNA was transferred to a clean tube. To 
remove precipitated salt and make DNA easier to re-dissolve, 900 µL of 100% ethanol and 
50 µL of sodium acetate were added to precipitate DNA. In the last step, the precipitated 
plasmid DNA was centrifuged at 13,000 rpm for 20 min at 4°C and resuspended in 200 µL 
of sterile water. Plasmid DNA concentration was measured using spectrophotometry and the 
sample was stored at -20°C until next use. 
 
2.5 HEK 293 cell transfection 
2.5.1 Culture and transfection with IGF-1Ea and IGF-1Stop plasmids 
Human Embryonic Kidney 293 (HEK 293) cells were grown in adherent culture in complete 
medium containing Dulbecco’s Modified Eagle’s Medium with 4500 mg/L glucose (DMEM, 
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Sigma-Aldrich, Gillingham, UK - #D5795), 10% Fetal Bovine Serum (FBS, Sigma-Aldrich, 
Gillingham, UK - #F4135), 0.1 mM MEM Non-essential Amino Acids (Invitrogen, 
Carlsbad, CA, USA - #111140-068), 100 units/mL penicillin and 0.1 mg/mL streptomycin 
(p/s, Sigma-Aldrich, Gillingham, UK - #P4333), and 1 mM MEM Sodium Pyruvate 
(Invitrogen, Carlsbad, CA, USA - #11360088). HEK 293 cells were maintained at 37°C in a 
5% CO2 (v/v) humidified incubator. Every 72 hours cells were washed twice with 1X PBS, 
displaced by adding trypsin-EDTA solution (Sigma-Aldrich, Gillingham - UK #T3924) to 
the dish culture for 5 minutes at 37°C in a 5% CO2 incubator, and split 1:3 onto 60 mm cell 
culture dishes (VWR, Lutterworth, UK - #734-0068). Cells were sub-cultured for not more 
than 20 passages. Cells were allowed to grow until they reached 80-90% confluence and 
transfected with IGF-1Ea-pcDNA™ 3.3 or piRES2-IGF-1Stop vectors and Lipofectamine. 
Briefly, 8 µg of plasmid and 20 µL of Lipofectamine were added to sterile tube 500 µL of 
Opti-MEM® medium and incubated at RT. In a separate sterile tube, 20 µL of 
Lipofectamine were added to 500 µL of Opti-MEM® medium. After 5 minutes, the tubes 
were combined, gently mixed and incubated at RT for 20 minutes. The total medium of 1 
mL was added to the cell culture dish containing HEK 293 cells and this was incubated for 
24-36 hours at 37°C in a 5% CO2 humidified incubator to allow transient transfection with 
IGF-1Ea-pcDNA™ 3.3 or piRES2-IGF-1Stop vectors and secretion of the respective IGF-
1Ea and IGF-Stop proteins in the cell culture medium. A control cell culture dish was added 
with Lipofectamine and Opti-MEM® only. After 30 hours from transfection, an aliquot of 
cell culture medium was stored at -80°C for immunoblotting analysis as described in Section 
2.7.5 and assessment of protein secretion. 
 
2.5.2 Preparation of cells for in vivo injection 
In order to allow direct cell tracking after injection in vivo, HEK 293 cells untransfected and 
HEK 293 cells transfected with IGF-1Ea-pcDNA™ 3.3 or piRES2-IGF-1Stop plasmids 
were labelled with 4’,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, Gillingham, UK - 
#D9545) (Chen et al. 2011). Cells were incubated for 2 hours with 50 µg/mL DAPI, washed 
twice with 1X PBS, trypsinised for 5 minutes, and centrifuged at 1,000 rpm for 5 minutes at 
RT. Cells were counted using a haemocytometer Neubauer chamber (VWR, Lutterworth, 
UK, #HECH47112). Cells were diluted 1:5 with complete medium to facilitate counting, 
and 10 µL were added to a tube containing 10 µL of filtered Trypan Blue (Sigma-Aldrich, 
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Gillingham, UK, # T8154). Cell number was counted in four squares and calculation was 
performed using the following formula: 
 
Total number of 
cells in 4 squares 
 




After counting, HEK 293 cells were divided in aliquots containing 3 x 106 cells in 5 mL of 
complete culture medium and incubated at 37°C in a 5% CO2. Before injection, cells were 
centrifuged at 1,000 rpm for 5 minutes at RT and re-suspended at a concentration of 1 x 106 
cells/50µL of sterile 1X PBS ready for intra-ventricular injection as described in Section 
2.6.2 below. 
 
2.6 In vivo model of pathological cardiac hypertrophy and cell 
transplantation 
2.6.1 NOD.SCID immunodepleted mice 
Male NOD.CB17 Prkdscid/JHjuHSD mice (NOD.SCID) of 8-9 weeks of age were 
purchased from Harlan laboratories (Harlan Laboratories, Horst, The Netherland). 
NOD.SCID mice have an autosomal recessive, single nucleotide polymorphism within 
Prkdc gene on chromosome 16 that causes a severe combined immunodeficiency affecting 
the immune response, in particular T and B cell development, providing an efficient model 
for cell transplantation experiments.  Mice were kept in a temperature controlled flexible 
film isolator (Harlan Laboratories, Horst, The Netherland) at 26°C with 12 hours/12 hours 
light-dark cycles to satisfy their isolation and containment requirements. All animal studies 
were performed in compliance with international (Directive 2010/63/EU of the European 
Parliament) and national (UK Home Office, Act 1986) regulations. 
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2.6.2 Intra-myocardial cell transplantation 
In vivo cell transplantation in mice, rats, rabbits, pigs and dogs has been constantly 
employed to deliver different type of cells, from embryonal and adult stem cells to adult 
differentiated cardiomyocytes, and to release factors in the target tissue (Templin et al. 
2012, Alshammary et al. 2013). HEK 293 cells are highly secretory cells and therefore were 
chosen as a vehicle for IGF-1Ea or IGF-1Stop delivery and to constantly release the proteins 
in the myocardial tissue. The entire protocol for cell transplantation was published on the 
Journal of Visualized Experiments in 2013 (Poggioli et al. In press) 
Under a laminar flow hood to maintain sterility, NOD.SCID mice between 10 and 11 weeks 
were weighed and anaesthetised with a subcutaneous injection of 1 mg/kg medetomidine 
(Domitor®, Janssen-Cilag, High Wycombe, UK) and 75 mg/kg ketamine hydrochloride 
(Ketaset®, Fort Dodge Animal Health, Southampton, UK) diluted in 0.9% sterile saline 
solution. The commonly used tracheotomy technique was used to intubate the mouse. Hair 
removal cream was applied on the throat area and loose hairs were wiped away after 5 
minutes and the mouse was placed in supine position. Pain-relief solution was given at a 
concentration of 0.01 mg/mL buprenorphine (Vetergesic®, Alstoe Animal Health, York, 
UK). A midline ventral incision of 0.5 cm length was performed below the cricoid cartilage 
and the skin was separated from connective tissue to visualize the salivary glands. Salivary 
glands were pulled sideward following their natural midline division. Magnetic chest 
retractors were used to expose the trachea. After this, the tongue was gently pulled on the 
side to expose the larynx and the intubation cannula was carefully inserted into the trachea. 
The cannula was immediately connected to a small animal respirator (MiniVent Type 845 
microrespirator, Harvard Apparatus, Hollston, MA, USA) and this was set to 200 µL stroke 
volume at a range of 110/150 strokes per minute depending on the animal weight. A vertical 
tail to head 1.5 cm skin incision was performed with blunt scissors and forceps were used to 
separate connective tissue, and major and minor pectoralis muscles. Next, thoracotomy was 
performed by pinching the tissue between the 3rd and 4th ribs, and 4 chest retractors were 
placed to maximise chest cavity opening. The left ventricle was exposed paying particular 
attention not to damage the pericardium and cell injection was performed. 
A precision microliter syringe (Hamilton, Bonaduz AG, Switzerland - #PB600-1) was 
loaded with 150 µL of 1X PBS containing 3 x 106 cells. To prevent perforation of 
myocardium during the injection and ensure correct injection in the left myocardium, a 20G 
plastic canula (introcan-W 20G) was secured on the needle tip leaving 1 mm exposed. Five 
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injections of 10 µL each were performed in 5 different locations to deliver a total of 1 x 106 
cells. A successful injection was confirmed by a visible white area and by the absence of 
major backwash of the cells. Mice not showing the features of a successful injection were 
excluded from the study. After successful cell injection, the retractors were removed and the 
intercostal space was closed by two non-continuous sutures using non-absorbable 6-0 
polypropylene suture material (Ethicon, Johnson & Johnson, Brussels, Belgium). Pectoralis 
muscles were moisturized with 1X PBS and were gently pushed back in their original 
position. After suturing the skin with the 6-0 polypropylene suture, 1 mg/kg antipamezole 
(Antisedan®, Janssen-Cilag, High Wycombe, UK) in 0.9% sterile saline solution was 
injected subcutaneously to invert the effect of the anaesthesia and the mouse was de-
intubated as soon as it started breathing autonomously. Following surgical procedure, the 
mouse was placed overnight in a 30°C chamber with wet diet to allow recovering. Analgesic 
solution was injected during the following hours if signs of pain and distress were observed 
in the mouse. 
Three different experimental groups of mice were included in this study. A control group to 
evaluate the physiological effects of HEK 293 cells was injected with 106 of HEK 293 cells 
only. A second group of mice was injected with 106 HEK 293 cells transfected with piRES2-
IGF-1Stop plasmid (HEK 293/IGF-1Stop) and a third group with 106 HE K293 cells 
transfected with IGF-1Ea-pcDNA™ 3.3 (HEK 293/IGF-1Ea). A summary of the 
experimental group is showed in Table 2.3. 
 
2.6.3 Isoproterenol model of hypertrophy in vivo 
Catecholamines are commonly used to increase contractile force, cardiac pumping output 
and oxygen consumption of the heart (Nichtova et al. 2012) and excess of catecholamines in 
circulation is responsible for myocardial tissue damage, fibrosis and necrosis (Cebelin and 
Hirsch 1980). Isoproterenol is a dual β1– and β2–AR agonist frequently used to induce 
cardiac overload, cell loss and cardiac remodelling leading to pathological cardiac 
hypertrophy (Osadchii 2007, Dhalla et al. 2009). In this study, isoproterenol was used to 
induce cardiac hypertrophy via daily intraperitoneal (i.p.) injection. Isoproterenol 
hydrochloride (Iso, Sigma-Aldrich, Gillingham, UK, #I6504) was injected i.p. at a 
concentration of 1 mg/kg/day in 0.9% sterile saline solution (Figure 2.2). Mice were 




Figure 2.2 Cell transplantation and the isoproterenol model of cardiac hypertrophy NOD.SCID 
mice received 106 cells in the left ventricular wall. Twenty-four hours after surgery, the treatment of 
1 mg/kg/day isoproterenol was used to induce pathological cardiac growth by i.p. injections. After 7 
days, mice underwent MRI functional analysis and tissues were used for RNA, proteins and 
histology. 
 
All mice that underwent cell transplantation were treated i.p. with Iso for 7 days. A control 
group that did not receive cell transplantation was injected i.p. with approximately the same 
volume of 0.9% sterile saline solution (Table 2.3). 	  
Table 2.3 The five experimental groups included in this study 





Saline / / 5 µL/gr 
Iso / 1 mg/kg/day / 
HEK 293 1 x 106 1 mg/kg/day / 
HEK 293/IGF-1Stop 1 x 106 1 mg/kg/day / 
HEK 293/IGF-1Ea 1 x 106 1 mg/kg/day / 	  
A first set of experiments was performed to assess cardiac morphology (haematoxylin and 
eosin, Section 2.8.3; and wheat germ agglutinin, Section 2.8.4) and a second set of 




2.6.4 Cardiac functional assessment by MRI 
MRI was used to non-invasively analyse cardiac function in a second set of mice. The mice 
were anesthetized with 1.5% to 2.5% isofluorane (v/v) in O2 and positioned supine in a 
purpose built, temperature-regulated cradle. Electrocardiography (ECG) electrodes were 
inserted into the forepaws and a respiration loop was taped across the chest. Imaging 
experiments were carried out using a 38 mm quadrature driven birdcage RF coil (Rapid 
Biomedical, Wurzburg, Germany) on an 11.7 T vertical bore MR system with a Bruker 
console running Paravision 2.1.1. ECG trigger levels were adjusted so that acquisitions were 
initiated at the same point in the cardiac cycle. A stack of contiguous, 1.5 mm true short axis 
ECG-gated cine images were acquired to cover the entire heart. 
End-diastolic (EDV) and end-systolic (ESV) frames were selected as those with the largest 
and smallest cavity volumes, respectively. Left Ventricular Ejection Fraction (LVEF) was 
calculated as ([EDV-ESV/EDV]*100(%)). Stroke volume (SV) was calculated as 
(SV=EDV-ESV). Left ventricular mass (LVM) was used to calculate left ventricle mass-to-
body weight ratio (LVM/BW ratio). 
 
2.6.5 Use of p38 inhibitor in vivo 
A group of NOD.SCID mice was treated with an inhibitor of p38 MAP kinase to test 
whether this could compromise the potential cardio-protective effects of HEK 293/IGF-1Ea 
from isoproterenol treatment. In the literature, the p38 inhibitor (SB203580) was originally 
used as inflammatory cytokine synthesis inhibitor and was found to be a selective inhibitor 
of p38 MAP kinase only later. SB 203580 inhibits the catalytic activity of p38 MAP kinase 
by competitive binding in the ATP pocket (Underwood et al. 2000). The HEK 293 cells 
were transfected and prepared for cardiac injection as described in Section 2.5.2. Cell 
transplantation was performed following the protocol reported in Section 2.6.2. 
Intraperitoneal injection of the p38 inhibitor (Calbiochem, Merck KGaA, Darmstadt, 
Germany - #559389) was performed daily for at a concentration of 5mg/kg/day, starting 12 
hours before cell transplantation. Isoproterenol i.p. injection (1 mg/kg) was performed daily 
in the afternoon to avoid interference with p38 inhibitor injection. The last injection of p38 
was performed 3 hours before harvesting the heart for morphological analysis. 
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2.7 Tissue sampling 
Mice were sacrificed to perform morphological, histological and molecular analyses on 
cardiac tissue. To harvest tissues, mice were first weighed and anaesthetized using 4% (v/v) 
isofluorane, and the abdominal cavity opened with blunt scissors. The abdominal inferior 
vena cava (IVC) was exposed only after anaesthesia effectiveness was confirmed by toe-
pinch stimulation. A total of 1 mL of blood was removed from the IVC using a 25G needle 
and stored in a 4 mL Vacutainer tube (Fisher Scientific, Loughborough, UK - #VCT-090-
050W). The heart was then exposed by removing the diaphragm membrane and by making 
two incisions on the left and right sides of the rib cage. A total of 750 µL of sterile, cold 
(4 °C) 1X PBS were carefully and slowly injected in the cardiac left ventricular cavity to 
wash the heart from remaining blood cells. The heart was removed while avoiding any 
pressure and consequent damage on atria and ventricles, and placed in a Petri dish with cold 
1X PBS to remove blood. For following analysis of heart weight, fat tissue was removed 
and the aorta, the superior vena cava and the pulmonary trunk were cut always at the same 
high to maintain consistency between animals. After drying the heart from remaining PBS, 
this was weighed (HW) with a precision scale and heart weight-to-body weight ratio 
(HW/BW) was calculated. The lung (LW), liver (LiW) and kidney (KiW) weight were also 
recorded to calculate the heart lung-to-body weight ratio (LW/BW), the liver weight-to-body 
weight ratio (LiW/BW) and the kidney weight-to-body weight ratio (KiW/BW). Part of the 
cardiac tissue was dissected with a scalpel and immediately stored in liquid nitrogen for 
following RNA and protein extraction and analysis. As described in Section 2.8, the 
remaining cardiac tissue was used for cardiac tissue sectioning and immunostaining. Tissue 
samples for RNA and DNA were then stored at -80°C until further processing. 
 
2.7.1 RNA isolation and manipulation 
RNA analysis was carried out to investigate gene expression in harvested tissues in vivo and 
in cell culture in vitro. The bench area for the RNA isolation was prepared by cleaning all 
surfaces with RNaseZap® (Ambion, Inc. Applied Biosystems, UK - #AM9780) to 
decontaminate from RNase and only filtered RNase free pipette tips were used. RNA isolation 
consists of a first step of extracellular matrix disruption in tissue samples and plasma membrane 
of cells to release RNA and a second step of homogenization to reduce viscosity of the sample. 
 
65	  	  
2.7.1.1 RNA extraction from tissue 
Cardiac mouse tissue (20-30 mg) was placed in a 15 mL tube (plastic, rounded end) and 0.5-
1 mL of TRIzol reagent (Invitrogen, Carlsbad, CA, USA - #15596-026) was quickly added 
to the tube under a fume cabinet. TRIzol consists of a mixture of acidic phenol, guanidine 
isothiocyanate and other compound that allow isolation of protein, RNA and DNA. It is very 
important that samples are transported from -80°C to the fume hood by using dry ice and 
quickly treated with TRIzol to avoid thawing and activation of RNases. Tissue samples were 
disrupted with a rotor-stator homogeniser (Polytron PT 2500 E) for 40-50 seconds to disrupt 
and homogenize by mechanical shearing. Homogenate was centrifuged for 10 minutes at 
13,000 rpm in a pre-chilled microcentrifuge (4°C) to remove cell debris, and supernatant 
was transferred in a 1.5 mL microcentrifuge tube. A total of 200 µL of chloroform per mL 
of TRIzol were added to each sample and mixed by manually inverting them for 15 seconds. 
The samples were then incubated at RT for 3 minutes followed by centrifugation at 13,000 
rpm for 15 minutes at 4°C. Chloroform and centrifugation separate each sample in a lower 
organic phase, an interphase and an aqueous phase containing RNA. The aqueous phase was 
carefully removed without displacing and mixing the interphase, and placed in a new 1.5 
mL tube. The samples were added with 0.5 mL isopropanol and mixed manually. After 10 
minutes incubation at RT they were centrifuged at 13,000 rpm for 15 minutes at 4°C the 
resulting precipitated RNA was washed once with 75% EtOH (v/v) in sterile water, 
centrifuged at 8,600 rpm for 5 min at 2-8ºC and washed a second time with 100% EtOH 
(v/v). After removing the supernatant, the pellet was air-dried from EtOH residues and 
dissolved in 100 µL of sterile RNase-free water.  The following steps consisted in the 
purification of RNA from contaminants such as DNA and it was performed by adding 2 
different solutions to the 100 µL containing RNA. First 350 µL of RLT buffer supplemented 
with 1% β-mercaptoethanol (β-ME) (v/v) and then 250 µL of 100% EtOH after brief mixing 
were added. RLT buffer contains a high concentration of guanidine isothiocycanate, which 
supports the binding of RNA to the silica membrane of the column. The solution was 
immediately poured onto an RNeasy Mini spin column and RNA purification was 
performed according to the manufacturer’s protocol using the RNeasy Mini Kit (QIAGEN, 
Crawley, UK - #74104). Briefly, after centrifugation at 11,000 rpm for 15 seconds, the 
column was washed with 350 µL of wash buffer (RW1) and 80 µL of DNase I (QIAGEN, 
Crawley, UK - #79254) were added directly on the column membrane to remove 
contaminating DNA. The column was incubated for 15 minutes at RT and washed a second 
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time with 350 µL of RW1. Two wash of the spin column were performed with 500 µL of 
RPE buffer to remove traces of salts. In the final step, 40 µL of RNase-free water were 
added directly to the spin column membrane and this was centrifuged for 1 min at 13,000 
rpm at 4°C to elute RNA in a new 1.5 mL tube. RNA was quantified as described in Section 
2.7.4 and stored at -80°C. 
 
2.7.1.2 RNA extraction from cells 
Isolation of RNA from cells in vitro was performed using the protocol described for RNA 
extraction from tissue in Section 2.7.1.1 with some modifications. Tissue culture dishes with 
cells were washed twice with cold 1X PBS after the cell culture medium was removed. 
TRIzol was added onto the cells (500 µL/well for 12 well plates and 1 mL/well for 6 well 
plates), and these were mechanically detached using a cell scraper and transferred into a 1.5 
mL centrifuge tube. To facilitate membrane disruption and RNA release from cells, samples 
were passed ten times through a sterile 23G syringe needle and incubated at RT for 10 
minutes for complete dissociation of nucleoprotein complexes. The following steps were 
performed as described in the previous section, with the difference that the aqueous phase 
containing RNA, formed after addition of chloroform and centrifugation, was added directly 
on the RNeasy Mini spin column for RNA purification. 
 
2.7.1.3 RNA quantification 
RNA samples isolated from tissue and/or cells were kept in ice after purification and a small 
aliquot was used for RNA quantification. Samples were diluted in Tris-EDTA (TE) buffer 
composed by 100 mM tris-HCl and 10 mM EDTA with a pH of 8.0, at a dilution dependent 
on the expected RNA yield (i.e. 1:50 dilution for RNA isolated from tissue and 1:10 dilution 
for RNA isolated from cell cultures). RNA quantification was performed by 
spectrophotometry by measuring absorbance at 260nm (A260nm). The photospectrometer 
(BioPhotometer Plus, Eppendorf, Cambridge, UK) was first blanked using 50 µL of TE 
buffer in UVette plastic cuvettes (Eppendorf, Cambridge, UK - #0030.106.318) and samples 
with diluted RNA were then measured. One unit of absorbance at 260nm is equivalent to 40 
µg of RNA/mL and this correlation was used to measure RNA concentration with the 
following formula: 
RNA (µg/µL) = A260nm *40 *dilution factor 
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To determine purity of the RNA samples, the ratio between the absorbance measured at 
260nm and 280nm (A260nm/A280nm) was analysed. Pure RNA samples should have a 
A260nm/A280nm ratio between 1.9 and 2.1. Contamination from protein or phenol was 
determined by looking at the A260nm/A230nm ratio. Very low or no contamination is confirmed 
when the A260nm/A230nm ratio is >1.7. 
 
2.7.2 Gene expression analysis by qPCR 
The analysis of mRNA isolated from tissues and specific cell types provides a powerful 
approach to accurately determine gene expression in vivo and in vitro. The traditional 
polymerase chain reaction (PCR) technology involves detection and quantification of an 
amplified DNA or cDNA template at the end of the last PCR cycle, using post-PCR analysis 
such as gel electrophoresis and image analysis. Real-time quantitative PCR (qPCR) is a 
more efficient and precise technology, and the amount of cDNA is measured after each 
cycle by the use of fluorescent probes incorporated into the PCR product. The increase in 
fluorescent signal detected during the qPCR is directly proportional to the number of PCR 
product molecules generated in the exponential phase of the reaction, and is used to 
determine the amount of starting mRNA of interest in the original sample. Quantitative PCR 
consists of a first step where reverse transcription of either total RNA or poly(A)+ RNA into 
complementary-DNA (cDNA) is performed using a reverse transcriptase. In the second and 
last step, the cDNA is transferred to a separate tube and qPCR is performed as described in 
Section 2.7.2. Internal controls such as 18S or GAPDH are used for normalization of total 
mRNA amount. 
 
2.7.2.1 Complementary DNA synthesis 
RNA is easily degradable while cDNA is more stable, thus RNA samples were used for 
cDNA synthesis immediately after RNA isolation. Samples were kept in ice to inhibit 
RNase activation and filtered pipette tips were used to avoid contamination. A master mix 
was prepared using the TaqMan® reverse transcription kit (Applied Biosystems, Carlsbad, 
CA, USA - #N8080234) as described in Table 2.4 and it was aliquoted into nuclease-free 
PCR tubes. Random hexamers, short oligodeoxyribonucleotides of random sequence that 
anneal to random complementary sites, were included in the reaction. Their priming begins 
at multiple points along the template and makes several overlapping cDNAs, facilitating 
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complete retrotranscription of the target RNA. Reverse transcriptase was added immediately 
before the aliquots for each sample were prepared, to avoid potential decrease in enzyme 
activity. 
 
Table 2.4 Complementary DNA synthesis recipe 
REAGENT FINAL CONCENTRATION 
AMOUNT (µL) 
20µL reaction 
10X RT buffer 1X 2 
MgCl2 5.5 mM 4.4 
dNTPs 500 µM each dNTP 4 
Random hexamers 2.5 µM 1 
RNase inhibitor 0.4 U/µL 0.4 
MultiScribe reverse 
transcriptase 
1.25 U/µL 1.25 
RNase-free water - 
6.95 
RNA 10 ng/µL 	  
A total reaction of 20 µL was obtained by adding, in the final step, 6.95 µL of RNA (i.e. a 
total of 200 ng of RNA) to the corresponding PCR tube already containing 13.05 µL of 
master mix. The tubes were briefly mixed, centrifuged and left on the bench for 2 minutes to 
reach room temperature, and finally added to a PHC-3 Thermal Cycler (Techne Bibbi 
Scientific, Stone, UK). The machine was set using the conditions reported in Table 2.5. 
 
Table 2.5 Thermocycler conditions for cDNA synthesis 
STAGE DURATION (min) TEMPERATURE (°C) 
Primer binding 10 25 
Extension 30 48 
Enzyme denaturation 5 95 	  
The retro transcriptase-PCR (RT-PCR) products containing cDNA were diluted to a 
concentration of 2ng/µL with RNase-free water and stored at -20°C until needed for qPCR. 
 
2.7.2.2 Real-time Quantitative PCR 
Complementary DNA samples were used to perform qPCR on an ABI 7500 FAST machine 
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(Applied Biosystems, Carlsbad, CA, USA) with the TaqMan® Fast Advanced Master Mix 
(Applied Biosystems, Carlsbad, CA, USA - #4444557). TaqMan® probes were used to 
detect a known sequence of cDNA of the gene of interest (GOI) and consist of an 
oligonucleotide with a fluorescent reporter dye FAM™ at the 5’ end emitting light at 520 
nm upon excitation, and a non-fluorescent quencher dye as well as a minor groove binder 
(MGB) at the 3’ end. MGBs allow increasing the melting temperature (Tm) and the 
possibility to design shorter probes.  A reporter probe, carrying a reporter VIC® dye at the 5’ 
end and a TAMRA quencher at the 3’ that emits light 580 nm upon excitation, is included in 
each reaction. The DNA polymerase contained in the Master Mix has a 5’ to 3’ nuclease 
activity and cleaves the primer and the probes that have bound the target of interest if this is 
present during the qPCR reaction. This process induces separation of the reporter dye and 
the quencher dye, resulting in increased fluorescence. On the other end, when the probe is 
intact, the reporter fluorescence is suppressed by the proximity to the quencher dye by 
Föster type energy transfer (Förster 1948) (Invitrogen protocol - 
http://tools.lifetechnologies.com/content/sfs/manuals/cms_042996.pdf). The mechanism 
behind this process is named Fluorescence Resonance Energy Transfer (FRET) and allows 
to directly detect accumulation of PCR products by monitoring the increase in fluorescence 
of the reported dye. At some point of the PCR reaction, a sufficient amount of amplicons 
will have accumulated such that the fluorescence signal crosses a threshold, called the cycle 
threshold value (Ct). The Ct value of a GOI (Ct-GOI) is first normalized against the Ct value of 
an housekeeping gene (Ct-HG) (i.e. 18S gene for this study) to produce the ΔCt. 
ΔCt. =  Ct-GOI - Ct-HG 
The relative expression of the gene of interest for each sample is then calculated using the 
ΔCt of a reference sample in the study group (ΔCt-ref), usually a control or untreated sample 
and applying the formula: 
ΔΔCt (relative expression of GOI) = 2-ΔCt-ΔCt-ref 
The qPCR reaction was set up in a total of 20 µL for each sample, including 3 µL of cDNA 
at a concentration of 2 ng/µL. Every cDNA samples was thawed in ice, mixed by vortexing 
and quickly centrifuged before adding it to Fast optical tubes (0.1 mL, Applied Biosystems, 
Carlsbad, CA, USA - #4358297, #403012) or to a 96-well plates (Applied Biosystems, 
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Carlsbad, CA, USA - #403012). The master mix was prepared as described in Table 2.6 and 
all probes used for this study are reported in Table 2.13. Taqman Fast Advanced Master 
Mix was added to the master mix immediately before this was pipetted in the tubes or wells 
containing the cDNA. 
 
Table 2.6 Recipe for qPCR Real Time reaction on a ABI 7500 FAST machine 
REAGENT FINAL CONCENTRATION AMOUNT (µL) 20µL reaction 
TaqMan Fast Advanced 
Master Mix 
1X 10 
18S reference gene probe 1X 1 
GOI probe 1X 1 
DNase/RNase-free water - 5 
cDNA sample (2 ng/µL) 6 ng 3 
	  	  
The plates were sealed with optical adhesive film (Applied Biosystems, Carlsbad, CA, USA, 
# 4311971) and centrifuged at 1,500 rpm for 2 minutes at RT. qPCR conditions are reported 
in Table 2.7. 
 
Table 2.7 Conditions for qPCR Real Time reaction 
STAGE DURATION TEMPERATURE (°C) 
Hold 10 min 95 
1st cycle 
15 sec 95 
60 sec 60 
 
 
2.7.3 Gene Card Array 
A wider gene expression analysis was performed on RNA samples isolated from the heart of 
saline, Iso, HEK 293, HEK 293/IGF-1Ea and HEK 293/IGF-1Stop mice using TaqMan® 
Array Micro Fluidic Cards. These 384-well cards preloaded with TaqMan® Gene 
Expression Assays allow to measure gene expression using the comparative Ct (ΔΔCt) 
method of relative quantitation described in the previous section. The key features of this 
technology are the small-volume design that minimizes sample and reagent consumption 
and the access to high-throughput, 384-well format without liquid-handling robotics. 
Custom Micro Fluidic Cards (Applied Biosystems, UK - #MFC-384) with pre-selected 
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TaqMan® assays were kindly provided by Professor Michael Schneider’s laboratory and a 
list of probes included in the cards is reported in Table 2.14. Two different housekeeping 
genes were used as control (Hmbs and Ubc). Briefly, single-stranded cDNA was generated 
from RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
UK - #4368814). The reaction mix for the Gene Cards was prepared with cDNA, nuclease-
free water and 50 µL TaqMan® Gene Expression Master Mix (Applied Biosystems, UK - 
#4369016) in a total volume of 100 µL. Each mix containing cDNA from a single sample 
was loaded on the fill port as shown in Figure 2.3. A total of 48 TaqMan® Gene Expression 
Assays, including the 2 housekeeping genes, were performed. 	  
	  
Figure 2.3 The TaqMan low density assay Each 100 µL sample-specific PCR reaction is 
transferred into the Array by a micropipette. The fill port gives access to the Array and is filled 
directly with the PCR solution. 
 
The Gene Cards were centrifuged to distribute the reaction mix to the reaction wells, sealed 
and run on an Applied Biosystems 7900HT Fast Real-Time PCR system installed with a 
thermal cycling block (Applied Biosystems, UK - #4329001). The programme for the run 
was set up and the results were analysed with the SDS software V2.4 (Applied Biosystems, 
UK) that includes the RQ Manager programme. 
 
2.7.4 Protein isolation from cells and tissue 
Proteins were isolated using 1X buffer containing 1X RIPA buffer (Cell Signaling 
Technology, UK - #9806; 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 
mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin), 1X DTT (1.25 M, Cell Signaling, 
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Danvers, MA, USA - #9806) and supplemented with 1 mM phenylmethylsulfonyl fluoride 
(PMSF; Roche Applied Science, Burgess Hill, UK -#10837091001), 1X PhosSTOP 
Phosphatase Inhibitor Cocktail (Roche Applied Science, Burgess Hill, UK - #11206893001) 
and 1X Complete Protease Inhibitor Cocktail (Roche Applied Science, Burgess Hill, UK - 
#04906845001). 
Tissue samples were kept in dry ice, rapidly weighed to avoid thawing and moved to a glass 
homogenizer containing 10 µL of 1X buffer/mg of tissue. The homogenizer was kept in ice 
and the tissue was dismembered by rotation with a pestle and transferred to a 1.5 mL 
eppendorf tube. Further homogenization and disruption of the tissue was performed by 
sonication using a Vibra Cell sonicator (Sonics & Materials, Newtown, CT, USA). The 
homogenate were then centrifuged at 13,000 rpm for 20 minutes at 4°C in a microcentrifuge 
and the supernatant was used for protein quantification as described in Section 2.7.4.1. 
Before transferring the protein samples at -80°C for long storage, these were diluted using 
3X reducing loading buffer (Cell Signaling technology, Inc., UK - #7722: (pH 6.8), 6% 
(w/v) SDS, 30% glycerol, 187.5mM Tris-HCl and 0.03% (w/v) bromophenol blue) 
supplemented with 125 mM dithiothreitol (DTT), which reduces disulphide bonds in the 
proteins, and divided in 30 µL aliquots at a concentration of 2 µg/µL. Protein levels and 
protein phosphorylation were measured by western blot technique as described in Section 
2.7.5. 
Conditioned medium was harvested from cell culture to measure secretion of IGF-1 and 
IGF-1Stop from HEK 293 cells previously transfected with the correspondent plasmids. The 
medium was filtered and stored at -80°C as described for protein extracted from cells. 
Aliquots were prepared and diluted in 3X reducing loading buffer and DTT. 
For total protein isolation from primary cells (i.e. neonatal cardiomyocytes) or cell lines (i.e. 
HEK 293) in vitro, the tissue culture medium was removed and stocked at -80°C if 
necessary for future protein secretion analysis. The tissue culture dish was washed twice 
with cold, autoclaved 1X PBS, placed in ice and incubated for 5 minutes with cold 1X RIPA 
buffer (300 µL for a 10cm dish). Using a cell scraper, cells were removed from the dish, 
aspirated and placed in a 1.5 ml tube. The tube was incubated in ice for 10 minutes to 
complete cell lysis. The samples were centrifuged at 13,000 rpm for 20 minutes in a pre-
cooled (4°C) centrifuge to remove pellet containing cell fragments. Supernatant was used 
for protein quantification and stored in aliquots of known concentration at -80°C. 
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2.7.4.1  Protein quantification 
Protein quantification was performed using the DC Protein assay Kit (Bio-Rad Laboratories, 
Hemel-Hempstead, UK - #500-0112), a colorimetric assay similar to the well-known Lowry 
assay, with some improvement to stabilize the reactions and to reduce the time of the 
experiment. The assay is based on the reaction of protein (protein standard or sample) with 
an alkaline copper tartrate solution in an alkaline medium and the subsequent reduction of 
Folin reagent by the copper-treated protein. These two steps lead to colour development 
with maximum and minimum absorbance at 750 nm and 405 nm. The amount of coloured 
product is proportional to the amount of amino acids tyrosine and tryptophan. To measure 
protein concentration of unknown samples, a standard assay was prepared with a range of 
different concentrations of Bovine Serum Albumin (BSA), as shown in Table 2.8.	  	  
Table 2.8 Standard curve generated with different concentrations 
of BSA protein diluted in water 
Tube # 1 2 3 4 5 6 7 8 9 
BSA µg/µL 0 0.2 0.4 0.6 0.8 1 1.2 1.6 2 
µL of 2 µg/µL 0 5 10 15 20 25 30 40 20 
µL of ddH2O 20 45 40 35 30 25 20 10 0 
	  	  
A microplate assay protocol was used as described by the manufacturer. Unknown protein 
samples were first diluted 1:10 to facilitate accurate measurement and then 5 µL of 
standards or protein samples were pipetted in duplicate into a clean, dry 96-well microtiter 
plate. Twenty µL of reagent “S” were added to 1 mL alkaline copper tartrate and 25 µL of 
this solution were added into each well already containing the pipetted proteins. After 
adding 200 µL of Folin reagent, the plate was incubated for 15 minutes in the dark and the 
absorbance of the samples was measured at 750 nm (A750nm) using a µQuant microplate 
reader (Bio-Tek Instruments, Potton, UK) and the software KC Junior v1.41.3. The values 
of absorbance were plotted against the amount of proteins and a standard curve was 
obtained using linear regression (Figure 2.4). 	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Figure 2.4 Representative example of a standard curve BSA dilutions prepared as by Table 2.8 
were measured and plotted against their absorbance at 750nm. The R2 and curve equation are 
reported. 
 
The R-squared value reported in Figure 2.4 indicates a good fit of linearity when is >0.99, 
which means that the regression line gives correct predictions. Protein concentration (x) of 
the unknown samples was calculated by matching their absorbance values (y) against the 
standard curve using the graph equation. 
 
2.7.5  Western blotting 
Differences in protein levels and phosphorylation can be identified by Sodium Dodecyl 
Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE), also known as Western blot, a 
widely used technique. This consists in the separation of proteins from one another 
according to their size by using gel electrophoresis. The consequent identification of 
proteins is performed using specific antibodies. Two different protocols were carried out for 
normal sized proteins (Section 2.7.5.1) and small sized proteins (i.e. IGF-1, Section 2.7.5.2). 
 
2.7.5.1  Western blotting for normal sized proteins 
The electrophoresis gel for proteins with molecular weight >10 kDa were self-made in our 
laboratory. Polyacrylamide gels were prepared using a mixture of 30% acrylamide (29:1) 
and the cross-linker bis-acrylamide (Bio-Rad Laboratories, Hemel-Hempstead, UK - #161-
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0157). The polymerization of the gel was initiated by the addition of 10% ammonium 
persulfate (APS; Bio-Rad Laboratories, Hemel-Hempstead, UK - #161-0700) along with 
N,N,N,N-Tetramethylethylenediamine (TEMED; Bio-Rad Laboratories, Hemel-Hempstead, 
UK - #161-0801). The gel consisted of a three-dimensional network of long hydrocarbons 
cross-linked by methylene groups, and the separation of molecules within the gel was 
determined by the relative size of the pores formed within the gel. The volume percentage of 
acrylamide and cross-linker in the total volume of the solution determines the pore size of 
the gel. As the total amount of acrylamide increases, the pore size decreases and therefore 
lower percentage gels (5%) were used to separate proteins between 57 and 212 kDa while 
higher percentage gels (15%) were used to separate proteins between 12 and 43 kDa. 
The resolving gel was prepared accordingly to the molecular weight of the protein to be 
separated and identified, as described in Table 2.9. 
 
Table 2.9 Lists and recipes for a range of 6-to-15 % bis-acrylamide resolving gels for protein 
electrophoresis	  
 REAGENTS % OF RESOLVING GEL (mL) 
 6% 8% 10% 12% 15% 
ddH2O 2.6 2.3 1.9 1.6 1.1 
Acrylamide mix (30%) 1.0 1.3 1.7 2.0 2.5 
1.5 M Tris (pH 8.8) 1.3 1.3 1.3 1.3 1.3 
10% SDS 0.05 0.05 0.05 0.05 0.05 
10% APS 0.05 0.05 0.05 0.05 0.05 
TEMED 0.004 0.003 0.002 0.002 0.002 	  
The single components were added to a 15 mL tube and immediately after addition of APS 
and TEMED they were poured into the cast, leaving approximately 2 cm below the top of 
the pouring plates to allow enough space for the stacking gel. To level the gel’s surface, 
100% EtOH was added into the cast and removed after polymerization was completed. In 
the meanwhile, the stacking gel was prepared as detailed in Table 2.10 and APS and 
TEMED were added in the mixture immediately before pouring the whole solution on the 
polymerized resolving gel. 
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Table 2.10 Reagents and recipe for a 1 mL bis-acrylamide stacking gel solution used in protein 
electrophoresis 
REAGENTS STACKING GEL (mL) 
ddH2O 0.68 
Acrylamide mix (30%) 0.17 
1.0 M Tris (pH 6.8) 0.13 
10% SDS 0.01 
10% APS 0.01 
TEMED 0.001 	  
Gel comb ranging from 0.75 to 1.5 mm thickness with 10 or 15 wells were carefully inserted 
and the gel was allowed to polymerize for 15 minutes. 
Electrophoresis was carried out using a BioRad Mini-PROTEAN® system (Bio-Rad 
Laboratories, Hemel-Hempstead, UK - #165-8000) filled with 1X electrophoresis buffer (25 
mM tris base, 0.192 M glycine, 0.1% (v/v) SDS, pH 8.3). 
Before loading the diluted proteins onto the gel, each protein solution was boiled at 95°C for 
5 minutes to denaturate the proteins, and briefly centrifuged. The samples, containing equal 
amount of denaturated proteins with a uniform charge-to-mass ratio proportional to their 
molecular weight, were loaded onto the gel and the proteins were separated depending on 
molecular weights. A pre-stained molecular weight marker was used (Invitrogen, Carlsbad, 
CA, USA -#LC5800) to facilitate protein identification. 
Electrophoresis was performed at constant voltage of 120 V with a PowerPac300 (Bio-Rad 
Laboratories, Hemel-Hempstead, UK) at RT, until sample buffer reached the bottom of the 
gel. 
The proteins were subsequently transferred from the gel to a membrane by electroblotting 
using a wet-transfer BioRad Mini-PROTEAN® system (Bio-Rad Laboratories, Hemel-
Hempstead, UK - #165-8004).  The polyacrylamide gel was removed from the cast and 
placed on a 0.20 µm pore size nitrocellulose membrane (Bio-Rad Laboratories, Hemel-
Hempstead, UK - #162-0150), carefully removing air bubbles between gel and membrane to 
avoid interference with protein transfer. Gel and membrane were inserted in a transfer 
cassette between two layers of Whatman 3 MM chromatography paper (Thermo Fisher 
Scientific, Loughborough, UK - #CJF-500-050X) and a Fiber pad on each side, as shown in 
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Figure 2.5, previously soaked in transfer buffer (Tris base 25 mM, 0.192 M glycine, 15% 
(v/v) MeOH). The tightly assembled transfer cassette was placed in the Mini Trans-blot Cell 
Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hemel-Hempstead, UK - #170-3930) 
with the nitrocellulose membrane between the anode side and the gel.  A stir bar was used to 
maintain even distribution of ions and buffer temperature. 	  
	  
Figure 2.5 Protein transfer apparatus After protein separation via gel electrophoresis, proteins are 
transferred from the gel onto a membrane. Gel and membrane are placed between filter paper and 
filter pads, and tightly closed in the transfer cassette. Available from http://www.bio-
rad.com/webroot/web/pdf/lsr/literature/M1703930.pdf. 
 
The transfer was carried on at constant voltage for 75 minutes at 100 V either with a cooling 
unit inside the tank or in a cold room at 4°C. 
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To assess correct transfer of protein from the gel, the membrane was submerged with 
Ponceau S solution (TWEEN® 20, Sigma-Aldrich, Gillingham, UK - #P7170) for 1 minute 
to determine uniform transfer of protein bands. The membrane was then extensively washed 
in 1X PBS-tween 0.2% (v/v) (PBS-T, TWEEN® 20, Sigma-Aldrich, Gillingham, UK - 
#P5927) until no staining was visible. 
To prevent non-specific background binding of the primary and/or secondary antibody, the 
membrane was blocked using either 5% (w/v) BSA or 5% (w/v) blotting grade milk powder 
in PBS-T for 1 h at RT. BSA is recommended for analysis of phospho-proteins over non-fat 
milk that contains casein, which is a phospho-protein that causes high background. The 
membrane was then incubated overnight (16-18 hours), in constant shaking at 4°C, with a 
blocking solution containing primary antibody at a final dilution of 1:500-1:5000 (v/v), as 
recommended by the manufacturer. After overnight incubation, the membrane was washed 
three times for 10 minutes, at RT, on agitation, using enough PBS-T to submerge the 
membrane. The wash ensured removal of residual primary antibody. A secondary HRP-
conjugated antibody was diluted 1:1000 (v/v) in blocking solution and used to incubate the 
membrane on a shaker for 1 hour at RT. The membrane was washed thrice in 1X PBS-T for 
10 minutes at RT and incubated with a mix of ECL Plus reagent A and reagent B 40:1 (v/v) 
(AmershamTM ECL PlusTM Detection Reagent kit; GE Healthcare, UK - #RPN 2132). The 
ECL was distributed evenly on the membrane, and after 5 minutes this was drained and 
exposed to Amersham Hyperfilm ECL in a darkroom (GE Healthcare, Little Chalfont, UK - 
#28-9068-37). The film was developed in developer solution for 1 minute, briefly washed 
with tap water, and fixed in fixation agent for 3 minutes (Kodak® GBX Developer and 
Fixer; Sigma-Aldrich, Gillingham, UK - #P7042, P7167). Protein bands were quantified 
using ImageJ 1.47 on the scanned film. 
 
2.7.5.2  Western blotting for small sized proteins 
Detection of small proteins (e.g. IGF-1) was performed using pre-made Tris-Tricine 
gradient gels ranging from 10-20% (Bio-Rad Laboratories, Hemel-Hempstead, UK - #456-
3114). Protein samples were diluted 50% (v/v) in Tricine Sample Buffer (Bio-Rad 
Laboratories, Hemel-Hempstead, UK - #161-0739) containing 2% (v/v) β-ME (Sigma-
Aldrich, Gillingham, UK - #M6250). The gel electrophoresis was performed as described 
above but two different buffers were used inside the electrophoresis tank. An anode buffer 
(0.2 M tris, pH 8.9) was used to fill the outer reservoir of the tank, whereas a cathode buffer 
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(0.1 M tris base, 0.1 M tricine, 1% (v/v) SDS) was poured in the inner space between the 
two gels. The samples were run for the time required to separate the proteins on the gel and 
the following transfer was performed using a modified buffer (25 mM tris base, 0.192 M 
glycine) containing 40% methanol (v/v) to promote small peptide transfer to the membrane. 
The transfer was carried out using a 0.20 µm pore size nitrocellulose membrane (Bio-Rad 
Laboratories, Hemel-Hempstead, UK - #162-0150) for 120 minutes at 4°C at the constant 
voltage of 100 V. 
 
2.7.6 Membrane stripping 
Membranes where occasionally re-used to investigate more than one protein on the same 
blot (e.g. internal control or a protein with a different molecular weight) but this protocol 
was not carried out to detect phospho-proteins after stripping. Membranes were “stripped” 
to remove primary and secondary antibodies by incubation at 50°C, on agitation for 30 
minutes, with a buffer containing 2% SDS (v/v), 62.5mM Tris HCl pH 6.8 and 100mM β-
ME in ddH2O. To remove any traces of β-ME after stripping, membranes were washed three 
times in 1X PBS-T for 10 minutes at RT. Blocking, primary and secondary antibody 
incubation and membrane development were performed as described in Section 2.7.5.1. 
 
2.7.7 Kinexus phosphorylation-sites array 
Kinetworks™ Custom (multi-antibody) Protein Screen (KCPS 1.0) (Kinexus Bioinformatics 
Corporation, Vancouver, Canada) was used to track the phosphorylation states of 20 
different proteins. Protein samples isolated from the heart of saline, Iso, HEK 293, HEK 
293/IGF-1Ea and HEK 293/IGF-1Stop mice were screened for specific phosphorylation 
sites (i.e. one phosphorylation site for each of the 20 chosen proteins) known to be a 
potential target for post-translational modification in cardiac tissue. The KCPS utilizes a 
proprietary technology based on multi-immunoblotting that generates a unique identification 
pattern for each sample analyzed and can provide information about the quantitative 
phosphorylation level for each protein detected. A representative example of the results is 
reported in Figure 2.6. 	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Figure 2.6 Example of a Kinexus multi-antibody pattern The figure shows an example of gel 
electrophoresis screening for one sample. Each of the 19 vertical lines indicates bands relative to a 
single antibody used to detect phospho state of a specific protein. Available from 
http://www.kinexus.ca/pdf/KinetworksCust_InfoPckg.pdf. 
  
Protein samples were extracted, quantified and diluted in protein buffer as described above 
in Section 2.7.4.1 and shipped in dry ice for the screening. Nineteen antibodies for the 
screen were selected based on their predicted involvement in phosphorylation pathways in 
the heart. One housekeeping protein (i.e. gamma-tubulin) was included as control and used 
to normalize the 19 antibodies selected. Bands intensity across samples were analysed using 
counts per minute, which represents the trace quantity of the band corrected to a scan time 
of 60 seconds. A list with the selected antibodies is reported in Table 2.16. 
 
2.8 Histology 
Immunohistochemistry and immunofluorescence approaches are used to detect the 
expression and the localization of specific proteins in organs, tissues and cells. Both consist 
in protein-specific primary antibodies and species-specific secondary antibodies used on 
processed cell or tissue preparation. Co-localization or intracellular localization studies and 
sensitivity of the marker to be detected are some of the parameters considered in the choice 
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between the former and the latter techniques, which are described in the following three 
sections. 
 
2.8.1 OCT cardiac sections for DAPI+ cells detection 
Mice were sacrificed as described in Section 2.7 and the heart was harvested. In order to 
determine whether intra-ventricular transplantation of DAPI+ HEK 293 cells was successful 
and whether cells were present in the myocardium one week from the transplantation, 
selected hearts were embedded in a square mold containing Optimum Cutting Temperature 
(OCT; VWR, Lutterworth, UK - #25608-930) freezing compound. This was immediately 
submerged in liquid nitrogen and stored at -80°C until further processing. A Leica CM 850 
cryostat (Leica Microsystems, Milton Keynes, UK) maintained at -20°C was used to cut 
transversal heart sections of 8 µm. The sections were mounted on polysine slides (VWR, 
Lutterworth, UK - #631-1349) and stored at -80°C in absence of light. The presence and 
localization of DAPI+ HEK 293 transplanted cells in the heart were analysed using a Nikon 
DMx1200 camera mounted on a Zeiss Axioscope microscope, and images were captured 
using NIS elements software V (Nikon Instruments, Melvile, NY, USA). 
 
2.8.2 Paraffin embedding 
Cardiac samples used for immunofluorescence or immunohistochemistry were harvested has 
described above in Section 2.7 and fixed in 10% (v/v) formal saline (1.54 M NaCl, 10% v/v 
formaldehyde). Samples were kept at 4°C overnight to allow the formal saline to penetrate 
the tissue. After fixing, samples were placed in 50% EtOH (v/v) for long-storage or directly 
embedded in paraffin using a Leica TP 1020 tissue processor (Leica Microsystems, Milton 
Keynes, UK). During this process, the tissue is dehydrated through a series of EtOH baths to 
displace the water, then infiltrated with paraffin and finally embedded into paraffin blocks. 
 
2.8.3 Hematoxylin and Eosin staining 
Hematoxylin and Eosin (H&E) staining is a routine histology technique performed to 
preliminary investigate abnormal growth or division of the cells and to analyse tissue 
morphology. It consists of two separate dyes, one used to stain chromatin and nuclear 
material in the nucleus (i.e. hematoxylin) and the other used to stain cytoplasmic material 
including connective tissue and collagen (i.e. eosin). Transversal mouse heart sections were 
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stained with H&E to investigate cardiac morphology and structure. Briefly, paraffin 
embedded heart sections were cut at a thickness of 5 µm and placed on polysine slides. The 
slides where dried overnight at 37°C and the following day they were taken through brief 
changes of xylene, alcohol and water to deparaffinise and hydrate the tissue. This part of the 
protocol gives the tissue/cells an affinity for the dyes. Deparraffinization steps are described 
in Table 2.11. 
 
Table 2.11 Reagents and timing for deparaffinization and rehydration of paraffin sections 
REAGENT TIME 
Xylene 3 min 
Xylene 2 min 
EtOH (100%) 2 min 
EtOH (100%)  2 min 
EtOH (70%)  2 min 
Running tap H2O 5 min 	  
Deparaffinised sections were immersed in hematoxylin (Sigma-Aldrich, Gillingham, UK - 
#HT15) for 8 minutes and unbound stain was removed by washing the slides first with a 
solution of 1% hydrochloride (v/v) and 70% EtOH (v/v) for 10 seconds and then with 
running cold water for 2 minutes. Eosin staining was performed by immersing the slides in 
eosin (Sigma-Aldrich, Gillingham, UK - #HT110180) for 10 minutes and finally washing 
them in running tap water. The slides were then dehydrated in a reverse manner, as 
described in Table 2.12. 
	  
Table 2.12 Reagents and timing for dehydration and clearing of slides 
REAGENT TIME 
EtOH (70%) 10 sec 
EtOH (100%) 30 sec 
Xylene 10 sec 
Xylene  10 sec 	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Finally, the slides were mounted using DPX mounting medium (VWR, Lutterworth, UK - 
#LEIC08600E), covered with a coverslip and dried for 30 minutes at RT. On the following 
day, cardiac sections were analysed for presence of high density of nuclei and lack of eosin 
staining, indicating presence of isoproterenol-induced damage. 
 
2.8.4 Cardiac sections staining with wheat germ agglutinin 
Wheat Germ Agglutinin (WGA) has been used extensively to stain cell surface and cardiac 
myocytes in heart sections. This protein of the lectin family binds to N-acetyl-D-
glucosamine and sialic acid residues found on the surface of cell membranes (Savio-
Galimberti et al. 2008). WGA staining was used to detect pathological cell growth in cardiac 
sections. Paraffin embedded sections cut at 5 µm thickness were dried overnight at 37°C, 
deparaffinised and rehydrated as described in Section 2.8. Antigen retrieval was performed 
to allow immuno-histochemistry staining of cardiac sections with WGA. Aldehyde-
containing fixatives, used to fix the tissue for paraffin embedding, causes cross-linking of 
the proteins within the tissue sample. This cross-linking can mask the protein epitope and 
block the primary antibody from recognizing and binding it. The epitope can be unmasked 
by antigen retrieval, causing a reversal or unfolding of proteins within the tissue and 
allowing the antibody to successfully bind. Antigen retrieval was performed by immersing 
the slides in 10 mM sodium citrate buffer at pH 6.0 followed 10 minutes in a microwave 
oven to increase the temperature. The slides were cooled down at RT and washed with tap 
water. WGA staining was performed with the following steps: on the first day 
permeabilization (0.1% Triton X for 5 minutes), blocking (3% BSA + 5% normal mouse 
serum for 45 minutes) and primary antibody incubation (WGA, 5 µg/mL; Sigma-Aldrich, 
Gillingham, UK - #L4895) overnight at 4°C. On the following day, the slides were washed 
twice with 1X PBS, incubated with secondary antibody anti-mouse IgM-Alexa Fluor® 594 
(1:1000; Invitrogen, Carlsbad, CA, USA - #A-21044) produced in goat for 1 hour at RT, and 
washed in 1X PBS. To stain cell nucleus, slides were incubated with DAPI at a 
concentration of 100 ng/mL for 4 minutes and finally mounted as described above. The 
images were taken at 40X magnification and analysed using NIS elements software and the 
cross-sectional area (CSA) average value of each heart was calculated using five different 
areas for each section and counting ≥40 cell areas for each section. 
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2.8.5 Analysis of apoptosis via TUNEL assay 
Detection of programmed cell death (i.e. apoptosis) was performed to investigate whether 
transplanted HEK 293 cells were viable and whether isoproterenol treatment contributed to 
an increase in this mechanism. Cleavage of DNA during apoptosis may induce the 
formation of double-stranded DNA fragments or single-strand breaks. The terminal 
deoxynucleotidyl transferase 2´-Deoxyuridine, 5´-Triphosphate (dUTP) nick end labeling 
assay (TUNEL assay; Roche Applied Science, Burgess Hill, UK, #11684795910) allows 
identification of DNA strand breaks by labelling free 3’-OH termini with modified 
nucleotides in an enzymatic reaction. The terminal deoxynucleotidyl transferase included in 
the kit catalyses this reaction and the nucleotide polymers, which incorporate Fluorescein 
labels, can be detected and quantified by fluorescence microscopy. Briefly, paraffin 
embedded cardiac sections were deparaffinised and rehydrated as described above and pre-
treated with Proteinase K (20 µg/mL) for 30 minutes at 37°C. Slides were rinsed twice with 
1X PBS and covered with 50 µL of TUNEL reaction mixture containing 1/10 of Enzyme 
solution and 9/10 of Label solution. Control sections were incubated with label solution only. 
Slides were incubated at 37°C in a humidified atmosphere in the dark. After 1 hour, they 
were washed twice with 1X PBS for 5 minutes and incubated with 100 ng/mL DAPI for 10 
minutes. Mounting was performed as above. TUNEL positive signal was investigated using 
fluorescence microscope with an excitation wavelength of 488 nm and detection in the range 
of 515-565 nm. 
 
2.9 Neonatal mouse ventricular cardiomyocytes isolation and culture 
Neonatal mouse ventricular cardiomyocytes (NMVM) were isolated and cultured using a 
modified and optimized version of the Worthington protocol (Worthington Biochemical 
Corp., Lakewood, NJ, USA), using the enzymes provided by the company. Under a Class II 
Biological Safety Cabinet, the enzymes were prepared before starting the procedure and 
preserved at -20°C for long storage or at 4°C immediately before cardiomyocytes isolation. 
One vial of trypsin (213 u/mg; Worthington Biochemical Corporation, USA - #LK003225) 
was reconstituted with 2 mL of Ca2+ and Mg2+ free Hank’s buffered salt solution (HBSS; 
Sigma-Aldrich, Gillingham, UK - #H6648). Trypsin inhibitor (Worthington Biochemical 
Corporation, USA - #LK003235) was dissolved in 1 mL HBSS, whereas collagenase (1,085 
u/mg; Worthington Biochemical Corporation, USA - #LK003245) was reconstituted in 5 
85	  	  
mL Leibovitz L-15 serum-free medium (L-15; Sigma-Aldrich, Gillingham, UK - #L1518). 
The two day protocol consists of a first step (day 1) where dissected hearts are incubated 
with trypsin and a second step (day two), where cells are treated with collagenase and pre-
plated for separation of cardiomyocytes from stromal and endothelial cells. On day one, 10-
to-13 neonatal (1-2 day old) mouse pups were sprayed with 70% industrial methylated 
spirits (IMS) after cervical dislocation, the head was removed and the chest was opened. 
The beating heart was excised and sterilized with 70% IMS and immediately placed in cold 
HBSS in ice. Under a sterile tissue culture hood the hearts were washed twice in the falcon 
tube with 10 mL cold HBSS to remove traces of blood and transferred to a 6 cm Petri dish. 
Using two sterile, disposable scalpels, the atria and surrounding connective tissues were 
removed and the remaining ventricles were finely minced. Drop by drop, 1 mL of cold 
HBSS was added on the dissected tissue and then slowly aspirated to remove remaining 
traces of blood. The clean and homogenized ventricular tissues were incubated overnight 
(14-16 hours) at 4°C, with 3 mL of HBSS and 333 µL of trypsin solution. A 6 well- or 12 
well- culture plates were coated with fibronectin (Sigma-Aldrich, Gillingham, UK - #F0895) 
to facilitate NMVM seeding on the following day. Fibronectin was diluted with HBSS at a 
final concentration of 0.01 mg/mL and it was added to a 6 well plate (1 mL) or a 12 well 
plate (500 µL). Plates were left overnight at 4°C. On the following morning (day 2) the 
tissue were transferred to a T75 tissue-culture grade flask (BD Biosciences, UK - #353136) 
and 166 µL of trypsin inhibitor were added to block the effect of trypsin. The flask was 
mixed and placed horizontally to expand the surface for trypsin inhibitor action and 
incubated at a 37°C in a humidified CO2 incubator. The 6 well or 12 well plates coated with 
fibronectin were aspirated of the HBSS and let dry under a cell culture hood with the lead 
removed. After 15 minutes of trypsin inhibitor, 833 µL of collagenase were added to the 
flask and this was placed horizontally in a 37°C shaking water bath. Tissue digestion was 
allowed for 35-45 minutes. Only when sufficient degree of tissue digestion was determined 
by eye, the flask was placed under a sterile hood and 10 mL of previously equilibrated L-15 
medium (37°C) was added. Using a 10 mL serological pipette, the cell suspension was first 
aspirated ten times in order to completely dissect the tissues. The cell suspension was 
filtered on a 0.7 µm cell strainer (BD Biosciences, UK - #352350) to remove large, 
undigested tissue and transferred to a 50 mL falcon tube. An additional 10 mL L-15 medium 
were used to collect remaining cells in the flask and added to the falcon tube. This was 
centrifuged at 1,500 rpm for 5 minutes to pellet the cells and remove non-viable cells, the 
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supernatant was aspirated and the pellet re-suspended in 10 ml of pre-warmed cell culture 
medium (preparation described in Section 2.2.1, and transferred to a T75 tissue culture flask. 
A first pre-plating was performed by keeping the flask at 37°C, in a humidified CO2 
incubator. This process allows fibroblasts and endothelial cells to attach to the flask and to 
aspirate the NMVM that remain in suspension. After 30 minutes, the cell culture medium 
containing NMVM was transferred to a 50 mL falcon tube and 10 mL of complete medium 
were used to rinse the flask and collect the remaining NMVM. The attached fibroblasts and 
other cardiac cells could be observed under the microscope and were maintained in culture 
by adding 5 mL of complete medium in the flask. This flask was passaged and the cells used 
as control for future experiments. A second pre-plating was performed. Centrifuged NMVM 
were re-suspended in 10 mL of complete medium, transferred to a new T75 cell culture 
flask and kept for 40 minutes in at 37°C in the humidified incubator. NMVM density was 
measured using a haemocytometer (VWR, Lutterworth, UK - #HECH47112). From the 
falcon tube with NMVM re-suspended in 5 ml complete medium, a total of 10 µL were 
mixed with 10 µL of Trypan Blue (Sigma-Aldrich, Gillingham, UK, # T8154), which is 
used to detect apoptotic cells. Total cell number was estimated by using the following 
formula:  
 
Total number of 
cells in 4 squares 
 
*2dilution with Trypan Blue *5*104= Total n of NMVM/mL 
 
4 
NMVM were seeded onto a 6 well or 12 well plates at a density of 1 x 106 cells or 0.5 x 106 
cells/well, respectively. Complete NMVM confluence in the wells is fundamental to avoid 
fibroblasts proliferation and consequent contamination of the experiments. Consequently, 
cell counting and seeding must be performed precisely. Cell culture plates were incubated 
for 3 days in a 37°C humidified CO2 incubator to allow NMVM to attach firmly. After this 
period, cells were beating synchronously and were ready to be treated for experiments as 
described in the next section. Complete medium was changed to serum-free medium the 
night before starting the experiment. 
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2.9.1 IGF-1 conditioned medium and NMVM cardiac hypertrophy in 
vitro. 
In order to understand the role of different IGF-1 isoforms in cardiac hypertrophy, isolated 
neonatal cardiomyocytes were pre-conditioned with different cell culture medium 
containing IGF-1 isoforms and treated with isoproterenol to induce hypertrophy in vitro. As 
described in Section 2.5, 80-90% confluent HEK 293 cells were transfected with IGF-1Ea or 
IGF-1Stop plasmids, whereas control cells were incubated with Lipofectamine only. After 
24hrs, the conditioned medium was harvested from the cells, filtered on a 0.7 µm cell 
strainer and centrifuged at 8,000 rpm at 4°C for 10 minutes to remove cell debris. Aliquots 
were prepared and immediately stored at -80°C. Isolated NMVMs were cultured as 
described in the previous section, serum-starved overnight and washed with 1X sterile PBS. 
The culture medium was changed to 1-3 mL of conditioned medium containing IGF-1Ea, 
IGF-1Stop or with control medium from untransfected HEK 293 cells. After 24 hours, 
isoproterenol was added to the well at a final concentration of 10 µM. The multi-well plates 
were incubated at 37°C in a humidified CO2 incubator. After 5 or 30 minutes the medium 
was removed, cardiomyocytes were washed twice with cold 1X PBS and treated for RNA or 
protein extraction as described in Section 2.7.1 or 2.7.4, respectively. 
A similar approach was used to culture NMVM with conditioned media from P19-
GFP/IGF-1Ea or P19-GFP cells. The cell culture media were collected and stored at -80°C 
until required. When the NMVC where ready to be treated, the conditioned media was 
thawed and added for 24 hours on the cardiomyocytes. 
 
2.10 Data and Statistical analysis 
GraphPad Prism V.6® (GraphPad Software, LaJolla, USA) programme was used for 
statistical analysis and comparison of 3 or more samples was performed by analysis of 
variance (ANOVA). Bonferroni post-testing (compare all pairs of columns) was included in 
all statistical comparisons. Values are expressed as mean relative expression or mean fold 
induction ± standard error of the mean (SEM). * p < 0.05, ** p < 0.01, *** p < 0.001. 	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Table 2.13 List of TaqMan Gene Expression assays used for qPCR 
Gene Name Gene symbol Applied Biosystems Probe  
18S ribosomal RNA Mouse 18s rRNA 4310893E 
Actin, alpha 1, skeletal muscle Mouse Acta1 Mm00808218_g1 
Angiotensin II receptor 1a Mouse Agtr1a Mm01957722_s1 
ATPase, Ca2+ transporting, cardiac muscle, slow 
twitch 2 
Mouse Atp2a2 Mm01201431_m1 
Insulin-like growth factor 1 Mouse Igf-1 Mm00439560_m1 
Natriuretic peptide precursor type A Mouse Nppa (ANP) Mm01255747_g1 
Natriuretic peptide precursor type B Mouse Nppb (BNP) Mm01255770_g1 
Myosin, heavy polypeptide 6, cardiac muscle, alpha Mouse Myh6 (α-MHC) Mm00440359_m1 
Myosin, heavy polypeptide 7, cardiac muscle, beta Mouse Myh7 (β-MHC) Mm00600555_m1 
Vascular endothelial growth factor A Mouse VEGFA Mm01281449_m1 
   
 
Table 2.14 List of probes for Gene Card Assay 
Gene Name Gene Symbol Applied Biosystems Probe  
A disintegrin and metallopeptidase domain 12 (meltrin alpha) Adam12  Mm00475719_m1 
ADAM metallopeptidase domain 17 Adam17 Mm00456428_m1 
Angiotensinogen Agt  
ATPase, Ca2+ transporting, cardiac muscle, slow twitch 2 Atp2a2  Mm01201431_m1 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 Atp5c1  Mm00662408_m1 
Catalase  Cat Mm00437992_m1 
Collagen, type I, alpha 1 Col1a1 Mm00801666_g1 
Connective tissue growth factor Ctgf  Mm01192932_g1 
Endonuclease G Endog  Mm00468248_m1 
Fibronectin 1  Fn1  Mm01256744_m1 
Hydroxymethylbilane synthase Hmbs  Mm01143545_m1 
Interleukin 6 (interferon, beta 2) Il6  Mm00446190_m1 
Mitogen-activated protein kinase kinase kinase 5 Map3k5  Mm00434883_m1 
Mitogen-activated protein kinase kinase kinase 7 Map3k7  Mm00554514_m1 
Mitogen-activated protein kinase kinase kinase kinase 4 Map4k4  Mm00500813_m1 
Myocyte enhancer factor 2C Mef2c  Mm01340842_m1 
Misshapen-like kinase 1 Mink1  Mm00489533_m1 
Matrix metallopeptidase 14 (membrane-inserted) Mmp14  Mm00485054_m1 
Matrix metallopeptidase 2 Mmp2  Mm00439498_m1 
Matrix metallopeptidase 9 Mmp9 Mm00442991_m1 
Myosin, heavy polypeptide 6, cardiac muscle, alpha Myh6  Mm00440359_m1 
Myosin, heavy polypeptide 7, cardiac muscle, beta Myh7  Mm01319006_g1 
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Myosin, light polypeptide 3 Myl3  Mm00803032_m1 
Myosin, light polypeptide 4 Myl4  Mm00440378_m1 
Nuclear factor, erythroid derived 2, like 2 Nfe2l2  Mm00477784_m1 
Natriuretic peptide precursor A Nppa  Mm01255747_g1 
Natriuretic peptide precursor B Nppb  Mm01255770_g1 
Oxidized low density lipoprotein (lectin-like) receptor 1 Olr1  Mm00454586_m1 
Phospholamban Pln  Mm00452263_m1 
Periostin, osteoblast specific factor Postn  Mm00450111_m1 
Peroxisome proliferator activated receptor alpha Ppara  Mm00440939_m1 
Peroxisome proliferator-activator receptor gamma Pparg  Mm01184322_m1 
Peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha Ppargc1a  Mm01208835_m1 
Serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1  Mm00435860_m1 
Superoxide dismutase 2, mitochondrial Sod2  Mm01313000_m1 
DNA primase, catalytic subunit Spp1 Spp1  Mm00436767_m1 
Transcription factor A, mitochondrial Tfam  Mm00447485_m1 
Transforming growth factor, beta 1 Tgfb1  Mm01178820_m1 
Transforming growth factor, beta 2 Tgfb2  Mm00436955_m1 
Transglutaminase 2 (C polypeptide, protein-glutamine-
gamma-glutamyltransferase Tgm2 Mm00436987_m1 
Tissue inhibitor of metalloproteinase 1 Timp1  Mm00441818_m1 
Tissue inhibitor of metalloproteinase 2 Timp2 Mm00441825_m1 
Tissue inhibitor of metalloproteinase 3 Timp3 Mm00441826_m1 
Tissue inhibitor of metalloproteinase 4 Timp4 Mm01184417_m1 
Tumor necrosis factor Tnf  Mm00443260_g1 
TRAF2 and NCK interactin kinase Tnik  Mm01286430_m1 
Ubiquitin conjugating enzyme Ubc Ubc  Mm01201237_m1 
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Table 2.15 List of antibodies used for western blot analysis 
Target protein Catalog # Company 
Phospoho-p38 4631 Cell Signaling, Danvers, MA, USA 
Total-p38 9212 Cell Signaling, Danvers, MA, USA 
IGF-1 I2157 Sigma-Aldrich, Gillingham, UK 
α-tubulin T6074 Sigma-Aldrich, Gillingham, UK 
Mouse IgG  Na931V GE Healthcare, Bucks, UK 
Rabbit IgG  Na934V GE Healthcare, Bucks, UK 
Goat IgG SC 2020 Santa Cruz Biotechnology, CA, USA 
GAPDH  2118 Cell Signaling, Danvers, MA, USA 	  
Table 2.16 Antibodies used for the Kinetworks™ Custom (multi-antibody) Protein Screen 
(KCPS 1.0) 
Target Protein Abbreviation Phospho Site 
3-phosphoinositide-dependent protein-serine kinase 1 PDK1 S241 
cAMP response element binding protein 1 CREB1 S133 
cAMP-dependent protein-serine kinase catalytic subunit 
alpha/beta  PKA Ca/b T198 
cAMP-dependent protein-serine kinase catalytic subunit β PKA Cb S339 
Connexin 43  Connexin 43 S368 
Extracellular regulated protein-serine kinase 1 (p44 MAPK)  Erk1 Y204 
Extracellular regulated protein-serine kinase 2 (p42 MAPK)  Erk2 Y187 
Extracellular regulated protein-serine kinase 5 (Big MAPK 
1 (BMK1) Erk5 T218+Y220 
Forkhead-like transcription factor 1 (FOXO3A)/Forkhead 
box protein O1A  
FKHRL1/ 
FOXO1A T32/ T24 
Glycogen synthase-serine kinase 3 alpha  GSK3a S21 
Glycogen synthase-serine kinase 3 beta  GSK3b S9 
Insulin-like growth factor receptor protein-tyrosine kinase IGF1R Y1280 
MAPK/ERK protein-serine kinase 3/6 (MKK3/6)  MEK3/6 (MAP2K3/6) S218/S207 
p21-activated protein-serine kinase 1/2/3  PAK1/2/3 S144/S141/S154 
Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and 
protein phosphatase and tensin homolog deleted on 
chromosome 10  
PTEN S380+T382+S385 
Protein-serine kinase B alpha PKBa (Akt1) S473 
Protein-serine kinase C alpha  PKCa S657 
Protein-serine kinase C delta PKCd Y313 
Raf1 proto-oncogene-encoded protein-serine kinase  Raf1 S259 	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Ischemic heart disease is one of the leading causes of death worldwide for both men and 
women. MI, which is one of the pathological events leading to heart failure (Segers and Lee 
2010, Mathers and Loncar 2006), results in death of millions of cells in the heart. The 
consequent replacement of apoptotic and necrotic cells by fibrotic, non-contractile tissue 
leads to remodelling of the cardiac structure and decreased global function. Different 
approaches have been used to treat patients affected by MI to prevent this pathological 
remodelling process, including implantable devices (Park et al. 2012) cell-based treatments 
(Sanganalmath and Bolli 2013) and pharmacological therapies based on naturally-occurring 
proteins (Krum and Teerlink 2011). In this context, IGF-1 and its isoforms have been 
correlated with cardio-protective mechanisms. Cardiovascular disease mortality is elevated 
2-fold among individuals with IGF-1 deficiency (Rosen and Bengtsson 1990) and low IGF-
1 levels were associated with coronary artery disease (Schuler-Luttmann et al. 2000). 
Importantly, IGF-1 was shown to inhibit cardiomyocyte apoptosis in the heart (Wang et al. 
1998a). Our laboratory has produced extensive research on the role of the IGF-1 propeptides, 
showing that IGF-1Ea is a key regulator of cardiac and skeletal muscle physiopathology. 
We previously demonstrated that IGF-1Ea levels are transiently increased in response to 
local damage in skeletal muscle (Musaro et al. 2001). Importantly, the work conducted by 
Dr Santini in our laboratory demonstrated that specific overexpression of IGF-1Ea in adult 
cardiomyocytes protects the mice heart from deterioration 2 months after MI (Santini et al. 
2007). On the basis of this previous research on transgenic models, it was hypothesized that 
the cardio-protective effects of IGF-1Ea could be extended to a clinical-like scenario, and 
two models of IGF-1Ea delivery during MI (Chapter 3) or during early phases of 
pathological hypertrophy (Chapter 4) were established to test this hypothesis. 
The aim of the present study was to test the efficacy of cardiac IGF-1Ea delivery in 
protecting the heart from deleterious mechanisms induced by pathological stimuli. This 
particular chapter describes the first approach aimed at understanding how IGF-1Ea may 
protect the heart from MI. For this purpose, a model of MI via ligation of the LCA followed 
by pluripotent P19 cell mediated-IGF-1Ea cardiac delivery was established, as described in 
Section 2.1. The results presented in this chapter demonstrate that IGF-1Ea protects the 
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heart from the development of pathological cardiac hypertrophy two months after MI injury. 
Functional and morphological analyses described in this chapter were performed by Dr. 
Bhawana Poudel, whereas the investigation of hypertrophic gene regulation in vivo and the 
additional in vitro experiments on isolated neonatal cardiomyocytes were part of my 
preliminary work included in this thesis. 
	  
3.2 Cell-mediated IGF-1Ea therapy 
To investigate a therapeutically relevant mode of IGF-1Ea cardiac delivery, pluripotent P19 
embryonal carcinoma cells (P19-GFP) (Moore et al. 2004) were transduced with a lentivirus 
encoding the IGF-1Ea gene driven by the CMV promoter, differentiated in cardiomyocytes 
(P19-GFP/IGF-1Ea CM), and injected in the left ventricle after induction of acute MI by 
permanent occlusion of the left-anterior descending coronary artery. P19-GFP cells were 
chosen because they are easy to manipulate in vitro and they can be rapidly differentiated in 
adult cardiomyocytes by adding DMSO to the cell culture medium. Before proceeding with 
the in vivo left ventricular transplantation, a detailed characterization of P19-GFP 
cardiomyocytes confirmed that they were mechanically active and possessed structural 
properties resembling mature cardiac myocytes (data not shown). A total of 106 P19-
GFP/IGF-1Ea CM were injected into the left ventricular wall of C57BL/6 mice immediately 
after LCA ligation. Sham operated mice and infarcted mice injected only with PBS in the 
left ventricle or transplanted with cells not transduced with the lentivirus (P19-GFP CM) 
were used as controls. Functional (Figure 3.1), morphological (Figure 3.2-3.3) and 
molecular (Figure 3.4) analyses were performed in mice 2 months after LCA ligation with 
or without cell transplantation. Results are presented in the following sections. This chapter 
also includes additional in vitro experiments, where isolated neonatal cardiomyocytes were 
treated with different conditioned media from the same cells described above for the in vivo 
experiments. 
 
3.2.1 IGF-1Ea P19 cell-mediated delivery improves local cardiac function 
To analyse whether IGF-1Ea delivery could preserve global and/or local cardiac function 
after MI, echocardiography assessment was performed 2 months after LCA ligation in 
control mice and in mice transplanted with 106 P19-GFP/IGF-1Ea or P19-GFP 
cardiomyocytes (Figure 3.1). Global cardiac function measured as percentage of ejection 
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fraction (data not shown) was significantly decreased in all infarcted groups when compared 
to non-infarcted mice, confirming that LCA ligation successfully induced deterioration of 
cardiac function. No improvement of global function (i.e. no changes in % of ejection 
fraction; data not shown) was induced in mice transplanted with P19-GFP cells with or 
without IGF-1Ea transduction. Local cardiac function was measured in the anterior and 
posterior walls of the left ventricle and the anterior (AWT) and posterior (PWT) wall 
thickening percentages were calculated for each parameter as: [(systolic wall thickness-
diastolic wall thickness)/diastolic wall thickness] x 100. As shown in Figure 3.1, wall 
thickening of the anterior wall (A), which is a measurement of the ventricular wall 
contractility in the area where the cells were injected in the transplanted mice and where the 
effect of LCA ligation are more evident, was significantly reduced in infarcted mice. 
Importantly, only mice receiving transplantation of P19-GFP/IGF-1Ea CM showed AWT 
levels comparable to the sham-operated group, with no statistical difference found. 
Transplantation of P19-GFP CM not expressing IGF-1Ea did not produce similar beneficial 
effects, suggesting a specific effect induced by the presence of IGF-1Ea in the cells. 
Although all infarcted hearts displayed a tendency to reduction of PWT (B), this was not 
significantly different among all groups. 	  
	  
Figure 3.1 Local functional analysis of the heart 2 months after MI and cell transplantation (A) 
Anterior and (B) posterior wall thickening (AWT and PWT) of sham-operated control mice (right 
bar) or infarcted mice transplanted with PBS (left bar), with P19-GFP/IGF-1Ea (middle-left bar) or 
with P19-GFP (middle-right bar) cardiomyocytes (CM) in the heart measured 2 months after 
permanent LCA ligation. Graphs show mean values ±SEM. One-way ANOVA test was used. ** = p 
< 0.01; *** = p < 0.001 and ns = not significant. n = 4-7. 
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Histological analysis (Figure 3.2 A) was performed on 5 µm cardiac sections treated for 
Masson’s trichrome staining to assess differences in fibrotic tissue 2 months after MI. 
Quantification of scar tissue extension in the left ventricle (Figure 3.2 B) showed no 
statistically significant differences between the three groups of infarcted mice transplanted 
with P19-GFP/IGF-1Ea CM, with P19-GFP CM or with PBS only, suggesting that no 
reduction of MI-induced fibrosis was modulated by P19 cells transplantation or by IGF-1Ea. 
 
	  
Figure 3.2 Histological analysis of scar tissue post-MI Left panels (A) show representative images 
of Masson’s trichrome staining of the short axis in paraffin embedded hearts. The analysis was 
performed 2 months after MI in hearts transplanted with PBS (left panel), with P19-GFP/IGF-1Ea 
CM (middle panel) or with P19-GFP CM (right panel). (B) Quantitative analysis of the scar size 
showing no difference between the three groups. Graph shows mean values ±SEM. One-way 
ANOVA test was used to quantify scar size. ns = not significant. n = 4-7. 
	  
3.2.2 IGF-1Ea modulates pathological hypertrophy 2 months after MI 
The local functional improvement induced by transplantation of P19-GFP/IGF-1Ea 
cardiomyocytes led to further investigations into the effects mediated by IGF-1Ea on the 
area of delivery. Myocardial infarction induces apoptosis of cardiac cells due to lack of 
sustained blood supply and the remaining cardiomyocytes initiate a process of remodelling 
(e.g. changes in molecular signalling, increased cell volume) in order to compensate the lost 
contractile force. If not regulated, this initial physiological response of the heart by cell 
hypertrophy can degenerate and develop to pathological increase of the ventricular lumen, 
with consequent deterioration of contractility and global cardiac function (Frey and Olson 
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2003). To investigate whether IGF-1Ea may maintain the local cardiac function described in 
the previous section by negatively interfering with cardiomyocyte hypertrophy, cardiac 
sections from the different experimental groups were used for immunofluorescence and 
analysis of cellular morphology. WGA was used to stain cell membranes and to measure 
cardiomyocytes cross-sectional area. As shown in Figure 3.3, cross-sectional area of 
cardiomyocytes bordering the scar tissue (delimited by the dashed line) was significantly 
increased 2 months after MI in infarcted hearts transplanted with PBS only (Panel A and left 
bar in graph D) compared to un-transplanted sham operated mice (right bar in graph D), 
confirming the onset of cell hypertrophy induced in the process of cardiac remodelling. 
Interestingly, transplantation of P19-GFP/IGF-1Ea CM blocked the increase in 
cardiomyocyte CSA (Panel C and second left bar in graph D) with values similar to un-
transplanted sham operated mice. On the contrary, transplantation of P19-GFP CM did not 
prevent the increase in cardiomyocyte CSA induced by MI (Panel B and second right bar in 
graph D). To determine whether the beneficial effects of IGF-1Ea extended distally from the 
site of transplantation, CSA was measured in the area distal to the infarcted region (data not 
shown). No improvement by IGF-1Ea was detected distally, indicating that IGF-1Ea acted 
locally and proximal to the injection site. Taken together, these data indicate that IGF-1Ea 
protects the heart from the development of cardiac hypertrophy measured 2 months post-





Figure 3.3 IGF-1Ea blocks hypertrophic growth of cardiac cells 2 months after MI CSA was 
measured in cardiac cells bordering the scar tissue in mice that underwent LCA ligation injected with 
PBS (A), P19-GFP CM (B) or P19-GFP/IGF-1Ea CM (C) after staining with Wheat Germ 
Agglutinin. Dashed line demarks the area bordering the scar tissue. Nuclei were stained with 
Hoechst dye. (D) Quantification of CSA. Statistical analysis was performed using one-way ANOVA. 
* = p < 0.05. n = 5. 
 
Pathological hypertrophy and the described increase in cardiomyocyte volume are the result 
of specific molecular changes in gene expression. Reactivation of the so-called cardiac fetal 
gene program in adult mice is a reliable marker of cardiac hypertrophy and is also found 
during heart failure (Kuwahara, Nishikimi and Nakao 2012). To analyse whether the 
beneficial effects induced by P19-GFP/IGF-1Ea CM transplantation may correlate with a 
specific molecular fingerprint, pathological markers of hypertrophy were investigated. The 
mRNA levels of beta myosin heavy chain (βMHC), alpha skeletal actin (alpha SA) and 
angiotensin II receptor 1a (Agtr1a) in myocardial samples from sham operated mice, 
infarcted mice and infarcted mice transplanted with P19-GFP/IGF-1Ea CM or P19-GFP CM 
were examined using qPCR. As expected during cardiac hypertrophy, βMHC, alpha SA and 
Agtr1a mRNA levels were increased in mice subjected to MI compared to sham operated 
mice 2 months after infarction (Figure 3.4 A-C). Interestingly, P19-GFP/IGF-1Ea CM 
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transplantation significantly normalized alpha SA and Agtr1a mRNA to control levels and 
mitigated βMHC mRNA. On the contrary, infarcted mice transplanted with P19-GFP 
cardiomyocytes or with PBS did not show any improvements. In conclusion, the molecular 
analysis showed that the presence of IGF-1Ea in the heart offered cardio-protection from the 
long-term expression of pathological genes generally recognized as associated with cardiac 
hypertrophy.	  	  
	  
Figure 3.4 Analysis of hypertrophic genes expression in vivo 2 months post-MI (A) Beta myosin 
heavy chain (β-MHC), (B) Alpha-Skeletal actin (Alpha SA) and (C) Angiotensin 2 receptor 1a 
(Agtr1a) mRNA levels analysed by qPCR in sham-operated control mice (right bar) or in infarcted 
mice transplanted with PBS (left bar), with P19-GFP/IGF-1Ea CM (middle-left bar) or with P19-
GFP CM (middle-right bar). Samples were normalized on 18S rRNA. Graphs show mean values 
±SEM. Statistical analysis was performed using one-way ANOVA. * = p < 0.05; ** = p < 0.01; *** 
= p < 0.001. n = 3. 
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3.3 Effects of IGF-1Ea on cardiomyocytes in vitro 
The modulation of pathological hypertrophy in vivo by P19-GFP/IGF-1Ea CM 
transplantation raised the question whether the P19 cells used as a vehicle for IGF-1Ea 
delivery may have an independent role in the observed results and interfere in the 
remodelling post-MI. To test whether factors released by the transduced P19-GFP cells may 
mediate this response and to investigate the effects of IGF-1Ea on cardiomyocytes, an in 
vitro approach was set up. Neonatal mouse cardiomyocytes were isolated from the ventricles 
of 1-to-2 day old FVB wild-type mice and treated for 24 hours with conditioned media from 
P19-GFP/IGF-1Ea or P19-GFP cells maintained in culture. The mRNA level was measured 
for the genes previously analysed in vivo, as described in the previous section. As shown in 
Figure 3.5, both P19-GFP and P19-GFP/IGF-1Ea conditioned media decreased the 
expression levels of the hypertrophic marker βMHC (Figure 3.5 A) compared to control 
cardiomyocytes cultured with complete medium. Alpha-SA (Figure 3.5 B), Agtr1a (Figure 
3.5 C) and αMHC (Figure 3.5 D) transcripts were not affected. Although these results hint 
at an apparent effect by P19 cells on βMHC expression beyond paracrine effects modulated 
by IGF-1Ea, the results were not sufficient to show any specific modulation of hypertrophic 
genes in vitro by IGF-1Ea or by P19 cells.	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Figure 3.5 Effects of IGF-1Ea conditioned media on neonatal cardiomyocytes in vitro Isolated 
neonatal cardiomyocytes cultured for 24 hours with normal complete medium (CTRL) or with media 
harvested from P19-GFP/IGF-1Ea or P19-GFP cells. Messenger-RNA was isolated and (A) βMHC, 
(B) alpha-SA, (C) Agtr1a and (D) αMHC gene expression was measured by qPCR. 18S was used as 
housekeeping gene to normalize expression levels. * = p < 0.05; ns = not significant. n = 3. 
	  
3.4  Angiogenesis and VEGF-A regulation by IGF-1Ea 
Coronary artery disease and ischemic cardiomyopathy inducing death of cardiomyocytes 
stimulates the development of supplemental collateral blood vessels that constitute 
endogenous bypass conduits around the occluded native arteries. This mechanism allows for 
partial restoration of perfusion of ischemic territories and improves oxygen supply to the 
cardiac tissue (Lavine et al. 2013, Losordo, Vale and Isner 1999). The vascular endothelial 
growth factor-A (VEGF-A) plays an important role in the revascularization process by 
promoting angiogenesis and consequently improving cardiac function after MI (Zangi et al. 
2013). 
To investigate any potential correlation between IGF-1Ea mediated response after MI and 
the angiogenic program, capillary density and VEGF-A gene expression were analysed in 
vivo and in vitro. As shown in Figure 3.6, infarcted mice transplanted with P19-GFP/IGF-
1Ea CM showed statistically significant increase in capillary density (B) compared to PBS 
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injected mice. This data correlated with a significant increase in VEGF-A transcript level 
(A) only in the P19-GFP/IGF-1Ea group compared to non-infarcted mice. 
 
	  
Figure 3.6 IGF-1Ea modulates angiogenic program in vivo and in vitro (A) Transcript levels of 
VEGF-A analysed in whole heart from the 4 experimental groups 2 months post-MI. (B) Capillary 
density measured in the whole heart of infarcted hearts transplanted with PBS or with P19-GFP/IGF-
1Ea cardiomyocytes. (C-D) VEGF-A mRNA level in isolated neonatal (C) cardiomyocytes or (D) 
fibroblasts treated with conditioned medium for 24 hours. * = p < 0.05; ** = p < 0.01. n = 3. 
 
To investigate this response in vitro, isolated ventricular neonatal cardiomyocytes and 
fibroblasts were treated separately with conditioned media from P19-GFP/IGF-1Ea or P19-
GFP cells. The aim of these experiments was to understand whether IGF-1Ea was directly 
responsible for the increase in VEGF-A detected in the heart and whether these effects were 
visible in both cardiomyocytes and fibroblasts. Interestingly, only cardiomyocytes (Figure 
3.6 C) exposed to IGF-1Ea conditioned medium showed significant increase in VEGF-A 
mRNA, whereas no difference was detected in fibroblast (Figure 3.6 D) treated under the 
same conditions. Taken together, these in vivo and in vitro data suggest a direct effect of 
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IGF-1Ea on improved capillary density stimulated by increased VEGF-A 2 months after 
LCA ligation. These effects are specific for cardiomyocytes, as no differences in VEGF-A 
transcripts were found in fibroblasts. 
 
3.5  Discussion 
Initial insights into the role of IGF-1Ea in cardiac and skeletal muscle were previously 
addressed using genetic models with overexpression of the transgene in skeletal (Musaro et 
al. 2001, Pelosi et al. 2007) and cardiac (Santini et al. 2007) myocytes. These studies 
showed that IGF-1Ea induces physiological hypertrophy and regeneration after injury in 
skeletal muscle and protects the heart from ischemic insult also during late phases after 
injury. However, they did not test the potential of IGF-1Ea as a therapeutic in a clinically 
relevant approach. To date, only limited studies have demonstrated the effectiveness of IGF-
1 delivery in the heart (Enoki et al. 2010, Padin-Iruegas et al. 2009), but they did not assess 
the potential of IGF-1Ea delivery during pathological stimulation in the heart. 
The experiments presented in this chapter aimed at understanding whether the delivery of 
IGF-1Ea immediately after injury via infected cells could protect the heart from myocardial 
infarction. The P19 cells/IGF-1Ea combinatorial therapy was selected for its potential to 
rescue the heart’s lost contractile force through the transplanted cells while stimulating a 
response from the native tissue via IGF-1Ea paracrine function. P19 cells can be efficiently 
differentiated in adult cardiomyocytes (Moore et al. 2004) and the hypothesis that local 
delivery of IGF-1Ea may have a paracrine and/or autocrine function is supported by a recent 
study performed in our laboratory showing that the E-peptides moieties promote local action 
and retention of the IGF-1 core peptide in the tissue of synthesis/release (Hede et al. 2012). 
The in vivo results presented in this chapter showed that IGF-1Ea decreased the 
hypertrophic response 2 months after MI. Cross sectional area of cardiomyocytes (Figure 
3.3) and expression of pathological markers (Figure 3.4) were beneficially modulated by 
IGF-1Ea with long-term effects. Importantly, IGF-1Ea induced increase of VEGF-A gene 
expression in infarcted hearts, which correlated with improved angiogenesis compared to 
sham operated mice or mice transplanted with P19-GFP CM (Figure 3.6). Studies in 
hypertensive human patients and animal models demonstrated that Angiotensin II receptor 1 
antagonists and angiotensin converting enzyme inhibitor repress the development of 
pressure-overload cardiac hypertrophy (Paradis et al. 2000). As described in Section 3.2.2, 
transplantation of P19-GFP/IGF-1Ea cardiomyocytes resulted in decreased Angiotensin 
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receptor II mRNA level in the heart, but no effects where induced by the transplantation of 
P19-GFP cardiomyocytes (Figure 3.4). Moreover, the hypertrophic markers Alpha-SA and 
βMHC were beneficially regulated by IGF-Ea in the heart. The correspondent in vitro 
experiments described here (Figure 3.5) reported a decrease in βMHC mRNA level in 
cardiomyocytes cultured media either from P19-GFP/IGF-1Ea or from P19-GFP CM, 
suggesting that the beneficial effects were due to the transplanted cells themselves, and did 
not correlate with the presence of the IGF-1Ea propeptide. Analysis of additional 
hypertrophic markers in vitro indicated no effects mediated by the use of any of the different 
conditioned media. Comparison of in vitro and in vivo results suggests that the regulation of 
the hypertrophic markers by the cell-gene combination treatment involves mostly changes in 
cardiovascular mechanisms and hemodynamic occurring during myocardial infarction. 
Overall, the experiments presented in this chapter suggest that IGF-1Ea confers a long-term 
protection from the onset of pathological hypertrophy in vivo by acting on the surviving 
myocardium. The observed improvement in anterior wall motion determined by P19-
GFP/IGF-1Ea did not correlate with reduction of global fibrosis and re-absorption of scar 
tissue, suggesting that the improvement of local function by IGF-1Ea expression was 
determined by modulation of hypertrophy and wall stress rather than increased tissue 
regeneration. 
A potential limitation of this study is represented by the employment of P19 cells as a 
therapeutic and as vehicle for IGF-1Ea local delivery. Although it has been suggested that 
the beneficial effects of transplanted cells are mainly due to increased angiogenesis (Zhang 
and Pasumarthi 2008), which is in agreement with our results on VEGF-A, the therapeutic 
use of adult cardiomyocytes differentiated from embryonal lineages is very challenging. The 
variability in yield of cardiomyocytes production, the electromechanical properties of 
differentiated cells and the immune response may overcomplicate the interpretation of the 
results. The difficulties related to cell therapy are well worth overcoming when 
contemplating the benefits that this approach may bring, but several aspects still need to be 
addressed (Abdelwahid et al. 2011). In our study, the low amount of IGF-1Ea protein 
secreted by the infected P19-GFP/IGF-1Ea differentiated cardiomyocytes (data not shown) 
compared to non-infected cells represented an important limitation for the interpretation of 
the preliminary results described. The next chapter will describe different approaches 
employed to achieve high expression/secretion of IGF-1Ea in the heart and the application 
of a different cell population as a vehicle for IGF-1Ea protein production and delivery. 
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4 Tools for IGF-1 cardiac delivery and pathological cardiac hypertrophy 
 
4.1 Introduction 
The study reported in Chapter 3 demonstrated the protective effects of IGF-1Ea cell-
mediated delivery in the heart after myocardial infarction. However, the employment of P19 
cells as a vehicle for IGF-1Ea delivery for a therapeutic purpose presented different 
technical challenges. Most importantly, in the preliminary in vitro analysis it was found that 
the high level of IGF-1 mRNA measured in the transduced P19-GFP/IGF-1Ea 
cardiomyocytes compared to control cells did not correspond to a similar increase in IGF-
1Ea protein, indicating potential complications during the post-transcriptional processes 
between mRNA and protein synthesis (data not shown). The results and in general the 
interpretation of the data reported in Chapter 3 may have been influenced by this technical 
limitation. Therefore, in order to optimize IGF-1Ea delivery in the heart, different 
approaches were tested following this preliminary study. This chapter describes the results 
of two main experimental settings designed to improve IGF-1Ea delivery to the heart. 
Importantly, the results obtained in Chapter 3 suggested the involvement of IGF-1Ea in 
cardio-protective mechanisms during the onset of cardiac hypertrophy induced by LCA 
ligation. The ligation of the left coronary artery is an established and widely used method to 
induce myocardial infarction, ischemic damage and cardiac remodelling (Ahn et al. 2004, 
Klocke et al. 2007, Gao et al. 2010). However, the degree of experience required to perform 
the procedure and the reproducibility between experiments can influence the analysis of 
signalling pathways involved in cardiac remodelling, where the phosphorylation status of 
specific proteins can be variable and transient. In order to test the role of IGF-1Ea 
specifically during cardiac remodelling in a reproducible pathological model, I employed 
the β–AR agonist isoproterenol to induce cardiac damage and cardiac hypertrophy. The 
results of these experiments are described in Section 4.4 of this chapter. 
Furthermore, one of the aims of the work described in this thesis was to identify potential 
differences in cardio-protection from pathological hypertrophy by IGF-1Ea and the fully 
processed, mature IGF-1 peptide (IGF-1Stop). IGF-1Stop indicates the circulating form of 
IGF-1, which contains only the core peptide shared between all the IGF-1 isoforms (Barton 
2006a). IGF-1Ea is distinguishable from the other isoform by the presence of the Ea 
extension peptide at the C-terminus of the protein. 
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In the following study, IGF-1 delivery and secretion in the heart was established by 
transfecting HEK 293 cells with the IGF-1Ea and the IGF-1Stop DNA vectors followed by 
transplantation in the left ventricle. The correspondent Material and Methods description 
can be found in Section 2.6.2. 
 
4.2 From IGF-1Ea lentiviral delivery to HEK 293 transplantation 
To overcome the potential caveat introduced by the P19 cell-mediated delivery step, a 
preliminary experiment of direct IGF-1Ea lentivirus injection in the left ventricle was 
performed. The pLenti4/TO/V5-DEST-IGF-1Ea lentivirus used for these experiments was 
available in our laboratory and it was chosen because it was previously used for the 
infection of P19 cells. The lentivirus was first purified and concentrated and the viral titer 
was determined by infecting HT 1080 cells (Figure 4.1 A). In order to infect cardiac cells 
with the purified lentivirus, FVB wild-type mice were injected directly in the left 
myocardium with different combinations of pLenti4/TO/V5-DEST-IGF-1Ea and pLenti/TR 
lentiviruses. A control group was injected with PBS only. IGF-1Ea expression is tightly 
regulated by a combination of the pLenti4/TO/V5-DEST-IGF-1Ea (i.e. that contains IGF-
1Ea) and the pLenti/TR (i.e. that represses IGF-1Ea expression) lentiviruses, with the 
addition of tetracycline (i.e. that reverses IGF-1Ea repression by inhibiting pLenti/TR 
effects) to the animal diet after viral injection, as described in Section 2.2. Two mg/ml 
tetracycline (Tet) were added to the water diet of mice injected with 1:1 and 1:2 
combinations of pLenti4/TO/V5-DEST-IGF-1Ea and pLenti/TR lentiviruses (red and blue 
bars), and control mice were injected with the same combinations of lentiviruses and treated 
with normal drinking water (white and yellow bars) (Figure 4.1 B). At 30 days after cardiac 
injection of lentiviruses, no differences in IGF-1 mRNA level were detected in the right 
ventricle, left ventricle, liver and lung of mice injected with the lentiviruses compared to 
control mice. These data show that direct viral-mediated delivery of IGF-1Ea in the heart 
was unsuccessful. 	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Figure 4.1 Titering of pLenti4/TO/V5-DEST-IGF-1Ea lentivirus and measurement of IGF-1Ea 
expression after lentiviral cardiac delivery (A) IGF-1Ea Virus titer measured by transducing HT 
1080 cells (as described by the manufacturer). Bottom panels from left to right: mock control 
without transduction, virus dilutions 10-2 and 10-3. Top panels from left to right: Virus dilutions 10-4, 
10-5, 10-6. (B) IGF-1 gene expression was measured in the left ventricle, right ventricle, liver and 
lung using mRNA isolated from 5 different mice (each different color represents a different mouse). 
Each mouse was treated differently. PBS injected control mouse (PBS, black bars) was used as 
negative control. Mice injected in the left ventricle with a 1:1 (2x104 T.U.) or 1:2 combinations of 
pLenti4/TO/V5-DEST-IGF-1Ea and pLent6/TR lentiviruses followed by tetracycline in the drinking 
106	  	  
water (1:1 Tet, red bars; 1:2 Tet, blue bars) or water without tetracycline (1:1, white bars; 1:2, yellow 
bars). 
 
4.2.1 Transfected HEK 293 cells secrete IGF-1Ea and IGF-1Stop proteins 
The results of direct lentiviral delivery in the heart did not reach the desired infection levels 
and the consequent IGF-1Ea expression could not be detected. Therefore, a more practical 
way of expressing and delivering IGF-1Ea was established and optimized. For this purpose, 
HEK 293 cells were used as a vehicle to express and secrete high amount of IGF-1 via 
transient transfection with DNA vectors and direct cardiac transplantation. DNA plasmids 
were cloned as described in Section 2.3.2. To test the potential use of this model, HEK 293 
cells 80% confluent were transiently transfected with IGF-1Ea or IGF-1Stop plasmids (see 
Section 2.4 and Section 2.5 for details on methodology). Transcript levels of IGF-1 were 
measured in HEK 293 cells transfected with the IGF-1Ea vector 24 hours after transfection. 
The result showed high level of IGF-1 mRNA when compared to un-transfected HEK 293 
cells (Figure 4.2 A). To investigate whether the IGF-1Ea and IGF-1Stop proteins were 
correctly translated and secreted into the cell culture medium, supernatants of HEK 293 
cells transfected with the IGF-1Ea or IGF-1Stop plasmids were analysed by immunoblotting. 
The same anti-IGF-1 antibody was used to detect the two different proteins. Importantly, 
results showed that comparable amounts of IGF-1Ea and IGF-1Stop were released by 
transfected HEK 293 cells, as visible from the distinguishable protein bands on the film 
(Figure 4.2 B) and in agreement with previous studies (Hede et al. 2012). Un-transfected 
cells showed no detectable IGF-1Ea or IGF-1Stop proteins in the medium, suggesting that 
no endogenous IGF-1 is secreted by HEK 293. 
The purpose of testing this model was to create an efficient tool for production and delivery 
of the two different IGF-1 peptides for a period of 7 days. To test the perdurance of IGF-1Ea 
and IGF-1Stop proteins secreted in the cell culture medium, western blotting analysis was 
performed on supernatant 7 days after transfection. To ensure that no accumulation of IGF-1 
proteins in the cell culture media could interfere with the results, fresh media were replaced 
24 hours before harvesting the respective conditioned media on day 7 post-transfection. 
Notably, high amount of IGF-1Ea and IGF-1Stop were detected in the respective media, 
confirming that HEK 293 maintained their ability to secrete the proteins even after 7 days 
post-transfection (Figure 4.2 C). Taken together, these data show that HEK 293 cells 
transfected with IGF-1Ea and IGF-1Stop plasmids release high amount of the respective 
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proteins also after 7 days post-transfection.	  	  
	  
Figure 4.2 IGF-1 gene expression and protein secretion (A) mRNA samples isolated from HEK 
293 cells untransfected (black bar) or transfected with the plasmid pcDNATM 3.3-IGF-1Ea (white 
bar) used to measure IGF-1 gene expression 24 hours from transfection. (B) Secretion of IGF-1Ea 
propeptide (IGF-1Ea, left band) and IGF-1 peptide (IGF-1Stop, right band) in cell culture media 
tested 24 hours after transfection of HEK 293 cells with the respective plasmids. Control cell culture 
medium from un-transfected HEK 293 cells (middle) is also reported as negative control. Equal 
amounts of protein from the different conditioned media were loaded in each lane and processed by 
immunoblotting. (C) IGF-1Ea and IGF-1Stop protein levels in the cell culture media from HEK 293 
transfected cells measured 7 days post-transfection. Blots are representative of 3 experiments. 	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4.3 HEK 293 transplantation and IGF-1 expression in the heart 
Once optimized an efficient method to obtain consistent secretion of IGF-1Ea and IGF-
1Stop peptides from HEK 293 cells, I tested whether HEK 293 cells may be employed as a 
vehicle to deliver and maintain the expression of both IGF-1Ea and IGF-1Stop proteins in 
the left myocardium of immunodepleted mice. HEK 293 cells were transfected for 24 hours 
with one or the other plasmids, incubated for two hours with complete medium containing 
DAPI to allow detection in the cardiac tissue, and transplanted in the left ventricle of 
NOD.SCID mice as previously described.  As shown in Figure 4.3, Haematoxylin & Eosin 
staining showed DAPI-labeled HEK 293 transplanted cells in the left ventricle forming 
transplanted islands, with a high nuclei/plasma ratio, 7 days after transplantation of 106 cells 
(Figure 4.3 A-B). The details of this procedure are described in Material and Methods and 
are currently in press (Poggioli et al. In press). The injected HEK 293 cells were found 
grouped in the area of transplantation surrounded by thin collagenous tissue (Figure 4.3 C-
D). To determine whether the HEK 293 transfected cells transplanted in the heart correctly 
expressed IGF-1, frozen sections where prepared from OCT embedded hearts 7 days post-
transplantation. The IGF-1Stop plasmid encoded a GFP reporter gene, which allowed the 
analysis of correct plasmid expression in vivo and in vitro. GFP+ cells were found in the area 
of injection and a high number of green fluorescent cells was detected among the DAPI+ 
HEK 293 cells transplanted (Figure 4.3 E-F) compared to sections of hearts transplanted 
with untransfected HEK 293 DAPI+ cells (data not shown).	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Figure 4.3 HEK 293 intra-ventricular transplantation and IGF-1 expression (A-B) H&E 
staining of cardiac sections from the left ventricle of mice injected with DAPI+ HEK 293 cells. Small 
arrows show transplanted islands detected 7 days after cell injection. (C-D) Trichrome staining 
shows collagenous tissue formed between HEK 293 cells and murine myocardial tissue (arrow). (E) 
106 transfected HEK 293 cells were incubated for 2 hours with 50 µg/ml DAPI and immediately 
transplanted in the left myocardium. Frozen sections show DAPI+ cells accumulated in the left 
ventricle in the area of injection. (F) GFP fluorescence from the pIRES2-EGFP-IGF-1Stop 
confirmed expression of the IGF-1 after 7 days from transplantation. Scale bar, 100 µm (A, B, C, E 
and F) or 10 µm (D). 
 
An important parameter of cell transplantation experiments is to establish whether the 
injected cells are viable in the host tissue. As shown in Figure 4.4, apoptosis of un-
transfected HEK 293 cells was tested by TUNEL assay. Transplanted DAPI+ HEK 293 cells 
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were clearly visible and accumulated in the left ventricle (Figure 4.4 A, 5x and 40x) and 
only few apoptotic loci were detected among the transplanted cells (Figure 4.4 B 5x and 
40x). These results suggest that the transplanted cells were viable after 7 days from 
transplantation in the left myocardium of immunodepleted mice.	  	  
	  
Figure 4.4 Injected HEK 293 cells viability detected 7 days post-transplantation by TUNEL 
assay (A) DAPI+ cells found in the area of injection in the left ventricle were accumulated and 
formed transplanted islands (A, 5x and 40x). (B) TUNEL assay was used to test apoptosis and 
positive cells show green fluorescence (B, 5x and 40x) 7 days after transfection. (C) Merge of DAPI 
and TUNEL positive signals. Scale bar, 100 µm (A, B, C; 5x) or 50 µm (A, B, C; 40x). 
 
4.4 Chemically induced model of cardiac hypertrophy 
Following optimization of HEK 293 transplantation and successful delivery of both IGF-
1Ea and IGF-1Stop in the left ventricle of NOD.SCID mice, a reproducible model of cardiac 
hypertrophy was tested using i.p. injections of isoproterenol, as described in Section 2.6.3. 
Two different concentrations of isoproterenol (1 and 10 mg/kg/day) were tested and injected 
i.p. in NOD.SCID mice. After 7 days, mice were sacrificed and their hearts were analysed. 
As shown in Figure 4.5 A, heart weight-to-body weight (HW/BW) ratio was significantly 
increased from 4.44 to 5.19 after the treatment with 1 mg/kg/day and to 5.43 after 10 
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mg/kg/day compared to saline injected mice.  Decompensation of the hypertrophic 
myocardium and the progression to cardiomyopathy is accompanied by interstitial fibrosis 
and disorganization of myocytes (Hunter and Chien 1999). Histological analysis was carried 
out to study the cardiac remodelling response. Sections of myocardium from non-injected 
and saline injected mice and from mice injected with 1 mg or 10 mg/kg/day isoproterenol 
were stained with WGA and DAPI to determine cardiac cell surface area.	  	  	  
	  
Figure 4.5 Pathological cardiac hypertrophy induced by isoproterenol (A-B) Heart-to-body-
weight ratio (HW/BW ratio, A) and cross sectional area (CSA, B) were measured in control non-
injected mice (white bar) and mice injected i.p. with saline 0.9% (black bar), 1 mg/kg/day (striated 
bar) or 10 mg/kg/day (dots bar) isoproterenol during 7 days. (C-D) Representative images of cardiac 
sections stained for WGA (green) and DAPI (blue) in saline (C) and 1 mg/kg/day isoproterenol (D) 
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injected mice showing increased cardiomyocytes CSA induced by isoproterenol. Scale bar, 100 µm. 
(E-F) H&E staining for the same groups as above showing presence of damage after 7 days of 
isoproterenol injections. ANOVA followed by Bonferroni post-tests were used to calculate statistical 
significance. * p < 0.05; ** p < 0.01; *** p < 0.001. n = 3-10 per group. Scale bar, 100 µm. 
 
As shown in Figure 4.5 B, both concentrations of isoproterenol induced a statistically 
significant increase in cardiomyocyte CSA. Quantification of CSA showed that the average 
cell area increased from 240 µm2 to 390 µm2 in response to 1 mg/kg/day isoproterenol and 
to 360 µm2 after 10 mg/kg/day isoproterenol over a period of 7 days. Analysis of H&E 
stained cardiac sections revealed the presence of diffused damage compared to saline 
injected mice (Figure 4.5 E-F). Taken together, these results suggest that both 
concentrations of isoproterenol induced cardiac hypertrophy when systemically 
administered in NOD.SCID mice over a period of 7 days. 
 
4.5 Discussion 
The results shown in this chapter represent an initial step towards the following 
investigation described in Chapter 5, where the effects of IGF-1Ea and IGF-1Stop in 
protecting the heart from isoproterenol were tested. The optimization of IGF-1 protein 
delivery in cardiac tissue and the establishment of a reliable methodology to induce 
pathological cardiac hypertrophy in immunodepleted mice described in this chapter were 
fundamental to proceed with this study and to test the main hypothesis of this thesis. 
My initial tests on IGF-1Ea lentiviral mediated delivery aimed at increasing the level of 
IGF-1Ea protein in cardiac tissue by using gene therapy. Myocardial gene therapy has been 
applied during more than two decades (Rosenberg et al. 1990, Losordo et al. 1999, Isner 
2002) and is currently being tested in clinical trials with positive preliminary results (Sikkel 
et al. 2013, Lyon et al. 2008). Substantial general and technical difficulties come with the 
application of viral vectors for gene therapy. Selection of the appropriate doses of viral 
vectors to combine safety and efficient infection of the target tissue and the high costs of 
production for clinical applications are some of the various hurdles that must be overcome 
in order to have an impact on function and clinical outcomes (Lyon et al. 2008). Injection of 
naked DNA, such as plasmid DNA, represents an alternative to viral vectors, but the 
efficacy of this approach is poor and high plasmid doses are required to achieve sufficient 
delivery of the target gene (Kastrup et al. 2005, Wright et al. 2001). My results (Figure 4.1) 
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show no expression of IGF-1 in the cardiac tissue after 30 days from lentiviruses injection 
followed by the required tetracycline administration to regulate the transgene expression. 
Even including purification and concentration of both lentiviruses to increase their titer, I 
could not obtain positive results with this approach. Whether the complexity of using a 
tetracycline-mediated expression of IGF-1Ea or whether other factors compromised the 
positive outcome of these experiments remains unknown. Nevertheless, viral mediated gene 
therapy remains one of the more specific and less invasive approaches for gene delivery in 
the heart and further studies in our research group are already on-going for the optimization 
of IGF-1 delivery by using adeno-associated viruses. 
In a second approach to successfully deliver IGF-1Ea and IGF-1Stop in the heart, I 
generated two cDNA expression constructs encoding IGF-1Ea propeptide and a plasmid 
carrying the mature IGF-1Stop (Figure 2.1) to transiently transfect HEK 293 cells. This cell 
line was chosen as a vehicle to produce both genes products due to its high efficiency of 
transfection, protein production and secretion. Transient transfection of HEK 293 cells 
showed high amount of IGF-1Ea and IGF-1Stop proteins secreted in the cell culture media 
at 24 hours and 7 days from transfection, confirming that they could be used as a vehicle for 
the production of high amount of IGF-1 proteins. HEK 293 cells are able to carry out most 
of the post-translational folding and processing required to generate functional, mature 
protein from a wide spectrum of mammalian and non-mammalian nucleic acids (Thomas 
and Smart 2005). Despite of their potential tumorigenicity, HEK 293 cells represent an 
effective way of expressing and secreting transfected plasmids in vivo and in vitro (Mineur 
et al. 2007). In my study, HEK 293 cells were used exclusively as a way to deliver and 
maintain the expression of IGF-1Ea and IGF-1Stop in the heart for a short period (7 days) 
but no therapeutic use of this specific cell line was proposed in my hypothesis. Importantly, 
my results show that transplanted HEK 293 cells were retained in the left ventricle of 
immunodepleted mice. Whether transfected or not with one of the two plasmids, the 
transplanted cells were easily detectable in the cardiac tissue thanks to the DAPI nuclear 
labeling performed before transplantation. Incubating the cells with DAPI was previously 
shown as an efficient way to track transplanted cells in vivo without affecting their viability 
or natural cellular mechanisms (Chen et al. 2011). The results showed in this chapter report 
that the injected cells were found grouped in the area of injection and were surrounded by 
fibrotic tissue. The NOD.SCID mice used for this study are immunodepleted and the 
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mechanisms related to toleration of exogenous material are not entirely clear. The formation 
of fibrotic connective tissue observed around the transplanted cells (Figure 4.3 C-D) can be 
considered as an encapsulation formed to isolate the transplanted material from the 
surrounding tissue. HEK 293 cells are non-contractile cells and their engraftment with the 
host tissue (i.e. surrounding cardiomyocytes) for electro-coupling was not prioritized for the 
purpose of this study. 
Another important parameter to be assessed was the viability of transplanted cells. As 
shown in Section 4.3, no significant level of apoptosis was detected in the myocardium after 
7 days from transplantation. Together with the previous data, these results indicate that HEK 
293 cells transfected with IGF-1Ea or IGF-1Stop plasmids are maintained in the host tissue 
for at least 7 days and are able to produce and secrete the two isoforms, as shown also by the 
in vivo and in vitro results showed above. 
Finally, following my preliminary results describing a potential involvement of IGF-1Ea in 
the blockade of cardiac hypertrophy (Chapter 3), a model of isoproterenol induced cardiac 
damage was established. Isoproterenol was injected in the peritoneum of NOD.SCID mice 
and both concentrations (1 mg/kg/day and 10 mg/kg/day) tested successfully induced 
cardiac hypertrophy measured as HW/BW ratio, cardiomyocytes cross sectional area and 
presence of cardiac damage (Figure 4.5). The treatment with 1 mg/kg/day was chosen for 
its lower mortality rate compared to the 10 mg/kg/day injections (0% vs. 30% mortality, 
respectively; data not shown). Previous publications using same concentration and duration 
of treatment (1mg/kg/day for 7 days) or employing different concentrations of isoproterenol 
for the same period demonstrate the feasibility and consistency of this protocol. Comparably 
to our results, Ferreira et al. showed that HW/BW ratio was increased from 4.53 mg/g to 
5.38 mg/g after 7 days of 1 mg/kg/day isoproterenol, mainly due to an increase in the left 
ventricle mass (Ferreira et al. 2007). The isoproterenol model of cardiac damage has been 
employed in different studies of structural and functional remodelling of the myocardium 
during the progression of cardiac adaptive response towards maladaptive hypertrophy 
(Nichtova et al. 2012, Fielitz et al. 2008). Isoproterenol injection or infusion via mini-pumps 
are widely used and this model is also employed as an in vitro model of hypertrophy 
(Murray et al. 2012). Functional impairment is also affected by isoproterenol, as shown by 
MRI analysis performed on isoproterenol treated rats that showed impaired cardiac function 
with diffused fibrosis (Heather et al. 2009). The overstimulation of β-ARs by isoproterenol 
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induces increases in the cardiac activity followed by imbalance between blood supply and 
tissues demands resulting in ischemic-necrotic tissue, the consequent left ventricular 
remodelling and eventually heart failure (Colucci et al. 2000, Landmesser and Drexler 2007). 
In our study, cardiac hypertrophy induced by isoproterenol was preferred over other 
methodologies (i.e. trans-aortic banding) because less invasive and more compatible with 
our model of cell transplantation in the heart. However, future studies in our laboratories 
will also consider trans-aortic banding and different pathological and physiological stimuli. 
Even though I was not able to successfully control the expression of IGF-1Ea in the heart 
via direct injection of pLenti4/TO/V5-DEST-IGF-1Ea and pLenti/TR lentiviruses, the 
objective to transplant and maintain viable HEK 293 cells and to use them as a vehicle for 
constant secretion of IGF-1Ea and IGF-1Stop during the onset of cardiac hypertrophy was 
achieved. Moreover, I optimized an efficient way of inducing cardiac damage and cardiac 
remodelling in the heart with no surgical intervention for this step. The results described in 
this chapter were particularly relevant for the following study described in Chapter 5, were 
the effects of sustained IGF-1Ea and IGF-1Stop secretion in the heart were tested during 
isoproterenol-induced cardiac hypertrophy. 
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5 IG1Ea VS. IGF-1 mature peptide in pathological cardiac growth 
 
5.1 Introduction 
Pathological cardiac hypertrophy is the increase of heart mass in response to excessive 
biomechanical stress caused by arterial hypertension or valvular heart disease (Frey and 
Olson 2003). Myocardial infarction, with the resulting cardiomyocytes necrosis and loss of a 
large amount of ventricular tissue, represents one on the main extrinsic stimuli contributing 
to the pathological growth of the heart (Anversa et al. 1985, Gajarsa and Kloner 2011). In 
the attempt to counterbalance the increase in wall stress and to replace the lost contractile 
force after an ischemic event, the muscle cells within the heart enlarge, leading to an 
increase in size and mass, and specific changes in contractile and metabolic properties are 
induced. These mechanisms are defined as cardiac remodelling (Bernardo et al. 2010, 
Hunter and Chien 1999, Sutton and Sharpe 2000, Braunwald and Bristow 2000). Although 
hypertrophy in response to the above events has traditionally been considered an adaptative 
response of the heart required to maintain efficient global function, prolonged hypertrophy 
is associated with progression to heart failure (Levy et al. 1990). 
Several therapeutic strategies have been employed in patients to normalize the pathological 
stress that is mainly induced on the left ventricle, including the application of left ventricular 
assisted devices (Zafeiridis et al. 1998) and the use of pharmacological treatment such as 
ACE inhibitors (Yusuf et al. 2000) and calcium channel antagonists (Takami and 
Shigematsu 2003). In Chapter 3, preliminary results showed that P19 cell-mediated IGF-1Ea 
delivery inhibited the onset of cardiac hypertrophy induced after myocardial ischemia. IGF-
1Ea is one of the propeptides originated by different transcription start sites and alternative 
splicing of the IGF-1 mRNA (Shavlakadze et al. 2005) and it differs from the other IGF-1 
isoforms for the presence of the C-terminal extension peptide (Ea).  Tissue-restricted 
transgenic expression of IGF-1Ea induced cardiac repair (Santini et al. 2007) and the mature 
peptide IGF-1 was shown to improve cardiac performance and morphology (Cuocolo et al. 
1996, Johnston et al. 1992) and stimulate physiological cardiac growth (Delaughter et al. 
1999). Considering these data and previous publications from our research group 
demonstrating major involvement of IGF-1Ea in skeletal and cardiac muscles repair 
(Musaro et al. 2001), I hypothesised that delivery of IGF-1Ea via transient transfection and 
direct transplantation of HEK 293 cells into the cardiac muscle may be protective against 
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cardiac hypertrophy. To test this hypothesis, isoproterenol i.p. treatment was chosen as a 
model of cardiac necrosis leading to cardiac remodelling and hypertrophy. 
In order to examine the in vivo role of IGF-1Ea, NOD.SCID mice were transplanted with 
HEK 293/IGF-1Ea cells in the left ventricular wall and, starting 24 hours post-surgery, 
treated i.p. during 7 days with 1 mg/kg/day isoproterenol. As described in Section 2.6.3, 
control groups included saline only i.p. injected mice (Saline), isoproterenol only i.p. 
injected mice (Iso) and mice transplanted with HEK 293 cells and injected with 
isoproterenol (HEK 293) to determine any physiological effects induced by transplantation 
of HEK 293 cells. Finally, to test the potential different effects induced by IGF-1Ea and 
IGF-1 mature peptide, a group of NOD.SCID mice transplanted with HEK 293/IGF-1Stop 
cells in the left ventricular wall and treated i.p. for 7 days with 1 mg/kg/day isoproterenol 
was included in the study. A schematic overview of the experimental groups included in this 
chapter is reported in Table 2.3. Functional cardiac assessment was performed using 
Magnetic Resonance Imaging and animal tissues were used to perform molecular and 
histological analyses (Section 2.6.4 and 2.7). 
Data presented in this chapter elucidate whether IGF-1Ea and IGF-1Stop have any 
protective effects against isoproterenol-induced cardiac remodelling by using a local cell-
based delivery protocol in a clinical-like scenario. 
 
5.2 Cardiac function after isoproterenol 
I initially tested the option of injecting isoproterenol to induce the pathology and after 12 
hours transplanting the HEK 293 cells, using a more specific clinical set-up. Because of the 
rapid deleterious effects induced by isoproterenol (Krenek et al. 2006), mice were not able 
to tolerate surgery and anaesthesia once the isoproterenol treatment had already started. 
Hence, I opted for the experimental protocol described in this chapter and in Chapter 4, 
where the isoproterenol treatment started 24 hours after HEK 293 cells transplantation in the 
left ventricle. Following saline or isoproterenol treatment ± cell transplantation, cardiac 
function and morphology were measured using MRI after 7 days. Values are summarized in 
Table 5.1 at the end of this section. Seven days of isoproterenol infusion induced significant 
hypertrophy and impaired global left ventricular function measured as a decrease in ejection 
fraction (Iso, 58.5%) compared to saline group (76%) (Figure 5.1). All three groups of mice 
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preconditioned with the transplanted cells and then injected with isoproterenol showed 
reduced EF% (HEK 293 = 68.8%; HEK 293/IGF-1Stop = 69.6%; HEK 293/IGF-1Ea = 
65.5%), although no statistical significant difference was found compared to saline.	  	  	  
	  
Figure 5.1 Isoproterenol reduces LV ejection fraction after 7 days Ejection fraction of the left 
ventricle (EF) is shown for the control groups (Saline, white bar, daily i.p. injection with saline 
(0.9%) only for 7 days; Iso, black bar, daily i.p. injection of 1 mg/kg isoproterenol for 7 days) and 
for the groups of mice transplanted with HEK 293 un-transfected cells (HEK 293) and treated with 
isoproterenol. Two additional groups of mice treated with isoproterenol received cardiac 
transplantation of HEK 293 cells transfected with the IGF-1Stop (HEK 293/IGF-1Stop) or with 
IGF-1Ea (HEK 293/IGF-1Ea) plasmids. * = p < 0.05 vs. Iso; ns = not significant vs. saline. All 
mean values are shown ±SEM. n = 6-8 mice per group. 
 
As shown in Figure 5.2, stimulation of β2-ARs by isoproterenol resulted in a significant 
36% increase in left-ventricular end-diastolic volume (LVEDV) compared to saline group (p 
< 0.01). Preconditioning the heart before isoproterenol treatment with transplantation of 
HEK 293 or HEK 293/IGF-1Stop cells did not maintain LVEDV to control level, resulting 
in significant difference compared to the saline group (p < 0.05). Importantly, 
transplantation of HEK 293/IGF-1Ea cells maintained LVEDV to levels comparable to 
saline treated mice (ns) (Figure 5.2 A). Equivalent results were observed in global left 
119	  	  
ventricular stroke volume measurements (SV). As shown in Figure 5.2 B-C, 7 days of 
isoproterenol injections resulted in a 21% increase in SV compared to saline (p < 0.01). 
Improvement of SV was induced only by HEK 293/IGF-1Ea and not by HEK 293 or HEK 
293/IGF-1Stop cells transplantation. SV results are presented as a bar graph (Figure 5.2 B) 
and as a scatter plot (Figure 5.2 C) to show distribution of values within each group. Scatter 
graph shows better the distribution of values for SV measurements. 	  
	  
Figure 5.2 IGF-1Ea improves deteriorated cardiac function in isoproterenol treated mice (A) 
Left ventricular end-diastolic volume (LVEDV) was measured in saline treated mice and in the 4 
different experimental groups treated for 7 days of 1 mg/kg/day isoproterenol. (B-C) Stroke volume 
values (SV), calculated as LVEDV – left ventricular end-systolic volume (LVESV), are reported for 
the same groups represented in Figure 5.1. Data for SV are represented as (B) bar graph and (C) 
scatter plot. The red line in the scatter graph indicates standard deviation of the saline group and 
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shows that 4 of 8 mice transplanted with HEK 293/IGF-1Ea are within one standard deviation of the 
saline group. One-way ANOVA was used to calculate the p values followed by Bonferroni post-tests 
to compare groups. * = p < 0.05; ** = p < 0.01. ns = not significant. All mean values are shown 
±SEM. n = 6-8 mice per group. 	  	  
Analysis of right ventricular function did not show significant alterations after isoproterenol 
in all groups examined, suggesting that cardiac impairment affected mainly left ventricle 
(data not shown). 
To determine whether functional changes corresponded to morphological alterations, mouse 
weights were recorded and MRI was used to determine left ventricular mass (LVM) (Figure 
5.3 A). LVM was significantly increased by isoproterenol compared to saline (p < 0.001) 
and no improvement was observed when hearts were preconditioned with HEK 293 or HEK 
293/IGF-1Stop transplantation (p < 0.001 vs. saline). Only treatment with HEK 293/IGF-
1Ea cells maintained LVM to control levels with no significant difference (ns vs. saline). 
Normalization of LVM on body weight (LVM/BW ratio) (Figure 5.3 B) confirmed these 
results and showed beneficial effects induced by HEK 293/IGF-1Ea (p < 0.01 vs. Iso; ns vs. 
saline). Representative H&E cardiac sections from each experimental groups confirmed 
conservation of heart size in HEK 293/IGF-1Ea mice (Figure 5.4).	  	  
	  
Figure 5.3 IGF-1Ea, but not IGF-1Stop, blocks the left ventricular hypertrophic growth 
induced by isoproterenol (B) Left ventricular mass (LVM) measured by MRI was normalized on 
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the body weight for each mouse to obtain left ventricular mass-to-body-weight ratio (B) (LVM/BW 
ratio). The analysis was performed after seven days as for the previous figures. All mean values are 
shown ±SEM. ns = not significant; * = p < 0.05; ** = p < 0.01; *** = p < 0.001. ns = not significant. 
n = 6-8 mice per group. 	  	  	  	  
	  
Figure 5.4 IGF-1Ea blocks pathological cardiac growth. Representative short axis sections of (A) 
saline group, (B) isoproterenol group, (C) HEK 293 group, (D) HEK 293/IGF-1Stop group and (E) 
HEK 293/IGF-1Ea group were stained for H&E. Scale bar, 1 mm 
 
Taken together, functional and morphological data reported in this section showed 
deteriorated cardiac function and increased hypertrophy after 7 days of isoproterenol. Mice 
transplanted with HEK 293/IGF-1Ea cells, but not those transplanted with HEK 293/IGF-
1Stop cells or with HEK 293 cells, were protected from the pathological growth and 
functional impairments induced by isoproterenol. These data suggest a specific effect 




Table 5.1 Comparison of cardiac function parameters measured in vivo by MRI after 7 days of 
treatment 
Cine MRI performed after saline or isoproterenol injection in the peritoneum. HEK 293, HEK 




Values are shown as mean ±SEM. HR = heart rate. LVEDV = left end diastolic volume. LVESV = 
left end systolic volume. SV = stroke volume. LVM = left ventricular mass. LVM/BW = left 
ventricular mass-to-body weight ratio. EF = ejection fraction 
* p < 0.05; ** p < 0.01; *** p < 0.001 vs. saline 
# p < 0.05; ## p < 0.01 vs. IGF-1Ea  
ns = not significant vs. controls 
 
  
7 days i.p. treatment with 1 mg/kg/day isoproterenol 
 
Saline Iso only HEK 293 HEK 293/ IGF-1Stop 
HEK 293/ 
IGF-1Ea 
HR (bpm) 533±14 539±9 494±16 515±19 511±16 
LVEDV 
(µL) 48.2±1.6 65.6±3.25** 61.5±2.02* 61±3* 59.7±3.0 ns 
LVESV (µL) 11.7±1.25 23.3±3.99* 19.5±2.3 18.8±1.83 20.8±2.34 
SV (µL) 35.5±1 43.13±1.5** 42.3±1.5* 42.13±1.66* 38.75±1.57 ns 
Cardiac 
output (µL) 19.5±0.98 22.73±0.94 20.8±0.76 20.99±1.41 19.18±0.97 
LVM (mg) 93.7±3.18 119.5±4.7*** 123.8±2.66*** 120.7±4.21*** 100±1.77 ns 
LVM/BW 
(mg/g) 3.70±0.12 4.89±0.199***/## 4.93±0.08***/## 4.85±0.19***/# 3.92±0.06 ns 
EF (%) 76±2.07 58.5±6.23* 68.8±2.53 69.6±1.7 65.5±2.51 
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5.3 Molecular analysis after 7 days isoproterenol 
The response to biomechanical stress induced by isoproterenol and hypertrophic stimuli 
includes changes in gene expression and protein translation and activation (Ruwhof and van 
der Laarse 2000). In order to examine whether the inhibition of cardiac pathological growth 
induced in mice pre-treated with HEK 293/IGF-1Ea cells correlated with a specific 
molecular fingerprint, global transcription profile and proteomic changes were investigated 
in the heart of the five experimental groups. Kinexus phosphorylation-sites assay screen 
(Section 2.7.7) and Gene Card Array (Section 2.7.3) were used to perform the analyses 
together with standard immunoblotting and Real-Time qPCR. Lists of genes and proteins 
screened with the correspondent values for each group are reported in Appendix I and II. 
Particular attention was drawn on the pathways of Mitogen-activated protein kinases 
(MAPKs). Positive and negative correlations between MAP kinases and the onset of cardiac 
hypertrophy have been extensively discussed in the literature with controversial results and 
interpretations (Braz et al. 2003, Seeger et al. 2010). In this study, proteomic analysis on 
whole heart protein extracts was performed at early stages of isoproterenol-induced 
pathology (7 days) and revealed that isoproterenol induced downregulation of MEK3/6 
(Figure 5.5 A, p < 0.01 vs. saline) and p38 (Figure 5.5 B-C, p < 0.01 vs. saline) 
phosphorylation compared to saline controls. This down-regulation was equally found in 
hearts transplanted with HEK 293 cells (p < 0.01 vs. saline) or HEK 293/IGF-1Stop cells (p 
< 0.01 vs. saline). Importantly, injection of HEK 293/IGF-1Ea cells maintained MEK3/6 
and p38 phospho-proteins at levels similar to saline mice (ns vs. saline). Moreover, 
significant difference in p38 phosphorylation was detected between the HEK 293/IGF-1Ea 
and Iso groups (p < 0.001), as shown in Figure 5.5 B. 
 
Taken together, these data suggest that IGF-1Ea, but not the IGF-1 mature peptide, protects 
the heart at the early stage of pathological hypertrophic development through maintenance 
of p38 signalling at the same levels as controls. 	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Figure 5.5 IGF-1Ea positively modulates the MEK3/6 signalling pathway. (A) The level of 
MEK3/6 protein phosphorylation detected by proteomic analysis was normalized on alpha-tubulin 
protein level. Dotted line shows level of control samples (saline, daily i.p. injection with saline 
(0.9%) for 7 days). n = 4 samples per group. (B) Quantification of p38 phosphorylation normalized 
on total p38 protein by immunoblotting. Diminished phosphorylation of p38 induced by 7 days of 
isoproterenol injection in vivo is rescued by HEK 293/IGF-1Ea cells transplantation in the left 
ventricle (checkered bar). (C) Representative blot showing phospho-p38, total p38 and alpha-tubulin 
protein bands. Proteins were extracted from whole heart. ** = p < 0.01; *** = p < 0.001. ns = not 
significant. All mean values are shown ±SEM. n = 5 samples per group. 
 
The fetal gene reprogramming is one of the main pathways indicating onset of hypertrophy 
(Dirkx, da Costa Martins and De Windt 2013). Gene Card Assay showed that isoproterenol 
induced increase in ANP, BNP and angiotensin precursor angiotensinogen mRNA, as 
expected during hypertrophy. Surprisingly, no repression of these genes was induced by 
HEK 293/IGF-1Ea, suggesting no direct correlation between the functional and 
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morphological improvements observed by MRI and an early regulation of the fetal gene 
reprogramming. 
 
5.4 p38 inhibition blocks HEK 293/IGF-1Ea beneficial effects 
As reported above, decreased phosphorylation of p38 protein in the whole heart of 
NOD.SCID mice correlated with hypertrophic development induced by 7 days of 1 
mg/kg/day isoproterenol. Transplantation of HEK 293/IGF-1Ea protected the heart from 
hypertrophy by maintaining the level of phospho-p38. On the contrary, HEK 293 or HEK 
293/IGF-1Stop transplantation did not induce any improvement compared to isoproterenol 
only injected mice, as described in the previous section. In order to test the effects of 
systemic p38 MAP kinase inhibition, the experiments of isoproterenol ± cell transplantation 
were performed with an additional experimental group of mice. This group of mice (G bar 
in Figures 5.6 and 5.7) was transplanted with HEK 293/IGF-1Ea in the left ventricle and 
treated daily with isoproterenol and in addition treated with the p38 inhibitor SB203580 i.p. 
at a concentration of 5 mg/kg/day for 7 days, as described in Section 2.6.5. SB203580 and 
isoproterenol daily injections were performed in the morning and in the afternoon, 
respectively, starting 24 hours from HEK 293/IGF-1Ea transplantation. 	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Figure 5.6 p38 MAP kinase inhibition reverts IGF-1Ea cardiac protection from isoproterenol 
Heart weight-to-body weight ratio (HW/BW) measurements at 7 days from cell transplantation and 
daily treatment with 1 mg/kg/day isoproterenol (C-G) or saline solution (B). The stripe bar in the 
graph (G) shows measurement for mice transplanted with HEK 293/IGF-1Ea in the left myocardium 
and injected i.p. daily with isoproterenol and 5 mg/kg/day of p38 kinase inhibitor SB203580. All 
mean values are shown ±SEM. ** = p < 0.01; *** = p < 0.001. ns = not significant. n = 10 samples 
per group. 	  
Seven days after the different treatments were performed, mice were sacrificed and the 
hearts were excised and analysed. As shown in Figure 5.6, isoproterenol injections induced 
significant increase in heart weight-to-body weight ratio compared to saline (4.52±0.22 
mg/g saline, B; 5.12±0.21 mg/g Iso, C. p < 0.001). HW/BW ratio was also significantly 
increased in HEK 293 (5.19±0.29 mg/g, D. p < 0.001 vs. saline) and HEK 293/IGF-1Stop 
(5.23±0.35 mg/g, E. p < 0.001 vs. saline) transplanted hearts. Notably, no significant 
difference was found between the HEK 293/IGF-1Ea group (4.81±0.23 mg/g, F) and saline 
mice. In the last experimental group, treatment with SB203580 and inhibition of p38 in 
HEK 293/IGF-1Ea transplanted mice blocked the effects of IGF-1Ea and maintained the 
HW/BW ratio values high (5.38±0.14 mg/g, G. p < 0.001 vs. HEK 293/IGF-1Ea) and 
significantly different from the HEK 293/IGF-1Ea group (F) and the saline group (B). Lung 
weight-to-body weight, liver weight-to-body weight and kidney weight-to-body weight 
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ratios were also calculated but no differences were found in the six different experimental 
groups (data not shown). 
To confirm these results at a histological level, cardiac sections from the six groups were 
prepared and stained with WGA (green) and DAPI (blue) to determine cell surface area. The 
significance of results from these measurements were similar to the outcome of the HW/BW 
ratio analysis, showing that IGF-1Ea protected the heart from pathological increase induced 
by isoproterenol and this process was blocked after inhibition of p38 in HEK 293/IGF-1Ea 
transplanted mice. As shown in Figure 5.7, 7 days of isoproterenol treatment increased 
significantly cell cross sectional area compared to saline (230±11 µm2 saline, B; 367±27 
µm2 Iso. p < 0.001, C). This increase was significantly smaller in HEK 293/IGF-1Ea mice 
that only reached 258±15 µm2 (F), and no difference was found compared to saline mice. 
Consistently with the HW/BW ratio results, inhibition of p38 kinase by SB203580 reverted 
the beneficial effects induced by IGF-1Ea in the HEK 293/IGF-1Ea transplanted mice 
(358±22 µm2, G. p < 0.001 vs. HEK 293/IGF-1Ea). Importantly, mice transplanted with 
HEK 293 or HEK 293/IGF-1Stop cells did not block the effects of isoproterenol on cardiac 
growth and showed significant increase in cell cross sectional area (325±28 µm2, D. p < 
0.001; HEK 293 vs. saline) (340±14 µm2, E. p < 0.001; HEK 293/IGF-1Stop vs. saline) 
(Figure 5.7 A). Micrographs representative of cardiac sections of the 6 different 
experimental groups are reported below the bar graph (Figure 5.7 B-G).	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Figure 5.7 IGF-1Ea preservation of cell cross-sectional area increase from isoproterenol is 
blocked by p38 inhibition (A) A total of 160 cross-sectional areas (CSA) per sample were 
measured from fluorescent micrographs using NISelements software. B = saline. C = Iso only. D = 
iso 7d + HEK 293. E = iso 7d + HEK 293/IGF-1Stop. F = iso 7d + HEK 293/IGF-1Ea. G = iso 7d + 
HEK 293/IGF-1Ea + 5 mg/kg/day SB203580 for 7d. (B-G) Representative fluorescent micrographs 
of myocardial sections from the same groups as A. Scale bar, 50 µm. All mean values are shown 
±SEM. *** = p < 0.001. ns = not significant. n = 4-6 samples per group. 	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5.5 Discussion 
This chapter examined the effects of IGF-1Ea and IGF-1 mature peptide (IGF-1Stop) 
delivery into the heart during the onset of pathological growth induced by isoproterenol 
injections. The aim was not only to test whether IGF-1 and IGF-1Ea may counteract the 
development of hypertrophy, but also to understand whether the Ea peptide included in the 
IGF-1Ea isoform may confer a different protein function compared to the mature, 
circulating IGF-1Stop peptide. As described in Chapter 4, a reproducible model of 
hypertrophy by isoproterenol was analysed and the feasibility of IGF-1Ea and IGF-1Stop 
secretion from HEK 293 cells was confirmed before carrying out the work described here. 
The experimental set-up performed in this study included surgical transplantation in vivo of 
HEK 293 cells and the starting of isoproterenol injections 24 hours after surgery. 
The results presented here demonstrate that IGF-1Ea, but not IGF-1 mature protein, protects 
from isoproterenol-induced pathological growth in a therapeutic-like scenario of HEK-293 
cell-mediated delivery in the heart. These protective effects determined by IGF-1Ea were 
mediated by MEK3/6 and p38 activation, suggesting the involvement of this MAPK 
pathway in anti-hypertrophic mechanisms. Results show that isoproterenol induced a 
decrease in phosphorylation of both MEK3/6 and p38, as revealed by proteomic analysis 
and immunoblotting (Figure 5.5). 
We and others have previously reported that IGF-1Ea is highly expressed in neonatal tissues 
and in the adult liver, but its levels decrease during aging (Musaro et al. 2001, Barton 
2006a). Importantly, IGF-1Ea is produced transiently in response to local damage (Hill and 
Goldspink 2003), protects neonatal mouse cardiomyocytes from Ang II induced hypertrophy 
in vitro (Vinciguerra et al. 2010) and is involved in cardiac and skeletal muscle repair 
(Santini et al. 2007, Musaro et al. 2001, Musaro 2005). IGF-1 mature peptide (in this study 
named IGF-1Stop) is constitutively expressed, and its levels were found reduced in patients 
with acute myocardial infarction (Conti et al. 2001). However, high levels of circulating 
IGF-1 were implicated in the restriction of lifespan (Longo and Finch 2003). To my 
knowledge, the study presented in this chapter is the first to examine, in a clinical set-up of 
cell-mediated gene delivery, the potential effects and differences between IGF-1Ea and IGF-
1 mature peptide in protecting the heart from pathological growth. 
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Non-invasive MRI analysis of the left ventricle demonstrated that isoproterenol 
administration induced significant reduction of ejection fraction and cardiac function after 7 
days. HEK 293, HEK 293/IGF-1Stop or HEK 293/IGF-1Ea transplanted groups showed 
reduced ejection fraction compared to saline mice, but the difference was not statistically 
significant (Figure 5.1). This apparent preservation in cardiac function was independent of 
IGF-1 or IGF-1Ea presence and it seems to agree with the finding of the study by Wall and 
colleagues showing that addition of non-contractile material to the damaged left ventricular 
wall reduces wall stress proportionally to the fractional volume of material added (Wall et al. 
2006), suggesting that simple injection of cells or biomaterial can mitigate post-injury loss 
of cardiac function. The involvement of HEK 293 cells in this study was not proposed as a 
potential therapy, but only as an effective vehicle for stable secretion of IGF-1Ea and IGF-
1Stop in the left ventricle. Results from end-diastolic volume and calculation of stroke 
volume showed no protection from isoproterenol induced by HEK 293 or HEK 293/IGF-
1Stop. Only transplantation of HEK 293/IGF-1Ea improved cardiac function by maintaining 
stroke volume and end-diastolic volume in the left ventricle at levels comparable to control 
hearts (Figure 5.2). Degree and evolution of cardiac damage induced by isoproterenol 
treatment depend on its duration and dose of administration, and the results obtained in this 
chapter should be interpreted accordingly. Low doses of isoproterenol (i.e. up to 6 
mg/kg/day for 7 days) induce cardiac hypertrophy, fibrosis and necrosis of the tissue 
(Goldspink et al. 2004, Zhang et al. 2007), whereas high doses (i.e. 85-300 mg/kg/day) 
provoke a damage similar to that induced by acute myocardial infarction and are used as a 
model of heart failure (Feng and Li 2010). In general, increased workload of the heart and 
imbalance between oxygen demands from the cardiac tissue and blood supply induced by 
isoproterenol lead to myocardial ischemia and necrosis, and these consequences are hardly 
distinguishable from the ischemia induced by coronary occlusion (Nichtova et al. 2012). 
The work presented in this chapter shows that only the delivery of HEK 293/IGF-1Ea in the 
left ventricle blocked the increase in end-diastolic and stroke volumes from isoproterenol, 
showing inhibition of hypertrophic remodelling mechanisms. No functional improvement 
and protection from isoproterenol was found in mice injected with HEK 293 cells only or 
with HEK-293/IGF-1Stop cells. Moreover, the hypertrophic growth of the left ventricle 
(LVW/BW, Figure 5.3) caused by isoproterenol was not detectable in mice transplanted 
with HEK 293/IGF-1Ea, confirming the potential antihypertrophic role of IGF-1Ea. 
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The involvement of IGF-1 and IGF-1Ea in tissue hypertrophy has been discussed in the 
literature by us and by other research groups, with different evidences in both cardiac and 
skeletal muscle physiopathology. In skeletal muscle, functional physiological myocyte 
hypertrophy was induced by IGF-1Ea overexpression locally (Musaro et al. 2001). Viral-
mediated delivery of IGF-1Ea or IGF-1Eb in skeletal muscle induced increase in total IGF-1 
content in the infected tissue, but only the presence of the IGF-1Ea isoform produced 
increase in muscle mass in adult mice (Barton 2006b). In cardiac tissue, young mice 
overexpressing IGF-1Ea in the heart displayed increase in cell size compared to wild-type 
control mice and an initial increase in ANP mRNA, clear evidences of increased muscle 
growth. This hypertrophic process was eventually normalized and no differences in 
cardiomyocytes size were found in adult mice (Santini et al. 2007). Together with these 
published studies, my functional and morphological data suggest a potential double role of 
IGF-1Ea in stimulating physiological growth and inhibiting pathological cardiac growth. 
The functional data obtained by MRI show that differential effects are induced by 
transplantation of HEK 293 cells transfected with IGF-1Ea or IGF-1Stop. Indeed, only IGF-
1Ea was able to block cardiac hypertrophy after 7 days of isoproterenol treatment. These 
results show for the first time, using the same pathological model in a potentially therapeutic 
approach, that the presence of the Ea peptide confers a beneficial role to the IGF-1 protein 
suggesting potential different biological functions for IGF-1Ea and IGF-1 mature peptide in 
the heart. Although low levels of IGF-1 in patients are considered as an independent risk 
factor for myocardial infarction (Subramaniam et al. 2005), high levels of IGF-1 increase 
predisposition to neoplasia (Chan et al. 1998). Therefore, balancing the availability of IGF-1 
seems to be important to maintain the minimum level of IGF-1 to induce the described 
beneficial effects in skeletal and cardiac muscle, without inducing collateral effects caused 
by high IGF-1 serum levels. As recently demonstrated by our laboratory (Hede et al. 2012), 
the presence of the Ea extension peptide at the C-terminal of IGF-1 influences the 
bioavailability of IGF-1 in tissues and in the circulation by increasing its affinity for the 
extracellular matrix. This feature of the Ea extension peptide would ensure IGF-1 retention 
at the site of secretion and prevent the increase of IGF-1 levels in the serum, as discussed 
more extensively in Chapter 7. 
At a molecular level, the results presented in this chapter showed that improvement in 
cardiac function and inhibition of pathological growth induced by IGF-1Ea correlated with 
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preserved MEK3/6 and p38 activation in cardiac tissue. After 7 days of isoproterenol 
injections, phosphorylation levels of both proteins were reduced compared to saline, and 
only mice transplanted with HEK 293/IGF-1Ea showed the same high levels of MEK3/6 
and p38 phosphorylation as the saline group (Figure 5.5). To investigate the correlation 
between p38 and IGF-1Ea in anti-hypertrophic mechanisms, I tested whether direct systemic 
inhibition of p38 may revert the cardiac protection induced by IGF-1Ea. Interestingly, i.p. 
injection of the p38 inhibitor SB203580 after HEK 293/IGF-1Ea transplantation and 
concomitantly with isoproterenol treatment blocked the beneficial effects mediated by IGF-
1Ea (Figure 5.6 and 5.7). These data suggest that p38 phosphorylation is directly involved 
in the IGF-1Ea anti-hypertrophic mechanisms in the heart reported in this study. 
In general, the role of MEK3/6 and its downstream p38 protein in hypertrophy remains 
controversial, and multiple studies have shown contrasting interpretations. Similarly to our 
results, in a transgenic approach published by Braz and colleagues, it was shown that mice 
overexpressing dominant negative MEK3, MEK6 or p38 alpha in cardiomyocytes displayed 
enhanced cardiac hypertrophy following aortic banding compared to wild-type mice that 
underwent the same pathological stimulus (Braz et al. 2003). They demonstrated that 
blockade of p38 kinase activity directly resulted in greater NFAT activity and showed a 
worsened hypertrophic phenotype after aortic banding or isoproterenol infusion compared to 
wild type control mice. This phenotype was manifested with progressive cardiac dilation of 
the left ventricle, significant increase in HW/BW ratio and augmented cardiomyocytes cross 
sectional area found in the MEK3, MEK6 or p38 dominant negative transgenic mice. 
Consistently with this publication and in agreement with my findings, Liu and colleagues 
demonstrated that transgenic mice expressing a dominant negative-p38α showed augmented 
left ventricular hypertrophy and increased incidence of premature mortality following 
chronic aortic banding (Liu et al. 2006), although it must be specified that this result was 
revealed only in female mice. Several studies have also shown activation of NFAT in the 
heart after MI (Heineke et al. 2005), after hypertrophic stimuli via aortic banding and in 
general during the development of pathological hypertrophy (Donaldson et al. 2009, Finsen 
et al. 2011). Moreover, mice lacking MEK4, an up-stream of p38 signalling, showed 
increased NFAT activity and greater pathological cardiac hypertrophy but swimming-
induced cardiac hypertrophy was unaffected (Liu et al. 2009). Similarly, NFAT signalling 
was significantly repressed in the adult heart after either swimming or voluntary wheel 
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running-induced physiological hypertrophy (Wilkins et al. 2004), suggesting a specific 
involvement of p38/NFAT signalling in pathological but not in physiological hypertrophy.  
Following the experimental observations presented in this chapter, it will be interesting to 
investigate how p38 phosphorylation and the related molecular signalling may antagonize 
the pathological hypertrophic growth response in the adult heart, especially in correlation 
with IGF-1Ea. Opposite and controversial results regarding p38 were reported in patients, 
where dilated and failed heart showed both increased (Cook et al. 1999, Haq et al. 2001) and 
decreased (Communal et al. 2002) p38 activity. It is also particularly interesting to mention 
that results from in vitro cultured cardiomyocytes suggested that p38, MEK3 and MEK6 are 
effectors of the hypertrophic response (Liang and Molkentin 2003, Wenzel et al. 2005, 
Zechner et al. 1997). A specific discussion on differential p38 activation during hypertrophy 
in vivo and in vitro will be undertaken in Chapter 6. Considering our experimental results 
and the observations reported in the literature, the role of p38, MEK3, MEK6 and in general 
the MAPK signalling in many aspects of cardiac stress response remains very complex and 
a straightforward prediction of a linear response to an hypertrophic stimulus (i.e. 
physiological or pathological) it is not yet permitted. 
The molecular analysis performed by Gene Card Assay (Section 2.7.3 and Appendix I) 
confirmed that pathological hypertrophy was induced, as shown by the increase in ANP and 
BNP mRNA after 7 days of isoproterenol infusion. Cardiac hypertrophy is generally 
accompanied by activation of a set of fetal cardiac genes, such as ANP and BNP (Antos et al. 
2002). Surprisingly, IGF-1Ea did not block the increase in expression of the two pathologic 
markers, suggesting that the antihypertrophic regulation induced by IGF-1Ea does not 
directly correlate with regulation of these two markers of pathological hypertrophy (Antos et 
al. 2002, Hill et al. 2002). A potential explanation can also be found in the protocol I 
employed to process the samples. Total RNA was isolated from the whole heart, while the 
HEK 293/IGF-1Ea cells were injected only in the left ventricular muscle. A specific analysis 
of differential gene expression in the right and left ventricle should have been performed to 
avoid dilution of the molecular response between the two ventricles. Even though we 
recently showed that IGF-1Ea overexpression in vitro protects HL-1 cardiac cells from 
hypertrophic stimuli (Vinciguerra et al. 2010), more specific experiments in vivo and in vitro 
will be required to ascertain the relative contribution of IGF-1Ea to the modulation of the 
fetal gene program in a therapeutic set-up. 
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In summary, the present study shows that IGF-1Ea delivery may protect the heart at early 
time-points after β2-adrenergic stimulation by MEK3/6-mediated signalling and suggests 
that propeptides may have distinct roles in modulating IGF-1 action. The finding that IGF-1 
mature peptide was unsuccessful in blocking the deleterious effects induced by isoproterenol 
suggests that among the different IGF-1 isoforms, IGF-1Ea may be a promising candidate 
for future pre-clinical studies.	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6 In vitro VS. in vivo hypertrophic models: IGF-1Ea and p38 
phosphorylation 
6.1 Introduction 
IGF-1Ea was demonstrated to protect the heart from pathological growth in response to 
isoproterenol injections at the early time points of the pathological hypertrophic 
development via sustained MEK3/6 and p38 phosphorylation (Chapter 5). This mechanism 
was confirmed by showing that inhibition of p38 using SB203580 blocked the positive 
effects induced by IGF-1Ea in the heart. However, the complexity of the experimental set-
up in vivo of cell transplantation did not clarify whether a specific modulation of 
hypertrophic markers and signalling pathways was induced by IGF-1Ea in the area of 
injection. Therefore, the aim of this chapter was to explore the role of IGF-1Ea as mediator 
of anti-hypertrophic pathways by using an in vitro model. To simulate the in vivo condition 
of induced β-ARs stimulation, an in vitro model was set-up using isoproterenol on 
cardiomyocytes that were isolated from the left ventricle of neonatal mice and 
preconditioned with different cell culture media containing IGF-1Stop or IGF-1Ea. The 
preliminary results and the work in progress are presented in the following sections. Specific 
results are shown in relation to p38 protein and the effects of IGF-1Ea on its 
phosphorylation and activation. Stimulation of isolated neonatal cardiomyocytes in vitro 
with isoproterenol (Somvanshi, Qiu and Kumar 2013, Liu et al. 2011) or Ang II (Watkins et 
al. 2012) were previously suggested as potentially reliable models of hypertrophy. 
Nevertheless, up- or down-regulation of specific signalling pathways do not always 
correlate between in vivo and in vitro approaches, as further discussed in Chapter 7. 
 
6.2 Effects of isoproterenol on neonatal mouse cardiomyocytes 
Data presented in the previous chapter demonstrated an anti-hypertrophic role of IGF-1Ea in 
cardiac tissue treated with isoproterenol. However, it was not shown whether this 
modulation directly affected cardiomyocytes. To investigate this possibility in vitro, 1-to-2 
day old FVB wild type neonatal mice where used to isolate cardiomyocytes from the 
ventricles. Neonatal cardiomyocytes were treated with 10 µM isoproterenol at different 




Figure 6.1 Isoproterenol induces increase in cardiomyocyte size and contractility in vitro 
Neonatal mouse cardiomyocytes were untreated (A1 and A2) or treated for 12 hours with 
isoproterenol (10 µM) (B). Total area was measured (C) in both experimental conditions using 
NISelements software. (D) Contractility of beating cardiomyocytes was measured as number of 
beats / minute in uniformly contracting cardiomyocytes cultures. Scale bar, 100 µm. *** = p < 0.001. 
n = 2 samples per group. 
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After twelve (Figure 6.1) or twenty-four (data not shown) hours, isoproterenol-treated 
cardiomyocytes (Figure 6.1 B) showed increased cell area compared to un-treated control 
cardiomyocytes (Figure 6.1 A1-A2). Visual analysis was confirmed by quantification and 
statistical comparison of values, confirming a significant increase in cell size induced by 
isoproterenol (Figure 6.1 C). Stimulation with isoproterenol also induced increased 
contractility measured as beats / minute (Figure 6.1 D), as expected after positive inotropic 
stimulation of cardiomyocytes using a β2-AR agonist (Mizutani, Kawahara and Okajima 
2012, Ginsburg and Bers 2004). 
 
6.3 IGF-1Ea normalizes p38 phosphorylation after isoproterenol in vitro 
To test whether early regulation of p38 phosphorylation may be involved in the hypertrophic 
changes induced by isoproterenol observed in the previous section, cardiomyocytes where 
treated with 10 µM isoproterenol for 5, 15 and 30 minutes. Results confirmed that ERK1/2 
(data not shown) and p38 phosphorylation were increased after 5 minutes and returned back 
to normal levels already after 15 minutes, as previously reported in the literature (Hong et al. 
2011). One of the aims of this chapter was to specifically investigate the modulation of p38 
by IGF-1Ea in vitro to confirm a potential interaction, as shown in vivo in Chapter 5. Thus, 
in order to simulate the experimental conditions used in vivo, isolated cardiomyocytes were 
preconditioned with cell culture media harvested from un-transfected HEK 293 cells (HEK 
293 c.m.), from HEK 293/IGF-1Stop cells (HEK 293/IGF-1Stop c.m.) or HEK 293/IGF-
1Ea cells (HEK 293/IGF-1Ea c.m.) for 24 hours before treating them with 10 µM 
isoproterenol for 5 minutes (Figure 6.2). Secretion of IGF-1Ea and IGF-1Stop peptides 
from the respective transfected HEK 293 cells was confirmed by immunoblotting and the 
corresponding bands were found as for Figure 4.2. To exclude variability between 
experimental replicates (n = 3 for each group), conditioned media for each of the three 
experimental groups was produced beforehand, aliquoted and stored at -80° C until required. 
Moreover, to avoid potential activation of p38 and other MAP kinases caused by changing 
the cell culture medium (Mackay and Mochly-Rosen 1999) isoproterenol was directly added 
onto each well without replacing the conditioned media on the cardiomyocytes. As shown in 
Figure 6.2, p38 phosphorylation was significantly increased after 5 minutes of isoproterenol 
treatment (0.35 ± 0.004 A.U., p < 0.001 vs. CTL) compared to un-treated cardiomyocytes 
(0.31 ± 0.003 A.U.). However, pre-conditioning of cardiomyocytes with HEK 293/IGF-1Ea 
c.m. maintained p38 phosphorylation (0.31 ± 0.03 A.U., not significant vs. CTL) at levels 
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similar to controls. Treatment with HEK 293 c.m. (0.34 ± 0.06 A.U., not significant vs. 
CTL) or with HEK 293/IGF-1Stop c.m. (0.34 ± 0.05 A.U., not significant vs. CTL) before 
isoproterenol showed increase in p38 phosphorylation compared to untreated control 
cardiomyocytes, although no significant difference was found. Addition of supplementary 
replicates will be necessary to clarify whether the lack of significance is dependent on the 
variability in each group. 
 
	  
Figure 6.2 Preconditioning of neonatal cardiomyocytes treated with isoproterenol and 
modulation of p38 phosphorylation Neonatal mouse cardiomyocytes were isolated from the 
ventricles of 1-to-2 day old mice and pre-conditioned for 24 hours with complete cell culture 
medium or with conditioned medium harvested from HEK 293, HEK 293/IGF-1Stop or HEK 
293/IGF-1Ea cells. (A) The level of p38 protein phosphorylation was analysed by immunoblotting 
after 5 minutes of isoproterenol treatment (10 µM) and normalized on p38 total protein level. 
Representative blot shows phospho-p38 and total p38 bands for the 5 experimental groups. Control 
cardiomyocytes were not treated with isoproterenol. (B) Quantification of p38 phosphorylation 
showed that increased phosphorylation of p38 induced by 5 minutes isoproterenol is maintained 
similar to control levels in cardiomyocytes pre-conditioned with HEK 293/IGF-1Ea cell culture 
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medium. *** = p < 0.001. ns = not significant vs. control. Mean value for that group is reported on 
top of each bar. n = 3 samples per group. 
 
6.4 Discussion 
This chapter presented preliminary evidence that p38 phosphorylation is up-regulated in 
cardiomyocytes in vitro after treatment with isoproterenol, a mechanism that correlates with 
increased cell size. Moreover, preconditioning cardiomyocytes with cell culture medium 
containing IGF-1Ea before isoproterenol treatment maintained p38 phosphorylation low at 
the control level, albeit the intermediate players of these mechanisms remain unknown. 
Previously published results from our laboratory demonstrated that neonatal cardiomyocytes 
overexpressing IGF-1Ea under a cardiac specific promoter are protected from the onset of 
Ang II-induced hypertrophy by blocking the pathological regulation of the fetal gene 
reprogramming (Vinciguerra et al. 2010). Given the different approach I have employed in 
this in vitro study, where IGF-1Ea is present in the cell culture medium and is added on the 
cardiomyocytes rather than overexpressed by the cardiomyocytes themselves, further 
experiments will be required to confirm whether the action of IGF-1Ea as paracrine effector 
in the cell culture medium can protect cardiomyocytes from isoproterenol-induced 
hypertrophic growth. Preliminary experiments on the molecular signalling involved (data 
not shown) showed that the experimental set-up with isoproterenol I employed did not 
induce modulation of the fetal gene reprogramming as expected (Galindo et al. 2009, Fielitz 
et al. 2008, Li et al. 2011), and consequently I was not able to assess whether IGF-1Ea could 
be involved in their regulation. 
Modulation of p38 phosphorylation by IGF-1Ea represents a meaningful indication that 
IGF-1Ea signalling may antagonize the pathological hypertrophic growth in vitro and 
protect cardiomyocytes from pathological stimuli. Significant evidences in support of this 
hypothesis are found in the literature. Overexpression of activated MEK3/6, the upstream 
positive regulators of p38 activity, in cultured neonatal cardiomyocytes was shown to induce 
hypertrophy and expression of pathological hypertrophic markers (Nemoto, Sheng and Lin 
1998, Zechner et al. 1997, Wang et al. 1998b). Adenoviral mediated gene transfer of MEK6 
in neonatal cardiomyocytes also induced increased surface areas and augmented sarcomeric 
organization, clear signs of pathological hypertrophic phenotype (Liang and Molkentin 
2003). Although controversial data reported on p38 activation in vitro show protection of rat 
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adult cardiomyocytes from β-adrenergic receptor-stimulated apoptosis (Communal, Colucci 
and Singh 2000), the pro-hypertrophic role of p38 activation in vitro has been broadly 
described in the literature. Direct inhibition of p38 kinase activity with the antagonists 
SB203580 or SB202190 has been reported to attenuate aspects of agonist-stimulated 
cardiomyocytes hypertrophy (Nemoto et al. 1998, Zechner et al. 1997) and ischemia in 
culture (Mackay and Mochly-Rosen 1999). In their study, Mackay and colleagues observed 
that during induced ischemia in cultured cardiomyocytes, two distinct phases of p38 
activation could be detected, with a first phase starting within 10 minutes from the stimulus 
and a second phase after 2 hours lasting throughout the ischemic period. They suggested that 
transient activation of p38 might have very different cellular consequences from sustained 
activation of p38 in cardiac myocytes. It is therefore tempting to speculate that p38 
activation may play a role in cellular damage immediately after cardiac injury or 
pathological stimulus and also be part of a protective response against ischemia during the 
late stage of pathological development. 
 
This hypothesis is particularly interesting for the interpretation of the contrasting in vivo and 
in vitro results described in this thesis. The trends of p38 phosphorylation presented in this 
chapter are in contrast with the in vivo data presented in Chapter 5, indicating an opposite 
correlation between p38 activation and pathological hypertrophy development in the two 
experimental settings. There it was shown that isoproterenol stimulation decreased p38 
phosphorylation leading to cardiac hypertrophy in vivo, whereas the in vitro experiments 
described in this chapter suggest that cardiomyocytes hypertrophy induced by isoproterenol 
correlates with an increase in p38 phosphorylation. These contrasting results could be 
attributed to two different roles played by p38 in two different phases of the pathological 
hypertrophic development (i.e. immediate and late). In support of this theory, Mackay and 
colleagues (Mackay and Mochly-Rosen 1999) observed that transient activation of p38 does 
not have deleterious effect on cardiomyocytes, while sustained activation correlates with 
increased apoptosis induced by ischemia. Further experiments are required to verify whether 
these hypotheses are correct or, on the contrary, whether there is a unidirectional correlation 
between p38 phosphorylation and pathological hypertrophy. It will also be interesting to 
investigate whether IGF-1Ea has a pivotal role in these mechanisms, as discussed in the 
final chapter of this thesis. 
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Besides the contrasting results in vivo and in vitro in relation to p38 activation, the 
significant data is that in both settings, the presence of IGF-1Ea maintained p38 
phosphorylation at the level of controls, suggesting that IGF-1Ea regulates specifically this 
kinase depending on the context of the environment. Moreover, the preliminary results 
presented in this chapter confirm that the presence of IGF-1Ea in the cell culture medium 
mediates anti-hypertrophic molecular mechanisms, suggesting a potential action as 
autocrine/paracrine factor. It is interesting to notice that in the in vitro experiments, only 
IGF-1Ea and not IGF-1Stop modulated the activation of p38. It has been shown by Taniike 
and colleagues that inhibition of p38 in neonatal rat cardiomyocytes stimulated by IGF-1 
enhances physiological hypertrophy (Taniike et al. 2008), suggesting a further analysis of 
the correlation between IGF-1Ea and p38 not only under pathological stimulation, but also 
during physiological conditions. 
Results showed in this chapter will need to be complemented with the analysis of IGF-1Ea-
mediated effects on cell growth, increase in protein synthesis and regulation of pathological 
genes induced by isoproterenol, three well-known features of pathological hypertrophic 
development (Nichtova et al. 2012). Moreover, it will be interesting to explore whether 
activation of p38 in vitro follows the same trend in other cardiac cell population and whether 
IGF-1Ea has a direct effect on cells other than cardiomyocytes. 
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7  General Discussion and Future Work 
 
7.1 General discussion 
Understanding the molecular mechanisms of cardiac remodelling occurring after myocardial 
infarction and during the consequent onset of pathological hypertrophy has been of great 
interest for the development of targeted pharmacological treatments in patients. Cardiac 
hypertrophy is associated with nearly all forms of heart failure (Levy et al. 1990) and it is an 
independent risk factor for myocardial infarction, arrhythmia and sudden death (Rials et al. 
1995, Elliott et al. 2006, Bernardo et al. 2010). Using transgenic overexpression in 
cardiomyocytes, IGF-1Ea has been previously implicated in cardiac protection of the mouse 
heart after ischemic injury and oxidative stress (Santini et al. 2007, Vinciguerra et al. 2012) 
and in the blockade of pathological hypertrophy in vitro in cardiomyocytes (Vinciguerra et 
al. 2010). The original aims of this study were to investigate i) whether IGF-1Ea delivery 
into the heart in a clinical-like scenario protects from pathological hypertrophy and ii) 
whether the potential beneficial effects are specifically mediated by IGF-1Ea and not by 
IGF-1 mature peptide. This was based on the preliminary findings described in Chapter 3 
showing that IGF-1Ea P19-cell-mediated delivery in the left ventricle after ligation of the 
left coronary artery abrogated the hypertrophic development by acting locally in the area of 
injection. Even if related to a potential applicable therapy, the experimental set-up used to 
produce those preliminary data presented some important limitations. Most importantly, 
poor engraftment of the transplanted cells in the myocardium and lack of sufficient IGF-1Ea 
protein production by the P19-transduced cells may have overcomplicated the experimental 
settings and the interpretation of the results. To overcome these technical difficulties, I 
tested two main approaches. 
Section 4.2 describes a first attempt to directly infect cardiac cells in vivo via lentiviral-
mediated delivery of IGF-1Ea in the heart, but results showed that no increase of IGF-1Ea 
mRNA was found in the left ventricle where the injections were performed. The lentivirus 
employed was the same used to transduce the P19 cells, as described in Chapter 2. The 
reasons for the unsuccessful transduction of cardiac tissue remain unknown. Despite these 
negative results, IGF-1Ea viral-mediated cardiac delivery in rodents and large animal 
models will need to be optimized in future studies in our laboratory. Further assessment of 
viral-mediated strategies are encouraged by the efficiency demonstrated in the application of 
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adeno-associated viral technologies in animal models and in particular in clinical trials 
(Wang et al. 2005, Bish et al. 2011, Kumarswamy et al. 2012, Tilemann et al. 2012, Sikkel 
et al. 2013). 
Although great interest and large economical and human resources have been placed on 
cardiac cell therapy in the last twenty years, results are not yet encouraging. Cell therapy is 
overall safe, with the caveat of ventricular arrhythmias, but clinical trials performed in the 
last ten years have reported limited improvement of cardiac function (Menasche 2011). A 
meta-analysis of 13 randomized trials shows that overall stem cell therapy improved LV 
ejection fraction by 2.99% and reduced myocardial lesion area by 3.51% in patients with 
different kinds of cardiac pathologies (Martin-Rendon et al. 2008). One major objective of 
cell therapy is to prevent late remodelling of the heart after injury, which has been identified 
as predictor of late adverse outcomes. Contrasting results were published and, for example, 
bone marrow cell therapy was shown to be unsuccessful in preventing post-infarction 
remodelling (Udelson and Konstam 2002). On the other hand, the positive results obtained 
with cell therapy have suggested the hypothesis that the growth factors and cytokines 
released by bone marrow derived cells may boost endogenous reparative pathways, limit 
apoptosis and improve ventricular elastic properties that may result in protection from 
cardiac dilation by acting in a paracrine fashion (Kinnaird et al. 2004, Uemura et al. 2006, 
Dai et al. 2008). Gene therapy and/or the beneficial paracrine effects on cardiac remodelling 
induced by factors released by the transplanted cells, more than the mechanical replacement 
of injured tissue by the cells themselves, have shown more consistent results, as reviewed in 
(Mirotsou et al. 2011). However, it remains unclear if paracrine effects of injected cells, 
trans-differentiation to functional cardiomyocytes, and/or recruitment of endogenous stem 
cells are responsible for the apparent improvements in cardiac function in experimental 
studies (Davis et al. 2006, Laflamme and Murry 2005). 
Because of the inefficiency of the first attempt described in Section 4.2 to directly infect the 
heart with a lentivirus encoding IGF-1Ea, I tested a second approach of HEK 293 mediated 
delivery of IGF-1Ea and IGF-1Stop in the heart of immunodepleted mice. As shown in 
Chapter 5, this approach guaranteed high secretion of IGF-1Ea and IGF-1Stop from the 
HEK 293 cells transfected with the respective DNA vectors and sufficient retention of the 
cells after transplantation into the left ventricle. The aim of this study was not to examine 
the therapeutic potential of HEK 293 cells, but to employ them as a tool for IGF-1Ea and 
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IGF-1Stop secretion. Moreover, it was in the interest of this study to investigate whether 
IGF-1Ea may have a paracrine action when secreted from the transplanted cells, using not 
only in vivo but also in vitro experimental settings. In support of these experiments, it was 
shown that injection of conditioned medium harvested from bone-marrow-derived 
mesenchymal stem cells (MSCs) infected with a retroviral vector encoding Akt significantly 
improved ventricular function, suggesting that the presence of Akt was fundamental to 
induce the observed beneficial outcome induced by cell transplantation (Gnecchi et al. 2006). 
In the context of the study described in this thesis, the potential paracrine action of IGF-1 
was also suggested by Haider and colleagues (Haider et al. 2008). Sustained secretion of 
IGF-1 protein for 7 days in the heart was obtained by transplanting MSCs infected with an 
adenoviral vector encoding IGF-1 (MSCs/IGF-1) in the left ventricle. Only transplantation 
of MSCs/IGF-1 during acute myocardial infarction enhanced cardiac repair and protected 
the heart from degenerative outcomes compared to injured hearts that were un-transplanted 
or transplanted with MSCs only (Haider et al. 2008). These data suggest that IGF-1 may 
have an autocrine and/or paracrine function by interacting with the infected cells and the 
surrounding native tissues. IGF-1 has been associated with cardiomyocytes survival and 
proliferation (Reiss et al. 1997) and improvement of cardiac structure and function (Li et al. 
1997), although opposite results show that patients with hyper-secretion of growth hormone, 
and consequently IGF-1, often develop cardiomyopathy with interstitial fibrosis and 
myocyte fibrosis (Lombardi et al. 1997). On the other hand, the IGF-1Ea isoform was 
shown to enhance cardiac repair after injury (Santini et al. 2007) and to block myocardial 
fibrosis in a mouse model of dilated cardiomyopathy (Touvron et al. 2012). In my study, 
IGF-1Ea first blocked the onset of hypertrophy when delivered by P19 derived 
cardiomyocytes (Chapter 3) and, in a second approach of HEK 293 mediated secretion, it 
protected the heart from isoproterenol-induced hypertrophy (Chapter 5). In contrast, 
delivery of IGF-1 mature peptide was not able to induce any significant functional and 
physiological improvements after isoproterenol. 
Taking into account the results in the literature and the outcome of this study comparing 
IGF-1 and IGF-1Ea, one may wonder whether systemic IGF-1 and the IGF-1Ea propeptide 
have different biological functions or whether the Ea extension peptide present at the C 
terminal of the IGF-1Ea isoform merely confers different spatio-temporal availability to the 
IGF-1 peptide. As demonstrated by Delaughter and colleagues, IGF-1 has transient 
beneficial effects in protecting the heart from injury and continued exposure to IGF-1 
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reduces systolic performance and increases interstitial fibrosis (Delaughter et al. 1999), 
suggesting that limiting the spatio-temporal exposure to IGF-1 may be the solution to 
balance its beneficial and deleterious side effects. IGF-1 is a small protein that diffuses 
rapidly through tissues, allowing it to signal over great distances, but this property could 
restrict its retention within a tissue for prolonged period and induce adverse effects (Davis et 
al. 2006, Fraidenraich et al. 2004), as shown by systemic administration of IGF-1 causing 
diabetic retinopathy (Wilkinson-Berka, Wraight and Werther 2006) and cancer (Chan et al. 
1998, Jabri et al. 1994). Possible explanations of the differences between IGF-1 and IGF-
1Ea can also be found in two distinct studies performed recently in our laboratory. It was 
first demonstrated that IGF-1Ea has significantly higher affinity to heparin and to the ECM, 
which contains heparin sulphate proteoglycan, compared to the mature IGF-1 (Hede et al. 
2012). This suggests that the presence of the Ea extension peptide may control the 
bioavailability of IGF-1 by maintaining high local concentrations of the growth factor at the 
site of synthesis. This hypothesis is consistent with previous observations that transgenic 
mice over-expressing IGF-1Ea, or another similar isoform (i.e. IGF-1Eb), in different tissues 
do not display increased IGF-1 serum levels (Musaro et al. 2001, Santini, Winn and 
Rosenthal 2006, Semenova et al. 2008), while mice over-expressing the IGF-1 transgene 
without any extension peptide show increased IGF-1 levels in the serum (Shavlakadze et al. 
2005). In agreement with these studies, the work published by Tokunou and colleagues 
demonstrated that an engineered IGF-1 peptide, specifically modified in order to have high 
affinity for heparin, selectively bound the ECM in neonatal cardiomyocytes and other cell 
populations without interfering with the IGF-1 downstream signalling (Tokunou et al. 2008). 
This hypothesis opens interesting therapeutical possibilities on the application of the Ea 
extension peptide in controlling the diffusion of specific peptide drugs from the site of 
delivery or synthesis, minimizing potential systemic adverse effects, as shown for IGF-1 
(Hede et al. 2012, Tokunou et al. 2008). 
In a second study from our laboratory (Tonkin et al. Submitted) it was shown that the 
presence of multiple IGF-1 isoforms (i.e. IGF-1Ea and IGF-1Eb) correlates with distinct 
biological functions during sequential phases after injury. In injured skeletal muscle, IGF-
1Ea overexpressing mice showed faster muscle regeneration with no inflammation and 
fibrotic tissue, whereas IGF-1Eb overexpressing mice displayed improved morphology of 
muscular fibres with a lower degree of regeneration, suggesting that the two isoforms are 
activated during two different stages after injury. Interestingly, IGF-1Eb and IGF-1Ea 
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propeptides were shown to be sequentially expressed by M1 and M2 macrophages during 
distinct moments of the reparative process (Tonkin et al. Submitted). These results suggest 
the intriguing hypothesis that Ea and the other extension peptides may not only increase 
retention and control bioavailability of the mature IGF-1 peptide but also determine a 
different biological function of IGF-1. Indeed, although IGF-1Ea and IGF-1 mature peptide 
activate the same IGF-1 receptor (the C domain of the IGF-1 core peptide has the main role 
of binding to the IGF-1 receptor (Bayne et al. 1989)), two different downstream signalling 
pathways are triggered, suggesting that the two isoforms potentially activate different 
phosphorylation sites on the IGF-1 receptor (Santini et al. 2007). It will be extremely 
relevant in the future to perform biochemical characterization of the interactions between 
IGF-1/IGF-1Ea and the IGF-1 receptor. In the analyses presented in this thesis, no data on 
the serum levels of IGF-1 after IGF-1Ea or IGF-1Stop delivery into the heart were produced, 
and therefore it is not possible to conclude whether the observed protection from 
hypertrophy was induced by a different retention of the IGF-1 peptide in the area of 
administration (Chapter 5). 
The experimental model of HEK 293 secretion of IGF-1Ea and IGF-1Stop described in this 
study represents a proof of principle that secretion of specific IGF-1 isoforms (i.e. IGF-1Ea) 
from a cellular source can mediate beneficial mechanisms during muscle injury. In future 
analyses it will be interesting to understand how direct delivery of IGF-1Ea and the other 
IGF-1 isoforms can stimulate endogenous responses in the target tissues during cardiac 
injury and hypertrophic remodelling. The use of cells naturally secreting IGF-1 isoforms (i.e. 
macrophages) and their activation during regenerative and reparative processes represents an 
additional interesting approach to test in future investigations (Santini and Rosenthal 2012, 
Tonkin et al. Submitted). 
In Chapter 5 and 6 I have demonstrated a direct correlation between IGF-1Ea and the 
modulation of p38 phosphorylation in the whole heart and in isolated neonatal mouse 
cardiomyocytes. Using the same approach of isoproterenol stimulated hypertrophy in vivo 
and in vitro, my results showed that IGF-1Ea maintains p38 phosphorylation at the level of 
the correspondent controls depending on the environment. Positive inotropic stimulation by 
isoproterenol resulted in two opposite trends of p38 phosphorylation, leading to up-
regulation in vitro and down-regulation in the whole heart. It was shown that different doses 
and duration of isoproterenol administration in animal models induced distinct degrees of 
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apoptotic, regressive or degenerative processes in the myocardium (Ellison et al. 2007, 
Angert et al. 2011). Sustained stress and activation of the adrenergic system induces and 
increase in L-type Ca2+ channel activity with enhanced contractility and sarcoplasmic 
reticulum Ca2+ load, eventually leading to hypertrophic development and progression to 
heart failure (Tang et al. 2010, Nichtova et al. 2012). On the other hand, chronic 
administration of very low doses of isoproterenol to guinea pig did not produce cardiac 
hypertrophy (Soltysinska et al. 2011). Distinct molecular processes leading to pathological 
hypertrophic growth may have determined the divergent p38 activation trends observed 
during isoproterenol administration in vivo and in vitro found in this study. Previously 
published data from in vitro and in vivo studies on the role of p38 have shown conflicting 
results. Most studies performed on cultured cardiomyocytes demonstrated a pro-
hypertrophic role for p38 (Liang and Gardner 1999, Nemoto et al. 1998, Wang et al. 1998b). 
However, in vivo studies with cardiac dominant negative p38 transgenic mice hypothesized 
that p38 signalling antagonizes the hypertrophic growth response (Braz et al. 2003, Liu et al. 
2006). Interestingly, p38 knockout mice showed hypertrophic hearts and a significant higher 
number of apoptotic cells compared to wild-type mice after 2 days of isoproterenol infusion 
(Nishida et al. 2004). In the same study, Nishida and colleagues show that in response to 
pressure overload, p38 knockout mice developed a similar degree of cardiac hypertrophy to 
controls, but displayed greater cardiac dysfunction and more fibrosis (Nishida et al. 2004). 
A different study employing cardiac-specific transgenic mice that express a dominant 
negative form of p38, as for (Braz et al. 2003), reported no difference in the hypertrophic 
response to pressure overload between transgenic and control mice, with the transgenic mice 
showing even less fibrosis (Zhang et al. 2003). 
Inconsistencies between many of these models may be attributed to the different genetic 
backgrounds or different mice genders employed or to the differences between in vitro and 
in vivo approaches, as extensively reviewed by Bernardo and colleagues (Bernardo et al. 
2010). Since the growth response of cultured neonatal cardiomyocytes is not the same as in 
the adult heart, a possible explanation of the different results found in p38 activation in vitro 
and in vivo in my experiments may be attributed to the immature status of cardiomyocytes in 
term of sarcomere organization and associated signalling complexes related to the T-tubules. 
This hypothesis is in agreement with the results from this thesis, suggesting that p38 
activation does not induce hypertrophic growth of the adult heart but leads to stimulation of 
cytoprotective mechanisms, in contrast to its deleterious effects on cultured neonatal 
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cardiomyocytes leading to hypertrophy (Nishida et al. 2004). On a different note, one could 
also argue that the dose of isoproterenol administered to NOD.SCID mice in my study 
induced physiological rather than pathological hypertrophy. Downregulation of p38 in 
swimming exercised mice was shown to induce an increase in physiological hypertrophy, 
with enlarged cardiomyocytes, no fibrosis and no ANP mRNA increase (Taniike et al. 2008). 
Even if it is recognized that the limit between physiological and pathological hypertrophy is 
very small, specific features are expected during the pathological development, including 
increased fibrosis and modulation of the fetal genes (Wilkins et al. 2004). The isoproterenol 
model I employed showed these specific characteristics, confirming that pathological 
hypertrophy was correctly induced. 
The p38-MAPK family consists of four isoforms but only α and β are expressed in the heart 
(Jiang et al. 1997, Clark, Sarafraz and Marber 2007). MEK3 and MEK6 are up-stream 
regulators of p38 in the heart and dominant negative mice for both MEK3 and MEK6 
displayed an exacerbated cardiac dysfunction after pressure overload. In my study in vivo, 
isoproterenol induced decrease in MEK3/6 phosphorylation and led to pathological 
hypertrophy, only rescued to normal levels by the presence of IGF-1Ea. It has been recently 
shown that manipulation of the p38 downstream protein NFAT is specifically correlated 
with pathological, but not with physiological hypertrophy (Wilkins et al. 2004, Molkentin 
2013). I have performed preliminary analysis on NFAT regulation by IGF-1Ea in the heart 
of mice used in my study (data not shown) but the data were inconclusive and they were not 
included in this thesis. Future investigations of this pathway will be necessary to understand 
the specificity of IGF-1Ea modulation in this mechanism. 
The described discrepancies between in vivo and in vitro models do not diminish the 
importance of either approach. Although cultured isolated cardiomyocytes are often 
criticised for lack of applicability in the adult heart and genetically modified models may 
induce compensatory alterations in the genome and influence the interpretation of the results, 
both methodologies remain valid tools to investigate the role of specific genes in physio-
pathological mechanisms. In particular, genetically modified models are useful to explore 
the effects induced by overexpression or downregulation of specific genes, although their 
translational potential is limited. The advantage of the strategy employed in this study is that 
the proteins of interest were delivered in the heart rather than overexpressed in the native 
tissue. Although employment of HEK 293 cells is not contemplated for a possible 
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application in clinical therapy, this study represent a proof-of-principle that IGF-1Ea 
administration induces protection of the heart from injury in a clinical-like scenario, 
suggesting the therapeutic potential of the propeptide in cardiac repair. Future studies will 
focus on understanding how the different IGF-1 isoforms stimulate endogenous responses 
during muscle injury in cardiac and skeletal tissues. 
 
7.2 Limitations and future directions 
The use of transfected HEK 293 cells was sufficient to produce high levels of IGF-1Ea and 
IGF-1Stop in the heart and to test the effects of the two isoforms during cardiac remodelling. 
For obvious reasons this model is not translatable to pre-clinical studies, and a specific 
delivery approach of IGF-1Ea will need to be optimized in future animal models. As 
previously discussed, adeno-associated viral vectors are commonly used in clinical trials and 
represent a valid and stable alternative. Moreover, further investigations on the interaction 
between macrophages and the different IGF-1 isoforms will reveal the therapeutic potential 
of an IGF-1/macrophages combined approach. 
Molecular alterations in the native tissue determined by HEK 293 transplantation and the 
lack of functional T- and B-lymphocytes in the NOD.SCID animal model employed in this 
study made difficult the interpretation of important remodelling pathways, such as fibrosis 
(Poggioli et al. In press). Molecular analysis of gene expression (Section 2.7.2) and protein 
activation (Section 2.7.5) in vivo revealed only partially the molecular signalling activated 
by IGF-1Ea and IGF-1Stop. Optimization of an efficient adenoviral-mediated IGF-1 cardiac 
delivery in future studies will be helpful to reduce side effects induced by the presence of 
transplanted cells. 
In order to investigate the molecular signalling stimulated by isoproterenol and the effects of 
IGF-1Ea and IGF-1Stop, I employed an in vitro set-up on isolated neonatal cardiomyocytes. 
A detailed analysis of the molecular mechanisms involving IGF-1Ea modulation of p38 
activation and blockade of hypertrophy could not be performed mainly due to time 
limitations. Ventricular cardiomyocytes make up one-third of the total cell number in the 
heart and represent between 70% and 80% of the heat’s mass (Bernardo et al. 2010). The 
interesting results reported in Chapter 6 regarding the regulation of p38 by IGF-1Ea are 
specific for cardiomyocytes but it will be interesting to investigate the signalling pathways 
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involved in this and in the other cardiac cell populations (e.g. fibroblasts, endothelial cells, 
vascular smooth muscle cells, mast cells). In addition, it is known that the responses seen in 
neonatal cardiomyocytes may not be the same in the adult heart, as also shown by the 
different regenerative capabilities showed by the adult and neonatal hearts (Porrello et al. 
2011, Haubner et al. 2012). Therefore, analysis of IGF-1 effects on adult cardiomyocytes 
will be useful to clarify the interaction between IGF-1Ea and fully differentiated cardiac 
myocytes. 
Finally, comparing the effects of IGF-1Ea and IGF-1Stop during a pathological model of 
hypertrophy induced by pressure overload and during a physiological model of hypertrophy 
induced by exercise will be interesting to understand the involvement of IGF-1 isoforms 
during different stimuli in the heart. It would also be important to investigate the molecular 
signalling modulated by the IGF-1 isoforms and by the other main players in the described 
beneficial pathways. 
 
7.3 Concluding remarks 
The results and techniques described in this thesis demonstrate that cell-mediated delivery 
of IGF-1Ea into the myocardium protected the heart from induced hypertrophic growth and 
impairment of cardiac function. The role of IGF-1Ea in cardiac injury and the comparison 
between IGF-1Ea and IGF-1Stop in cardiac hypertrophy were investigated using two 
different models of acute myocardial infarction (Dr Poudel) and stimulation of β-AR by 
isoproterenol administration. In the first model, IGF-1Ea delivery preserved cardiac function 
in the area of injection and promoted angiogenesis. The molecular analysis I performed and 
the morphological assessment revealed that IGF-1Ea blocked cardiac remodelling induced 
after MI by repressing the expression of hypertrophic markers and the increase in cell size. 
Comparing IGF-1Ea and IGF-1Stop in the isoproterenol hypertrophic model demonstrated 
that only the IGF-1Ea propeptide has specific beneficial effects on the heart. Molecular 
analyses of gene expression and protein activation did not clarify the exact molecular 
pathways involved in IGF-1Ea protection from isoproterenol. Nevertheless, the MAP kinase 
pathway related to MEK3/6 and p38 was found to be directly responsible for the inhibition 
of hypertrophic growth by IGF-1Ea. 
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In vitro analysis showed that IGF-1Ea increased VEGF-A expression in cardiomyocytes, in 
correlation with the increase in angiogenesis observed in vivo. A model of hypertrophy in 
vitro was successfully established by using isoproterenol on cardiomyocytes. Early 
activation of p38 MAPK led to cardiac hypertrophy and the presence of IGF-1Ea acting as 
paracrine factor reduced p38 activation. Further characterization of the in vitro experiments 
is required to identify candidate proteins involved in the IGF-1Ea/p38 interaction and to 
understand p38 dynamics during hypertrophic growth. 
Although a complete characterization of the pathways is still required, this thesis identified 
IGF-1Ea as a paracrine mediator of the protective mechanisms from cardiac hypertrophic 
stimuli in vivo and in vitro. The technical complications encountered during the preliminary 
work presented in this thesis were critically approached to find realistic solutions suitable to 
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Appendix I. Results of Gene Card Assay 













A disintegrin and metallopeptidase domain 12 (meltrin 
alpha) Adam12 Mm00475719_m1 1.0 2.19 4.74 4.21 6.34 
ADAM metallopeptidase domain 17 Adam17 Mm00456428_m1 0.84 1.20 1.10 1.11 1.17 
Angiotensinogen Agt  1.68 20.87 13.87 8.98 10.84 
ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 Atp2a2 Mm01201431_m1 0.93 0.83 0.71 0.79 0.67 
ATP synthase, H+ transporting, mitochondrial F1 




 0.82 1.00 0.99 
Catalase Cat Mm00437992_m1 1.07 1.15 1.03 1.10 0.97 
Collagen, type I, alpha 1 Col1a1 Mm00801666_g1 0.96 3.88 8.68 9.35 11.02 
Connective tissue growth factor Ctgf Mm01192932_g1 1.19 1.34 1.74 2.49 2.35 
Endonuclease G Endog Mm00468248_m1 0.91 1.16 0.98 0.99 0.92 
Fibronectin 1 Fn1 Mm01256744_m1 0.91 1.51 4.58 4.44 5.46 
Hydroxymethylbilane synthase Hmbs Mm01143545_m1 0.83 0.84 0.93 0.90 0.92 
Interleukin 6 (interferon, beta 2) Il6 Mm00446190_m1 0.96 1.21 6.98 7.95 9.11 
Mitogen-activated protein kinase kinase kinase 5 Map3k5 Mm00434883_m1 1.49 1.59 1.54 1.73 1.63 
Mitogen-activated protein kinase kinase kinase 7 Map3k7 Mm00554514_m1 1.04 1.52 1.33 1.25 1.48 
Mitogen-activated protein kinase kinase kinase kinase 
4 Map4k4 Mm00500813_m1 0.85 0.81 0.91 0.94 0.92 
Myocyte enhancer factor 2C Mef2c Mm01340842_m1 1.14 1.46 1.55 1.56 1.53 
Misshapen-like kinase 1 Mink1 Mm00489533_m1 0.95 1.11 1.24 1.25 1.39 
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Matrix metallopeptidase 14 (membrane-inserted) Mmp14 Mm00485054_m1 0.87 1.32 2.29 2.04 2.68 
Matrix metallopeptidase 2 Mmp2 Mm00439498_m1 1.87 2.29 2.82 3.18 3.2 
Matrix metallopeptidase 9 Mmp9 Mm00442991_m1 1.62 0.94 1.24 1.29 5.09 
Myosin, heavy polypeptide 6, cardiac muscle, alpha Myh6 Mm00440359_m1 0.78 0.80 0.78 0.75 0.60 
Myosin, heavy polypeptide 7, cardiac muscle, beta Myh7 Mm01319006_g1 1.72 0.55 1.02 1.22 0.97 
Myosin, light polypeptide 3 Myl3 Mm00803032_m1 1.17 0.98 0.91 0.86 0.66 
Myosin, light polypeptide 4 Myl4 Mm00440378_m1 9.71 4.17 5.55 8.33 5.28 
Nuclear factor, erythroid derived 2, like 2 Nfe2l2 Mm00477784_m1 1.00 1.04 1.16 1.26 1.16 
Natriuretic peptide precursor A Nppa Mm01255747_g1 1.83 6.61 8.23 10.73 11.17 
Natriuretic peptide precursor B Nppb Mm01255770_g1 1.18 2.23 2.69 4.09 4.30 
Oxidized low density lipoprotein (lectin-like) receptor 
1 Olr1 Mm00454586_m1 0.89 0.91 4.44 3.34 4.13 
Phospholamban Pln Mm00452263_m1 0.83 0.84 0.76 0.75 0.72 
Periostin, osteoblast specific factor Postn Mm00450111_m1 0.95 6.41 14.23 17.64 28.41 
Peroxisome proliferator activated receptor alpha Ppara Mm00440939_m1 0.75 0.90 0.72 0.84 0.69 
Peroxisome proliferator-activated receptor gamma Pparg Mm01184322_m1 1.71 2.55 2.20 3.13 2.64 
Peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha Ppargc1a Mm01208835_m1 0.91 1.05 1.06 0.99 0.85 
Serine (or cysteine) peptidase inhibitor, clade E, 
member 1 Serpine1 Mm00435860_m1 1.19 1.68 2.93 3.58 4.09 
Superoxide dismutase 2, mitochondrial Sod2 Mm01313000_m1 0.97 1.06 0.91 1.01 1.00 
DNA primase catalytic subunit Spp1 Spp1 Mm00436767_m1 1.77 16.97 34.61 30.99 92.79 
Transcription factor A, mitochondrial Tfam Mm00447485_m1 1.05 1.12 1.11 1.15 1.13 
Transforming growth factor, beta 1 Tgfb1 Mm01178820_m1 0.91 1.33 1.07 1.09 1.55 
Transforming growth factor, beta 2 Tgfb2 Mm00436955_m1 1.20 1.89 1.66 3.53 4.71 
Transglutaminase 2 (C polypeptide, protein-glutamine-
gamma-glutamyltransferase Tgm2 Mm00436987_m1 0.98 1.43 2.27 2.09 2.07 
Tissue inhibitor of metalloproteinase 1 Timp1 Mm00441818_m1 2.52 8.02 20.33 18.94 34.28 
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Tissue inhibitor of metalloproteinase 2 Timp2 Mm00441825_m1 0.97 1.24 1.79 1.82 1.77 
Tissue inhibitor of metalloproteinase 3 Timp3 Mm00441826_m1 1.05 1.21 1.45 1.51 1.35 
Tissue inhibitor of metalloproteinase 4 Timp4 Mm01184417_m1 1.01 1.18 1.02 1.18 1.21 
Tumor necrosis factor Tnf Mm00443260_g1 1.55 0.74 0.98 1.05 1.12 
TRAF2 and NCK interactin kinase Tnik Mm01286430_m1 1.83 3.92 2.75 2.99 3.64 
Ubiquitin conjugating enzyme Ubc Ubc Mm01201237_m1 1.03 1.19 1.07 1.10 1.09 	  












Appendix II. Results of Kinexus phosphorylation-sites array 
1 mg/kg/day Isoproterenol 7d 







3-phosphoinositide-dependent protein-serine kinase 1 PDK1 S241 162 81.5 96.50 197.3 
cAMP response element binding protein 1 CREB1 S133 186 80.3 162 80 
cAMP-dependent protein-serine kinase catalytic subunit alpha/beta  PKA Ca/b T198 123.8 106 110 126 
cAMP-dependent protein-serine kinase catalytic subunit β PKA Cb S339 113.3 91.75 92 128.7 
 Connexin 43  Connexin 43 S368 90.3 81.2 73.3 32 
Extracellular regulated protein-serine kinase 1 (p44 MAPK)  Erk1 Y204 45 32 43.2 50 
Extracellular regulated protein-serine kinase 2 (p42 MAPK)  Erk2 Y187 75.50 47.3 47.3 69.3 
Extracellular regulated protein-serine kinase 5 (Big MAPK 1 
(BMK1) Erk5 T218+Y220 110.3 81.3 94.7 61 
Forkhead-like transcription factor 1 (FOXO3A)/Forkhead box protein 
O1A  
FKHRL1/ 
FOXO1A T32/ T24 107.8 106.5 92 78.5 
Glycogen synthase-serine kinase 3 alpha  GSK3a S21 95.3 87.7 84 109 
Glycogen synthase-serine kinase 3 beta  GSK3b S9 127.3 88 76.75 106.3 
Insulin-like growth factor receptor protein-tyrosine kinase IGF1R Y1280 82 96.7 107.3 79.2 




S218/S207 58 58 57.3 76.7 
p21-activated protein-serine kinase 1/2/3  PAK1/2/3 S144/S141/S154 72 70.25 89 76.6 
Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and protein 
phosphatase and tensin homolog deleted on chromosome 10  PTEN S380+T382+S385 103.8 
102 105.3 66 
Protein-serine kinase B alpha PKBa S473 123.5 116 124.7 209.3 
186	  	  
(Akt1) 
Protein-serine kinase C alpha  PKCa S657 109.5 49. 48.0 57.7 
Protein-serine kinase C delta PKCd Y313 98.2 90 113.3 89.3 
Raf1 proto-oncogene-encoded protein-serine kinase  Raf1 S259 101 79 72.0 102.8 	  
Values show % of phospho-protein compared to saline 100%. All values were normalized on gamma-tubulin	  
